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Recombinant AAV Gene Therapy and Delivery for
Alzheimer’s Disease
Nikisha Christine Carty
ABSTRACT

Alzheimer’s disease (AD), first characterized in the early 20th century, is a
common form of dementia which can occur as a result of genetic mutations in the
genes encoding presenilin 1, presenilin 2, or amyloid precursor protein (APP).
These genetic alterations can accelerate the pathological characteristics of AD,
including the formation of extracellular neuritic plaques composed of amyloid
beta peptides and the formation of intracellular neurofibrillary tangles consisting
of hyperphosphorylated tau protein. Ultimately, AD results in gross neuron loss
in the brain which is evidenced clinically as a progressive decline in mental
capacity. A strong body of scientific evidence has previously demonstrated that
the driving factor in the pathogenesis of AD is potentially the accumulation of Aβ
peptides in the brain. Thus, reduction of Aβ deposition is a major therapeutic
strategy in the treatment of AD. Recently it has been suggested that Aβ
accumulation in the brain is modulated, not only by Aβ production, but also by its
degradation. Several important studies have demonstrated that Aβ degradation
is modulated by several endogenous zinc metalloproteases shown to have
vi

amyloid degrading capabilities. These endogenous proteases include neprilysin
(NEP), endothelin converting enzyme (ECE), insulin degrading enzyme (IDE)
and matrix metalloprotease 9 (MMP9). In this investigation we study the effects
of upregulating expression of several of these proteases through administration
of recombinant adeno-associated viral vector (rAAV) containing both
endogenous and synthetic genes for ECE and NEP on amyloid deposition in
amyloid precursor protein (APP) plus presenilin-1 (PS1) transgenic mice. rAAV
administration directly into the brain resulted in increased expression of ECE and
NEP and a substantial decrease in amyloid pathology. We were able to
significantly increase the area of viral distribution by using novel delivery
methods resulting in increased gene expression and distribution.
These data support great potential of gene therapy as a method of
treatment for neurological diseases. Optimization of gene transfer methods
aimed at a particular cell type and brain region in the CNS can be accomplished
using AAV serotype specificity and novel delivery techniques leading to
successful gene transduction thus providing a promising therapeutic avenue
through which to treat AD.

vii

INTRODUCTION

ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is a debilitating and devastating
neurodegenerative disorder that leads to a progressive decline in memory, the
ability to learn and reason, and loss of overall brain function ultimately resulting in
death. AD is the most common form of senile dementia (a group of conditions
that gradually destroy brain cells leading to progressive decline in mental
capacity) affecting approximately 4.5 million individuals in the United States
consequently causing a great financial burden on the U.S. economy. The
estimated annual costs of caring for individuals with Alzheimer’s disease are at
least $100 billion, according to the Alzheimer’s Association and the National
Institute on Aging. The molecular mechanisms underlying Alzheimer’s disease
(AD) have been extensively investigated. AD can occur as a result of genetic
autosomal-dominant mutations in the genes encoding presenilin 1, presenilin 2,
or amyloid precursor protein (APP) (Levy et al., 1990), (Goate et al., 1991),
(Hardy et al., 1992),(Scheuner et al.,1996). Interestingly, these autosomal
dominant genetic mutations only account for 1-2% of AD cases which are
inherited and commonly referred to as early onset Alzheimer’s disease or familial
AD (FAD)(Fidani and Goate, 1992). The cause of AD accounting for the majority
of the cases remains unknown, although Apolipoprotein E4 is a known risk factor.
1

These genetic alterations have been found to accelerate the pathological
characteristics of AD which include the formation of extracellular amyloid plaques
and the formation of intracellular neurofibrillary tangles consisting of
hyperphosphorylated tau. The accumulation of these amyloid plaques are not
only a crucial factor in the pathology of AD (Selkoe, 2001), (Bard et al., 2003),
but have been argued to contribute to the distinctive clinical symptoms of AD
such as progressive cognitive decline, loss of memory and decreased mental
capacity (Cummings et al., 1996a), (Nicoll et al., 2003), (Masliah et al., 2005).
The genetic mutations that result in AD pathology all cause alterations in the
normal processing of the amyloid precursor protein (APP) by altering the
proteolytic cleavage sites which cause the production and release of Aβ peptides
in the brain. Accumulation of these peptides leads to the formation of
extracellular deposits commonly referred to as neuritic plaques (Cummings et al.,
1996b), (Selkoe, 2001). Another hallmark pathological feature of AD are
intraneuronal neurofibrillary tangles which can occur independent of the neuritic
plaque. The tau aggregates which compose these tangles are nonmembrane
bound fibers arranged as pairs of helical filaments. Although the mechanism by
which neuritic plaques and neurofibrillary tangles can eventually lead to neuron
loss is debated among researchers, it has been repeatedly demonstrated that
reducing amyloid deposits in the brain can significantly improve cognitive deficits
(Janus et al., 2000), (Morgan et al., 2000), (Dodart et al., 2002). Consequently,
elucidating novel methods of decreasing or preventing amyloid accumulation has
been a primary focus in the treatment of Alzheimer’s disease.
2

AMYLOID PRECURSOR PROTEIN (APP) AND PRESENILIN 1 AND 2
The genetic etiology of AD provides important evidence supporting the
“Amyloid Cascade Hypothesis” first put forth by John Hardy in 1991 (Hardy and
Allsop, 1991), (Hardy and Selkoe, 2002). Specifically, all genetic mutations that
cause early onset or familial AD alter the production of Aβ in the brain (Kimberly
et al., 2000). The amyloid precursor protein (APP) gene was the first AD
susceptibility gene to be identified (George-Hyslop, 2000). The βAPP gene
encodes for a transmembrane glycoprotein that contains 770 amino acids, but
has several isoforms which vary in length (George-Hyslop, 2000). The
extracellular domain of the protein is the critical portion that normally undergoes
processing through a series of proteolytic cleavages. These cleavage pathways
involve an α-secretase, β-secretase, and γ-secretase that give rise to several
different peptides. The normal processing of the APP molecule only involves the
α-secretase cleavage which readily cleaves the βAPP695 isoform of APP
between the Lys687 and Leu688 residues in the extracellular domain. This
cleavage is subsequently followed by a γ-secretase cleavage which yields a
soluble APP molecule and a smaller P3 fragment. The abnormal processing of
APP involves a β-secretase cleavage followed by a γ-secretase cleavage
yielding Aβ peptide species Aβ1-40 and Aβ1-42 (Selkoe, 1998), (Sinha and
Lieberburg, 1999), (George-Hyslop, 2000). Cells that contain the APP mutation
readily produce larger amounts of the Aβ 1-42 peptide, the pathogenic species
which is slightly more hydrophobic causing it to aggregate, as opposed to the
Aβ1-40 species (Wang et al., 1999). This results in a change in the ratio of the
3

particular species which are normally produced by the cell, causing the peptides
to abnormally accumulate forming plaques which are primarily made up the Aß 142 peptide and deposited within the brain paranchyma (Cummings et al., 1992),
(Suzuki et al., 1994), (Cummings et al., 1996b), (Skovronsky et al., 1998). The
aberrant accumulation of Aβ peptides in the brain has been recognized as an
essential factor in the pathology of Alzheimer’s disease (AD). Due to the fact that
γ-secretase catalyzes the final step in the production of Aβ peptides and because
it determines the final length of the Aβ peptide variants, understanding this
protease has become an important target not only in the molecular genetics of
AD but has emerged as an important target in the development of potential AD
therapy.
The continued study of the molecular genetics of AD eventually revealed
the genes known as presenilin 1 (PS1) and presenilin 2 (PS2) (57 and 55 kDa
polypeptides, respectively) which were initially discovered in 1995. The
presenilins play an integral role in the molecular mechanisms leading to the
development of Alzheimer’s disease (Anwar et al., 1996), (Hutton et al., 1996),
(Hutton and Hardy, 1997), (Dewji and Singer, 1998), (Siman et al., 2000).
Several different functions have been credited to presenilin including a role in
promoting or reducing a neurons susceptibility to apoptosis, regulating
intracellular calcium signaling, trafficking of membrane proteins, processing of
the APP molecule, and involvement in the cleavage of other substrates (Ray et
al., 1999), (Siman et al., 2000), (Brunkan and Goate, 2005), (Dewji, 2005). The
presenilin 1 mutations account for the earliest and most aggressive forms of AD,
4

while presenilin 2 mutations have a later and more variable age of onset
(George-Hyslop, 2000), (Ishii et al., 2001). Over one hundred different mutations
have been reported in the PS1 gene, most of which are missense mutations, and
approximately 6 mutations found in PS2. The presenilins have been found to be
in part expressed at the cell surface with the majority of the protein being
expressed in the intracellular compartment. Reports have also indicated that
PS1 and PS2 are expressed in the endoplasmic reticulum and the golgi
apparatus as well as in nuclear membranes (Dewji, 2005). Ultimately, the
presenilin mutations lead to an increased production of cerebral Aβ1-42 peptides
and a 1.5 to 3 fold increase in Aβ42 containing plaques in human brain tissue of
FAD human tissue as opposed to sporadic cases of AD (Lamere et al., 1996).
The finding that presenilin mutations cause specific increases in Aβ1-42
production lead to the idea that mutant PS must play a role in the modulation of
γ-secretase activity and are essential for the γ-secretase cleavage of βAPP (Ray
et al., 1999). Results from transgenic mouse models with PS mutations and APP
mutations clearly indicate that PS mutations not only increase production and
deposition of Aβ species in the brain but also imply that presenilin may act as the
γ-secretase enzyme or an essential cofactor for the γ-secretase cleavage of
βAPP (Duff et al., 1996), (Ishii et al., 2001), (Brunkan and Goate, 2005). Despite
the breakthrough discovery of genes responsible for early onset AD this accounts
for only 1-2% of all AD cases and therefore investigation to identify AD
susceptibility genes have become an area of intense research.

5

TRANSGENIC MOUSE MODELS OF AMYLOID DEPOSITION
Almost ten years after the discovery of the FAD mutations in the APP
gene and the introduction of transgenic technology, researchers have used
knowledge of the numerous mutations on APP, PS1, and PS2 to create murine
models that have lead to an increased understanding of AD pathogenesis. The
first generation of an AD transgenic mouse model was based on the over
expression of the wild type human (hAPP) cDNAs and in most cases these
efforts failed to produce mice with the hallmark pathogenicity found in human AD
cases with the exception of the NSEAPP (APP751) mouse produced by Quon et.
al. in 1991. Investigators eventually discovered that the overexpression of the
hAPP in addition to either the Swedish mutation (APPK670N,M671L) or the London
mutation (APPV717F) was sufficient to produce enough Aβ peptides to cause
significant amount of amyloid deposition (Quon et al., 1991), (Higgins and
Jacobsen, 2003). This gave rise to the PDAPP mouse first presented by Games
et. al. in 1995 that contains the London mutation (APPV717F) under control of the
platelet derived growth factor promoter (PDGF). The Tg2576 mouse first
described by Hsiao et. al. in 1996 contains the APP695 isoform with the Swedish
mutation (APPK670N, M671L) under the prion protein promoter (PrP) which ensures
high CNS expression (Hsiao et al., 1996, Higgins and Jacobsen, 2003). These
mice exhibit a similar positive correlation between increased age and amyloid
deposition as well as selective distribution of amyloid within specific brain regions
such as cortex and hippocampus.
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Another single transgenic mouse model of amyloid deposition (APP23
mouse) was developed by Novartis and described by Sturchler-Pierrat et. al., in
1997 and contains the hAPP751 isoform with the Swedish mutation under the
control of the Thy-1 promotor to enhance neuronal expression. These mice also
emulate the PDAPP and Tg2576 mice in their region specific development of
amyloid deposits but unlike the two previous transgenic models the APP23
mouse has been shown to demonstrate neurodegeneration in the CA1 region of
the hippocampus which seems to correlate with increased plaque load (between
14-18 months of age) (Calhoun et al., 1998), (Higgins and Jacobsen, 2003). In
more recent years double transgenic mouse models of AD which express both
mutant APP and human presenilin with FAD mutations have been successfully
created (Higgins and Jacobsen, 2003). These mice have significantly enhanced
production of the Aβ1-42 peptide and also begin to develop amyloid deposits at a
much earlier age compared to their single transgenic counterparts (Borchelt et
al., 1997), (Holcomb et al., 1998). The PSAPP mouse overexpresses the PS1
gene with the M146L mutation (Duff et al., 1996) and the Swedish mutation
(Hsiao et al., 1996) and show significantly increased plaque pathology, beginning
around 3 months of age, which is associated with gliosis (Holcomb et al., 1998).
Interestingly, transgenic mice that express only FAD presenilin mutations alone
show no signs of amyloid deposition (Duff et al., 1996). The CRND8 transgenic
model expresses a double mutated form of the APP695 (APPV717F and APPK670N,
M671L)

under the PrP promoter. This model also results in accelerated plaque

deposition which is clearly evident at 3 months of age. PDAPP mice have also
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been shown to exhibit some behavioral deficits as early as three months of age
even before the development of amyloid plaque deposits could be detected
(Higgins and Jacobsen, 2003). The Tg2576 transgenic model differ from the
PDAPP animals in that they begin to develop cognitive deficits between 9-10
months of age and this correlates more closely with the development of amyloid
deposits in the brain (Hsiao et al., 1996). In early 2002 Westerman and
collegues proposed that cognitive deficits more likely are the result of increases
in soluble forms of Aβ (or small protofibrils of Aβ) rather than plaque deposition
(Westerman et al., 2002). More recent reports argue that large Aβ aggregates
may in fact play a neuroprotective role providing a mehcanims in which smaller
soluble Aβ moieties are sequestered into larger insoluble aggregates preventing
them from causing destruction. Specifically, the soluble oligomeric Aβ
assemblies have been implicated as the driving factor in AD pathogenisis as they
exhibit potent toxicity in their capacity to significantly decrease LTP, contribute to
learning and memory deficits in vivo and induce neuronal cell death in vitro
(Lambert et al., 1998), (El-Agnaf et al., 2000), (Klein, 2002; Glabe, 2005),
(Malaplate-Armand et al., 2006), (Townsend et al., 2006), (Cerpa et al., 2008),
(Varvel et al., 2008)

ZINC METALLOPROTEASES/ENDOGENOUS Aβ DEGRADING ENZYMES
In recent years a growing number of endogenous proteases have been
found to have Aβ degrading capabilities in the brain and other tissues both in vivo
8

and in vitro. Several of these enzymes are members of zinc metalloprotease
family and include neprilysin (NEP), insulin degrading enzyme (IDE; insulysin),
endothelin converting enzymes (ECE-1 and ECE-2), and angiotensin converting
enzyme (ACE). Recently, a number of other proteases have been shown to
degrade Aβ in vitro, including matrix metalloproteases 2, 3, and 9, and, the serine
protease, plasmin but the degree to which they may be involved in the normal
catabolism of Aβ remains uncertain (Yan et al., 2006), (Turner and Nalivaeva,
2007). Down regulation of these enzymes within the brain could potentially
contribute to Aβ accumulation and lead to development of AD.
NEP, a 92-kDa glycosylated ectoenzyme, was originally found as a kidney
enzyme and is capable of degrading multiple peptide hormones (Iwata et al.,
2000a). Also known as enkephalinase, it is capable of cleaving enkephalins and
termination of peptidergic neurotransmission. It is membrane bound and its
active site is oriented outside the cell. NEP has a very large range of regulatory
activity as it is capable of degrading numerous bioactive peptides including opioid
peptides, tackykinins, substance P, atrial natriuretic peptides, chemotactic
peptides and adrenocorticotropin hormone (ACTH) (Matsas et al., 1984a),
(Turner et al., 1996). NEP is expressed in the CNS and in the periphery
particularly in epithelial cells of the intestines, kidney and lungs (Fulcher et al.,
1982), (Matsas et al., 1984b), (Kenny et al., 1985). In the CNS NEP is
expressed in neurons, mainly pyramidal neurons, and glial cells types (Turner et
al., 2003). Therefore, NEP is involved in regulation of several different
physiological processes, such as cardiovascular activity, cell migration and
9

proliferation, inflammation, and neuropeptide regulation (Turner, 2003). NEP, is
a highly conserved protein and the NEP gene in located on chromosome 3
spaning more the 80 kb (Roques et al., 1993) in humans. Several homologues
of NEP have also been identified most of which remain uncharacterized (Turner
and Nalivaeva, 2007), (Nalivaeva et al., 2008). Although, one homologue named
NEP2 (also known as Sep and NL1) has been shown to also degrade Aβ, unlike
NEP it is expressed only in specific neuronal populations in the brain and in the
spinal cord. Furthermore, NEP2 is expressed in a membrane bound form in the
endoplasmic reticulum and a soluble secreted form but very little is known
regarding its function or whether it plays a role in Aβ metabolism.
Iwata et. al., in 2000 first demonstrated the ability of NEP to degrade Aβ
peptides in the brain parenchyma and also illustrated that suppressing NEP
would lead to an increase in Aβ deposition (Iwata et al., 2000). In 2002 Iwata et.
al.. also demonstrated that NEP activity decreased with age in regions where Aβ
accumulated such as the cortex and hippocampus, however in areas such as the
striatum where Aβ did not accumulate NEP was increased (Yasojima et al.,
2001b). Evidence from transgenic animal models demonstrate that NEP
deficient mice show a significant increase in amyloid deposition as opposed to
their wild type counterparts clearly indicating that NEP activity plays a significant
role in endogenous Aβ degradation (Iwata et al., 2002), (Iwata et al., 2004), (Marr
et al., 2004).
Another important Aß degrading enzyme is known as endothelin
converting enzyme (ECE). ECE, like NEP is a membrane bound
10

metalloprotease approximately 87 kd in size and exists in several isoforms
including ECE-1a, ECE-1b, ECE-1c, and ECE-2. ECE-1 has been found
localized in the Golgi and vesicles. Its primary function is to catalyze the
conversion of big endothelin (big ET) into vasoactive endothelins(Eckman et al.,
2003). ECE-1 has also been reported to hydrolyse other biologically active
peptides including bradykinin, neurotensin and substance P. ECE is a
homologue protein of NEP, yet an important structural difference between the
two is that ECE-1 exists as a disulfide linked dimer. ECE-1 is expressed in
endothelial cells as well as several other cell types including neurons and glia
within the brain that are particularly relevant to AD disease pathology. Although
several other isoforms of ECE exist, ECE-1c is the predominantly expressed
mRNA in humans. Each isoform has distinct subcellular localizations; specifically
ECE-1a, ECE-1c, and ECE1d are primarily localized at the cell surface, while
ECE-1b is found in the intracellular compartment. To date there are no
significant differences in the catalytic properties of the different isoforms (Turner
et al., 2004). The Aβ degrading capabilities of ECE were discovered when
Eckman et. al. observed that the metalloprotease inhibitor, phosphoramidon,
caused a rapid accumulation of Aβ in a cell line which expressed ECE and did
not cause this increase in cells not expressing ECE (Eckman and Eckman,
2005). Subsequent studies revealed that when ECE was overexpressed in the
cell lines the Aβ accumulation was reduced by approximately 90%. In vivo data
from ECE (+/-) transgenic mice which show about 27% reductions in ECE-1
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activity also show significant increases in both Aβ40 and Aβ42 levels in the brain
(Eckman and Eckman, 2005).
In addition to NEP and ECE, IDE (insulysin) has been suggested as
another Aβ degrading enzyme that may play an important role in the dynamic
process of Aβ degradation in the brain. Unlike NEP and ECE-1, IDE is primarily
localized in the cytosol but it can also be located, at low levels, in peroxisomes as
well as in the plasma membrane and in a secreted form in the extracellular
compartment (Turner et al., 2004). IDE is expressed in the human CNS in
cortical and subcortical neurons as well as in endothelial cells, pericytes and
smooth muscle cells (Morelli et al., 2004). In vitro, IDE is capable of degrading a
variety of substrates including insulin and its role in Aβ degradation in the brain
was first proposed by Kurochkin et. al., (Kurochkin and Goto, 1994), (Kurochkin,
2001), (Turner et al., 2004), (Farris et al., 2005). Several studies support the
importance of IDE activity in Aβ catabolism, including a correlation study
presented by Perez et. al. in 2000 revealed that IDE activity which correlated with
a decrease in soluble Aβ peptide degradation in the AD brain compared to
normal aged matched control brains (Perez et al., 1999). Furthermore, in
transgenic mice with IDE (-/-) deficiencies results in almost a 50% decrease in Aβ
degradation in not only the brain but in primary neuron cultures as well; while the
overexpression of IDE significantly reduces brain Aβ levels in APP mice (Farris et
al., 2003), (Leissring et al., 2003), (Farris et al., 2005).
The in vivo data from multiple studies involving NEP, ECE, and IDE
transgenic mice provides clear evidence that the activity of these specific
12

proteases are essential for the regulation of Aβ accumulation in the brain.
Therefore, the regulation of these proteases through novel methods such as
gene therapy provides a unique avenue through which novel therapeutic
treatments can be explored.

GENE THERAPY AND VIRAL VECTORS
Gene therapy has a fairly short and controversial history and was first
envisioned as a potentially viable scientific tool for the treatment of hereditary
single-gene defects. Beginning in the late 1970’s and 80’s gene therapy made
its unofficial clinical debut with two unapproved clinical trails. In the first trials,
two young boys with arginase deficiency syndrome were treated using in vivo
gene therapy with a wild-type Shope papilloma virus in an effort to replace the
missing enzyme with the viral arginase. Another trial involved the use of ex vivo
gene therapy in which a bone marrow transplant was performed using bone
marrow treated with a β-globin-containing plasmid in order to treat two patients
with β-thalassemia. The results were neither efficacious nor deleterious (Scollay,
2001). During the 1990’s the use of gene therapy in approved gene therapy
trials steadily increased and by the mid 2000 nearly 4000 patients have been
treated with gene therapy in more than 500 trials (Scollay, 2001). The majority of
the trials in the 1990’s were unsuccessful and in 1999 the first published death
resulting from gene therapy using an adenovirus vector was highly publicized
lending to a bad public perception of gene therapy and it’s potential as a viable
therapeutic avenue in the treatment of disease and revealing the need to further
13

understand the viral vector interactions with the human immune system.
Fortunately, by 2000 the first successful procedures were conducted in three
individuals suffering from severe combined immunodeficiency (SCID), (Scollay,
2001). This progress was the result of improvements in understanding different
types of viral vectors and in our understanding of genetics and the biology of
transducing cells.
There are several different mechanisms by which gene therapy can be
achieved and an important factor in the success of the method involves the type
of vehicle used to delivery the therapeutic gene to the target tissue (Thomas et
al., 2003). Viral vectors utilized in the first gene therapy attempts were extremely
inefficient and did not persist in the host cells and the transgene expression was
in most cases for a short time. A thorough understanding of the molecular basis
of how viruses and viral vectors interact with the host has been a major focal
point in the area of gene therapy. As a result over the past few years, several
vectors have been developed aimed at improved efficiency, specificity, and
safety which have also resulted in successful treatments (Thomas et al., 2003).
The diversity of diseases that gene therapy research has aimed at targeting is
expanding from the initial hereditary single gene defect treatment to include
acquired diseases such as cancer, cardiovascular disease, infectious disease
and neurodegenerative disease (Mandel and Burger, 2004). This means that no
one vector method will be the most efficacious for all disease categories. Thus
understanding and utilizing unique characteristics of different viral vector types is
essential for the success of gene transfer and persistence of the transgene.
14

There are five major categories of viral vectors which can be categorized
into two main groups (Thomas et al., 2003). The groups include viruses whose
genome integrates into the host cellular genome known as oncoretroviruses or
those which persist apart from the cellular host genome as an episome, or
extrachomosomal unit, within the cell nucleus. Retroviruses, such as human T
cell leukemia virus, sarcoma virus and HIV, are a class of viruses that can create
double-stranded DNA copies of their RNA genomes. These copies of its genome
can be integrated into the chromosomes of host cells. Lentivirus is characterized
by a long incubation period. Human immunodeficiency virus (HIV) is an example
of a lentivirus. Adenoviruses are a class of viruses with double-stranded DNA
genomes that cause respiratory, intestinal, and eye infections in humans. The
virus that causes the common cold is an adenovirus. Adeno-associated viruses
are a class of small non-pathogenic human parvovirus, single-stranded DNA
viruses that can insert their genetic material which can persist as an episomal
plasmid. Finally, herpes simplex viruses are a class of double-stranded DNA
viruses that infect a particular cell type, specifically neurons. Herpes simplex
virus type 1 is a common human pathogen that causes cold sores (Thomas et
al., 2003). There are advantages and disadvantages to each type of vector
which determines it’s suitability for specific treatments. Particularly, vectors such
as adeno-associated virus (AAV), adenovirus and herpes virus, which have nonintegrating vectors, usually have a persistent transgene expression only in non
proliferating cells whereas retroviruses with integrating genomes have persistent
transgene expression in dividing cells. The size of the viral vehicle can also be a
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determining factor mediating the type of gene that can be expressed. The table
below, published by Thomas et. al.. in 2003 summarized the advantages and
disadvantages of the five different viral vectors (Thomas et al., 2003).
Adeno-associated viruses are members of the parvoviridae family and are
subsequently a member of the helper virus genus which indicates that they need
a helper virus, in most cases adenovirus or herpes simplex virus, in order to
support successful infection and replication. When the helper virus is absent
AAVs will generate a latent infection within the cell and in 90% of cases this
means the AAV genome will persist as an episomal unit (Thomas et al., 2003),
(Tenenbaum et al., 2004a), (Wu et al., 2006).

ADENO-ASSOCIATED VIRAL VECTORS AND SEROLOGY
AAVs are one of the smallest viruses, approximately 25 nm in diameter,
and their DNA genome is less than 5 kb which contains two large open reading
frames with inverted terminals repeats located at either end (Samulski et al.,
1982), (Tenenbaum et al., 1994), (Tenenbaum et al., 2004b), (Wu et al., 2006).
AAVs must accomplish several major steps to achieve successful gene
expression which include attachment to the cell surface receptors, endocytosis,
trafficking to the nucleus, uncoating of virus which releases viral genome, and
finally conversion of the genome to double stranded DNA which is transcribed in
the nucleus. The efficiencies of rAAV transduction intricately depend on the
successful implementation of each step. AAV vectors arrive in a variety of
flavors otherwise known as serotypes. The AAV serotype refers to the efficiency
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by which the specific AAV can infect a particular cell type through attachment to
specific cell surface receptors. A new AAV serotype is defined by the inability of
an antibody that is reactive to the viral capsid protein of one serotype in
neutralizing those of another serotype (Choi et al., 2005). Through the
modifications to the viral genome and the capsids rAAV can be designed to be
more efficient at transducing specific cells or tissue types to optimize gene
therapy (Choi et al., 2005).
AAV2 serotype was the first to be cloned into bacterial plasmids by
Samulski et. al. in 1982 and to date it is the most characterized of all the
serotypes of which a total of 10 have been discovered, and has been shown to
effectively transducer neurons in the CNS in a number of animal studies
(Samulski et al., 1982), (Fu et al., 2003), (Burger et al., 2004), (Tenenbaum et al.,
2004b). AAV5 was originally discovered in a human clinical sample in 1984 as a
contaminant in adenovirus stock and it contains ITRs (inverted terminal repeats)
that are not unlike the structures of AAV2 ITRs and is the most divergent of all of
the serotypes (Choi et al., 2005), (Wu et al., 2006). AAV1 and AAV3 were also
initially found as contaminants of simian adenovirus 15, while AAV6 was
identified as a contaminant of adenovirus type 5 by Rutledge et. al. in 1998.
AAV7 and AAV8 were originally isolated from rhesus monkey tissue in 2002 by
Gao et. al.. AAV9, like AAV5, was originally discovered in human tissue, while
AAV10 and AAV11 are the most recently identified serotypes and initially were
isolated from cynomolgus monkey tissue in 2004 by Mori et. al. but they are not
well characterized (Mori et al., 2004), (Wu et al., 2006).
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The fairly recent identification of different AAV serotypes had advanced
the study of rAAV vectors which has quickly become a major dominant focus in
the field of gene therapy. There are a number of studies aimed at characterizing
the different AAV serotypes with respect to transduction efficiency, tissue
tropism, cell surface receptors, intracellular processing, and capsid structure.
AAV2 vectors are the most extensively characterized and due to their well
established safety profile and range of infectivity, approximately 20 clinical trails
have been conducted using the AAV2 vector serotypes in numerous patients
(Wu et al., 2007). In order to effectively study transduction efficiencies of
different serotypes of AAV vectors in different tissue types, scientists have
utilized the “cross-packaging” strategy which essentially enables an unbiased
direct comparison of the transduction rates without influence of ITRs on
transgene expression (Grieger and Samulski, 2005), (Wu et al., 2007). To
accomplish this the Cap genes of different serotypes are placed downstream of
the AAV2 Rep genes which ultimately allows the generation of serotypes specific
capsids while the packaged genomes within the capsids are identical, these are
also referred to as hybrid viruses (Rabinowitz et al., 2002), (Rabinowitz et al.,
2004), (Wu et al., 2006). In addition to transcapsidation first described by
Rabinowitz et. al. in 2002 there are several other techniques to accomplish the
formation of a hybrid virus armed with specific modifications to enhance
efficiency of gene uptake, transfer, and expression in a specified therapeutic
avenue. These include absorption modifications where the capsid surface is
modified to carry a foreign antibody that will bind to the cell surface receptor of
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interest to increase absorption efficiency. Mosaic capsids are another method to
increase transduction efficiency. This technique involves creating a mixture of
viral capsid proteins from different serotypes at various ratios in order to combine
tissue tropisms of interest (Xiao et al., 1999), (Rabinowitz and Samulski, 2000).
Finally, chimeric capsids can also provide a means of increasing transduction of
a particular specificity and this technique involves the packaging of capsid
proteins with foreign peptide sequences, such as a hemagglutinin (HA) tag fused
at either the N or C terminus of the capsid coding sequence to alter tissue
tropism (Yang et al., 1999), (Bowles et al., 2003), (Wu et al., 2006).
Although the data regarding AAV serotype specific tissue tropism is
subject to different interpretation due to variations in vector titer, promoters,
transgenes between studies, in general the transduction efficiencies for most of
the AAV serotypes have been determined. In the CNS serotype characterization
studies have revealed that AAV1, and 5 have higher transduction efficiencies
than AAV2 throughout the all regions and cell types of the CNS (Alisky et al.,
2000), (Burger et al., 2004), (Burger et al., 2005) while AAV4 will efficiently
transduce specific cell types such as astrocytes within the subventricular zone
(Davidson et al., 2000), (Weber et al., 2003), (Wu et al., 2006). Studies by Wolfe
et. al. also reveal that AAV7, 8, 9 and Rh10 expressing cDNA for lysosomal
enzyme are also capable of transducing neurons within specific regions in the
mouse brain. AAV9 and AAVRh10 appeared to have the highest transduction
efficiencies and were found to undergo vector genome transport through axonal
transport pathways (Cearley and Wolfe, 2006).
19

Despite the rapidly growing body of knowledge in the field of AAV vector
serology there is still much to be done. In addition to the 10 AAV serotypes that
have been found over 100 AAV variants have also been discovered and with the
technological advances in engineering hybrid vectors, including mosaic AAVs,
chimeric AAVs, absorbtion modifications and transcapsidation AAV vectors
appear to have a promising future in the field of gene therapy.
(AAV serotypes 6-11 are not currently commercially available).

ENHANCING DISTRIBUTION OF GENE PRODUCT
AAV vectors are a novel mean by which transgenes can be delivered to
potentially treat several types of degenerative brain diseases. Unfortunately, one
of the major disadvantages of a single intracranial injection into the brain
parenchyma using simple diffusion does not allow for efficient uptake of the
transgene or significant distribution of the AAV macromolecules to significantly
large areas of the affected regions within the brain. Convection enhanced
delivery (CED), first described by Bobo et al in 1994, is a method of delivering
clinically relevant volumes of therapeutic agents to significantly larger areas of
the brain in a direct intracranial injection procedure in comparison to simple
diffusion methods (Bobo et al., 1994). The CED technique is designed to utilize
the phenomenon of bulk flow and positive pressure to distribute macromolecules
to a large area within solid tissue. The CED technique was originally proposed
by scientists in the early 1990s as a method of delivering drugs directly to the
parenchyma that would not normally cross the blood brain barrier and that
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consisted of large macromolcules too large to diffuse throughout the tissue
(Raghavan et al., 2006). Due to the lack of approved drugs that can be directly
intracranially administered to the brain and the difficulty in predicting methods
that ensure delivery of the therapeutic agent to its target site in spite of its use in
clinical trails CED remains an experimental procedure and research of CED
delivery devices is under current investigation by several researchers
(Bankiewicz et al., 2000), (Raghavan et al., 2006).
This CED method has been investigated in gene therapy studies as a way
to increase the distribution of AAV vectors in the brain. Studies conducted by
Bankiewicz et. al. in 2000 revealed that CED can significantly increase in gene
transfer and distribution of AAV expressing AADC in the striatum of MPTPtreated monkeys. The AAV vector was found to be safely distributed throughout
the entire region of the striatum compared to the simple injection method where
the distribution was severely limited (Bankiewicz et al., 2000). Similar results
were replicated in the rat brain by Cunningham et. al. in 2000 with AAV2
expressing thymidine kinase (TK) where the CED method showed robust gene
transfer and increased distribution area within the putamen. CED injections in
the striatum were found distributed the AAV-TK throughout the striatum after a
single injection into this region and TK immunoreactive cells were also found
outside the striatum, in the globus pallidus, subthalamic nucleus, thalamus, and
substantia nigra (Hadaczek et al., 2006).
One of the mechanistic limitations of the CED method as well as the
simple injection method is the reflux of the injected material from the injection
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hole upon the removal of the cannula. In 2005 Krauze et. al. developed a reflux
free step cannula design which effectively eliminates reflux by placing silicone
coated tubing within the cannula creating a step that prevents the backflow of
fluid (Krauze et al., 2005b), (Krauze et al., 2005a). The optimization of more
efficient cannula designs coupled with the encouraging results from studies
showing enhanced gene transfer and distribution emphasizes the therapeutic
potential of the CED method in helping overcome some of the mechanical
disadvantages of gene delivery in regards to gene therapy (Krauze et al., 2005a).
The use of osmotic agents such as mannitol is an addition method that
can be used to increase the area of distribution of macromolecules throughout
the CNS. Mannitol is a blood brain barrier interruptive reagent and is also known
to temporarily increase vascular pressure subsequently reducing intracranial
pressure. High concentrations of mannitol intravenously infused are currently
used in patients with traumatic brain disease to reduce intracranial pressure.
This osmotic agent pulls fluid from the CNS by increasing vascular osmotic
pressure. Several studies have also shown that with intra-arterial infusion of
mannitol the blood brain barrier can be opened to enhance the distribution of
chemotherapeutics throughout the CNS in both rats and humans (Nilaver et al.,
1995), (Rapoport, 2001), (Fu et al., 2003).
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ABSTRACT
Reduction of Aβ deposition is a major therapeutic strategy in Alzheimer's
disease (AD). The concentration of Aβ in the brain is modulated, not only by Aβ
production, but also by its degradation. One protease involved in the
degradation of Aβ peptides is endothelin converting enzyme (ECE). In the
current study, we investigated the effects of an intracranial administration of a
recombinant adeno-associated viral vector (rAAV) containing the ECE-1
synthetic gene on amyloid deposition in amyloid precursor protein (APP) plus
presenilin-1 (PS1) transgenic mice. The recombinant AAV vector was injected
unilaterally into the right anterior cortex and hippocampus of six-month-old mice
while control mice received an AAV vector expressing GFP.
Immunohistochemistry for the haemagglutinin tag appended to ECE revealed
strong expression in areas surrounding the injection sites but minimal expression
in the contralateral regions. Immunohistochemistry for Aß decreased in the
anterior cortex and hippocampus of mice receiving ECE synthetic gene. Further,
decreases in Congo red positive deposits were also observed in both regions.
These results indicate that increasing the expression of β-amyloid degrading
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enzymes through gene therapy is a promising therapeutic avenue through which
to treat AD.

Key Words: Alzheimer’s disease; Beta Amyloid, Gene Therapy, Viral Vector,
Amyloid Degrading Enzyme, Zinc Metalloprotease.

INTRODUCTION
AD is the most common form of senile dementia (a group of conditions
that gradually destroy brain cells leading to progressive decline in mental
capacity) affecting approximately 4.5 million individuals in the United States. The
molecular mechanisms underlying AD have been extensively investigated (Hardy
and Selkoe, 2002). Although the mechanism by which neuritic plaques and
neurofibrillary tangles can eventually lead to neuron loss is debated, it has been
repeatedly demonstrated that reducing amyloid deposits in the brain can
significantly improve cognitive deficits in amyloid depositing transgenic mice
(Janus et al., 2000),(Morgan et al., 2000),(Westerman et al., 2002),(Wilcock et
al., 2006). Consequently, elucidating novel methods of decreasing or preventing
amyloid accumulation has been a primary focus in the treatment of AD.
In recent years several endogenous proteases have been found which
degrade Aβ in the brain and other tissues both in vivo and in vitro. These zinc
metalloproteases, include neprilysin (NEP), insulin degrading enzyme (IDE;
insulysin), and endothelin converting enzymes (ECE-1 and ECE-2). Other
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proteases that appear to play a role in Aß metabolism include matrix
metalloproteinase-9 (Yan et al., 2006), cathepsin B (Mueller-Steiner et al., 2006)
and plasmin (Turner et al., 2004). The overall accumulation of Aβ in the brain is
attributed to an imbalance between its production and degradation/clearance.
Down-regulation of these degrading enzymes within the brain during aging could
potentially contribute to Aβ accumulation eventually leading to development of
AD (Caccamo et al., 2005),(Yasojima et al., 2001).
Several current studies have implicated ECE as an important enzyme in
the degradation of Aβ and preventing its accumulation (Eckman and Eckman,
2005). ECE is a membrane-bound metalloprotease with an N-terminal cytosolic
domain and an extracellular catalytic domain. ECE-1 is expressed in endothelial
cells in all organs as well as other cell types including neurons, glia and
neuroendocrine cells. Two different genes encoding for ECE-1 and ECE-2 have
been identified, however ECE-1 is predominately expressed. ECE was
discovered for its ability to catalyze the conversion of big endothelin into
vasoactive endothelins (Shimada et al., 1996), (Eckman et al., 2003), (Leissring
et al., 2002), (Muller et al., 2003),(Hunter and Turner, 2006). ECE-1 has now
been reported to hydrolyse other biologically active peptides including bradykinin,
neurotensin and substance P. In humans, ECE-1 exists as four different
isoforms including ECE-1a, ECE-1b, ECE-1c,and ECE-1d (Muller et al., 2003),
(Hunter and Turner, 2006), (Turner et al., 2004), (Jackson et al., 2006).
Expression patterns have shown that these isoforms have distinct subcellular
localizations with slight variations depending on the species and cell type (Muller
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et al., 2003), (Hunter and Turner, 2006). To date, there are no significant
differences reported in the catalytic properties of the different isoforms (Turner et
al., 2004). The Aβ degrading capability of ECE was discovered when Eckman
(Eckman and Eckman, 2005) observed that the ECE inhibitor, phosphoramidon,
caused a rapid accumulation of Aβ in a cell line expressing ECE but not in cells
lacking ECE expression. Subsequent studies revealed that overexpression of
ECE in cell lines reduced Aβ accumulation by approximately 90%. In vivo data
from ECE (+/-) transgenic mice, which show 25% reductions in ECE-1 activity,
also show significant increases in both Aβ40 and Aβ42 levels in the brain
(Eckman and Eckman, 2005). Moreover, intraventricular injections of
phosphoramidon, increase Aß in wild type and APP transgenic mice (Eckman et
al., 2006). These studies indicate a clear correlation between ECE-1 activity and
Aβ load in the brain.
In the present study we investigated the effects of upregulating the ECE-1
enzyme by using a rAAV vector, serotype 5, on Aβ load in the brain. rAAV
vectors are desirable candidates for gene therapy in the central nervous system
because AAV is a nonpathogenic virus; it has low immunogenicity and it is
deficient for replication due to the removal of all the viral encoded genes.
Further, rAAV vectors have been shown to be very efficient in infecting neuronal
cells and maintaining long term expression (Burger et al., 2005), (Mandel et al.,
2006). We observed a significant reduction in the levels of Aβ in the mice
injected with the ECE virus which shows that this method may offer a promising
therapeutic avenue through which to treat AD.
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RESULTS
The ECE-1 synthetic gene within the rAAV was under the control of the
hybrid chicken β-actin cytomegalovirus (CBA) promoter and was tagged with
haemagglutinin (HA) peptide sequence for detection within the brain and
discrimination from endogenous ECE. Prior to virus production the rAAV vector
was tested in HEK 293 cells to evaluate the expression cassette. Cell lysate and
conditioned media from transfected and untransfected cells were examined by
Western blot analysis to determine ECE expression. Untransfected cell lysate
and media were negative for ECE-HA protein expression. ECE-HA protein
expression was only detected in the cell lyate fraction and not the media (Fig 1b).
The rAAV ECE-HA vector was tested for enzyme activity in vivo.
Nontransgenic mice (n=12) aged 9 months were injected bilaterally into the right
and left hippocampus. Group one received the rAAV-ECE-HA treatment and the
second group served as the control group and received no treatment (n=6 per
group). All injections were performed as described in Methods with each site of
injection receiving a total volume of 2 μl of the vector at a concentration of 1 x
1012 vg/ml. Six weeks post injection the animals were sacrificed and frozen
hippocampal tissue from the animals was homogenized and separated into
membrane and soluble fractions by centrifugation. The ECE specific activity was
determined as the nmole of MOCA/ min/µg protein. Within the homogenate and
in the membrane fractions of the homogenized tissue, animals receiving the ECE
treatment had significantly higher ECE-like specific activity than the control
animals (Fig 2). Error bars indicate ± standard error of the mean value from
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triplicates for each sample (specific activity/min/μg protein) for each treatment
group (n=6 per group).
rAAV was initially injected unilaterally into the right hippocampus and right
anterior cortical regions of six month old APP + PS1 mice. Each injection site
received 2μl volume and a concentration of 1 x 1012 vg/ml of material at a flow
rate of 0.5 μl/min. The expression of ECE was evaluated six weeks following
treatment. Immunostaining of the tissue with an anti-HA antibody revealed ECEHA expression in most animals. The expression patterns for the ECE protein
were confined to the areas surrounding the injection site. ECE-HA was detected
in CA4 neurons in the hilus and CA3 neurons of the hippocampus pyramidal cell
layer. In the dentate molecular layer, a number of round cells, possibly,
oligodendrocytes or astrocytes also expressed the label (Fig. 3b). In animals
receiving the rAAV-GFP control vector there was no positive HA staining in the
hippocampus, but the GFP expression pattern was comparable to that of the
ECE vector (Fig 4). In animals receiving the rAAV expressing ECE-HA there
were low levels of positive staining in the contra-lateral dentate gyrus (Fig. 3a).
When the cortical regions were analyzed for expression, there was a large
amount of ECE-HA expression which was also detected over a larger area of the
cortex. ECE positive expression was concentrated in the anterior cortex (Fig 3c),
but was observed also in the striatum, corpus callosum and septum along the
midline (Fig 3d) in the ipsilateral and contralateral hemispheres. In animals
receiving rAAV-GFP, GFP was detected in a similar expression patterns as ECEHA. GFP positive cells were limited to the areas immediately surrounding the
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injection site in both the cortex and the hippocampus and no GFP positive cells
were seen in the contralateral hemisphere (Fig. 4b, 4d and 4f respectively). This
data suggests that the rAAV vector serotype 5 is effective at transducing
neuronal cell types in vivo and expressing significant amounts of recombinant
ECE-1.
Our next goal was to evaluate the effects of a single intracranial
administration of the rAAV-ECE-HA vector in APP + PS1 transgenic mice, to
determine the effect of over expression of the ECE protein on amyloid deposition.
rAAV was injected unilaterally into the right anterior cortex and hippocampus of
six month old mice while the left untreated hemisphere. The control group was
treated with rAAV containing GFP. Total Aβ load was ascertained six weeks
after intracranial injections by immunohistochemical methods using a polyclonal
anti-Aβ antiserum which primarily recognizes the N-terminal domain of Aß, and
thus labels both Aβ1-40 and Aβ1-42 (gift of Gottschall, PE, Univ of Arkansas). The
regional Aβ distribution and density in APP + PS1 transgenic mice were similar to
those reported by Gordon et al. (Gordon et al., 2002). Immunohistochemistry
revealed darkly stained compact plaques and more lightly stained diffuse plaque
deposits in the APP + PS1 animal tissue. Plaque deposition was distributed
throughout the cortical regions as well as in the hippocampus (although most
concentrated in the molecular layers of the dentate gyrus and the CA1 region,
surrounding the hippocampal fissure). Animals injected with the control rAAVGFP showed Aβ immunohistochemical staining patterns throughout the cortex
and hippocampus comparable to those of untreated APP + PS1 transgenic mice
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of the same age (Fig 5a and 5b). A notable decrease in the amount of
hippocampal Aβ staining was observed in animals injected with the rAAV
expressing ECE-HA six weeks after the time of injection when compared to
animals injected with the control rAAV-GFP vector (Fig. 5c, 5d). The reductions
in Aβ deposition were limited to the areas surrounding the cortical and
hippocampal injection sites. ANOVA analysis of total Aß was significantly
decreased by 50% in mice receiving rAAV-ECE-HA in both the hippocampus and
the anterior cortex (Fig. 5e).
Congophilic plaque load was also analyzed following intracranial injections
of rAAV-ECE-HA vector. The area of congophilic labeling was substantially less
than Aβ immunochemistry, staining only compacted fibrillar Aβ deposits, as
expected (Gordon et al., 2002). Figures 6c and 6d indicate that the positive
congophilic staining for the mice receiving the ECE vector was visibly less,
especially in the hippocampus, compared to the control animals. The reductions
in congophilic deposition were limited to the site of injection in cortex and
hippocampus. Quantification of the Congo red staining by ANOVA analysis
revealed that animals receiving the rAAV expressing ECE-HA showed significant
reductions in the hippocampus (62%) as well as significant reductions in the
anterior cortex (46%; Fig 6e).

DISCUSSION
There have been several gene therapy approaches examined for the
treatment of Alzheimer’s disease. Initial experiments were based on the
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observation that application of neuronal growth factors mediated neuroprotection
and reduced the loss of cholinergic neurons in experimental lesion models (Hefti
and Weiner, 1986);(Williams et al., 1986). Therefore, NGF (nerve growth factor)
genes have been delivered to the brain using recombinant viral vectors, such as
AAV and lentivirus, or delivered via an ex vivo approach, with transformed
fibroblasts or neuronal stem cells (Tuszynski, 2007),(Cenciarelli et al., 2006).
These studies have shown rescue of cholinergic neurons and are being further
examined as a potential therapy. However, it is unlikely that NGF would cure AD
because the widespread neuronal loss that occurs in the later stages of the
disease would not be compensated by the early rescue of cholinergic neurons.
NGF rescue of neurons is currently being examined in clinical trials because it
offers a substantial decline in the rate of neuronal loss and could slow the
progression of symptoms of Alzheimer’s. Other growth factors that are also of
potential interest in AD include brain-derived neurotrophic factor and
neurotrophin-4/5 to address the neuronal loss in the cortex and hippocampus.
A second approach to treat Alzheimer’s pathology involves the reduction
of Aβ through immunization. It was observed that immunization against Aβ would
result in a significant reduction in Aβ deposits and improve learning and memory
deficits (Morgan et al., 2000),(Janus et al., 2000). Peripheral passive
immunization against Aβ with antibody injections has been successful in mouse
models and more recently viral vectors have been used as a gene therapy
approach to deliver Aβ antibodies (Fukuchi et al., 2006), (Levites et al., 2006).
This approach has demonstrated some promising reduction (25-50%) in the
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levels of Aβ deposition. AAV vectors have also been used as an Aβ vaccine,
with the over expression of Abeta42. This method has shown reduction in Aβ
deposition and some reduction in cognitive impairment in Alzheimer Tg mice
(Mouri et al., 2007), (Hara et al., 2004), (Zhang et al., 2003).
It has been demonstrated that the apolipoprotein E (apoE) gene is a major
risk factor for late-onset AD with the ApoE2 allele decreasing and the ApoE4
allele increasing the morbid risk for developing AD. Therefore to develop a gene
therapy approach to Alzheimer’s, Dodart et al. (2005) over expressed ApoE2
using a lentiviral vector. The authors observed a dramatically reduced
hippocampal Aβ burden in Tg mice. It is as yet unclear how ApoE2 is reducing
the Aβ but it may be increasing the Aβ clearance (Dodart et al., 2005).
A final gene therapy approach for the treatment of Alzheimer’s has been
the over expression of Aβ degrading enzymes such as neprilysin. Either using a
direct transduction of neurons using a viral vector or an ex vivo approach with
transformed fibroblasts, the increase in NEP expression has been shown to
significantly reduce the overall Aβ load on Alzheimer Tg mice (Marr et al., 2003),
(Iwata et al., 2004),(Hong et al., 2006), (Hemming et al., 2007). In this report we
are examining another Aβ degrading enzyme, ECE, for its ability to reduce the
Aβ load on Alzheimer APP + PS1 mice using rAAV for increased neuronal
expression of ECE.
Recombinant AAV has become widely used for the transduction of
neuronal cells. AAV is nonpathogenic, has low immunogenicity, lacks all viral
genes and is capable of long term expression in neurons. This makes rAAV a
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good candidate for the use as a gene therapy vector for neurological disorders
(Mandel et al., 2006), (Burger et al., 2005). Further, rAAV is currently being
examined in a number of neurological clinical trials (Mandel and Burger, 2004).
Here we are using rAAV for the over expression of the ECE protease which had
been previously shown to cleave Aβ peptide (Eckman and Eckman, 2005). We
believed that the over expression of ECE using rAAV would enable the clearance
of Aβ deposition within the mouse brain and ameliorate the pathogenesis of
Alzheimer’s.
rAAV serotype-5 ECE-HA vector was injected unilaterally into the mouse
hippocampus and anterior cortex. Examination of the expression profile of the
expressed ECE has shown that the rAAV of ECE can transduce several different
neuronal cell types within the mouse brain, and possible other cell types in the
dentate molecular layer. This is consistent with the previously published
serological specificity of this vector (Alisky et al., 2000), (Burger et al.,
2004),(Choi et al., 2005). The expression profile of ECE was similar to that
observed with our rAAV5 vector expressing GFP.
No noticeable toxic effects were seen in mice receiving the ECE-HA
vector compared to control animals. No neuron loss or gross morphometric
changes were observed in fixed brain tissue nor were there any signs of general
toxicity as evidence by abnormal behavior in the mice. Only one animal died
throughout the course of the study but this did not appear to be a result of toxicity
from the over expression of the ECE protein. All animals were weighed before
treatment and immediately before sacrifice and no significant changes in weight
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were noted indicating that up regulation of ECE does not appear to have adverse
effects or cause general toxicity in the mouse model, yet further investigation
must be done to confirm its safety profile. ECE has many endogenous peptides
including opioid peptides, tachykinin, atrial naturetic peptides, and other small
regulatory vasoactive peptides. It is uncertain whether interactions between
other potential substrates in the brain may limit the ability of ECE to degrade Aβ
or cause potential problems by reducing the levels of these other peptides.
Previous studies have revealed that in the AD brain as well as in the animal
model of AD, ECE (in addition to other Aβ degrading enzymes) are down
regulated specifically in areas that are prone to plaque formation (Iwata et al.,
2002), (Yono et al., 2004). Therefore, up-regulation of ECE to restore normal
levels of this endogenous protease should have minimal adverse effects. In
addition, ECE has been shown to have higher affinity for larger peptides such as
bradykinin, substance P, and neurotensin, hydrolyzing them at amino acid
hydrophobic residues (Johnson et al., 1999), (Lo et al., 1999). Monitoring
changes in these peptides between control and treatment groups may help
identify other potential toxic effects resulting from increases in ECE that could
occur in this model.
Our results from the over expression of ECE suggest that the upregulation of ECE through rAAV vectors can provide a viable method to decrease
total amyloid deposition in the brain. The activity level determined using an ECE
specific assay demonstrated that we achieved a several fold fold increase in ECE
activity in homogenates, most of which was membrane associated. This increase
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in ECE activity was able to significantly reduce total Aβ deposition in the anterior
cortex and hippocampal sites of injection (Fig. 5). Similarly, when Congo red
stained compacted deposits were measured; the ECE-HA vector significantly
reduced staining (Fig. 6). We were able to achieve a 50% reduction in the total
Aβ present in the cortex and hippocampal regions. Similarly, we reduced the
congophilic compact plaque load to ~50% of that of the controls. We have yet to
determine if this reduction in the Aβ levels in the mice with the ECE will lead to
significant improvement in behavioral tests such as the Morris water maze. We
are currently testing more injections of ECE to see if we can create a significant
reduction of whole brain Aβ levels and ameliorate the memory deficits that are
observed in the APP + PS1 mice. Our data are consistent with reports that ECE
can degrade Aß in vitro, and that partial knockdown of the ECE gene leads to
more rapid accumulation of Aß (Eckman et al., 2001), (Eckman et al., 2003).
The present work adds to the evidence that ECE plays an important role in Aß
deposition by demonstrating that local over expression of the enzyme activity can
dramatically reduce the deposition of amyloid in the brains of APP + PS1
transgenic mice. Thus, regulation of ECE may be used as therapeutic target for
the treatment of Alzheimer's disease.

MATERIALS AND METHODS
Generation of ECE Constructs and rAAV Production
The ECE-1 coding sequence (GI:4503442) was cloned using polymerase chain
reaction (PCR) from a GenePool cDNA library obtained from Invitrogen. The
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primers used for the full length ECE were
GAGGAATTCACCGGTCCACCATGCGGGGCGTGTGGCCGCCCCCGGTGTC
and GAGATCGATTACCAGACTTCACACTTGTGAGGCGG. The PCR product
was cloned into pBluescript and sequenced to confirm sequence identity. The
ECE was then cloned into the vector called pTR5-MCS at the Eco RI and Cla I
cloning sites. This vector contains the AAV terminal repeats for AAV virus
production and the CBA promoter for ECE mRNA transcription. A Hemagglutinin
(HA) tag was added to the C-terminus of ECE synthetic gene using the following
oligonucleotide
GTGTGAAGTCTGGATGGCTTCTAGCTATCTTATGACGTGCCTGACTATGCCA
TGTAA and its complement. The recombinant viruses were generated and
purified using the method of Zolotukhin et al. (2002). Infectious rAAV particles
are expressed as vector genomes (v/g)/mL. Vector genomes were quantitated
using the dot plot protocol, with a probe for the CBA promoter, as described by
(Zolotukhin et al., 2002).
Western Blot Analysis
Protein samples were boiled in Lamaelli sample buffer prior to loading on a 10%
polyacrylamide gel. The proteins on the gel were transferred to Millipore
Nitrocellulose membrane and probed with anti-HA antibody (Santa Cruz) and
antimouse-HRP conjugate (Amersham). Millipore Immobilon detection reagent
was used to visualize bands.
Transgenic Mice
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APP + PS1 mice (Holcomb et al., 1998) were acquired from the breeding
colonies at the University of South Florida. Multiple mice were housed together
whenever possible until the time of the experiment. Mice were then singlyhoused 1 week before surgical procedures until the time of sacrifice. Study
animals were given water and food ad libitum and maintained on a twelve hour
light/dark cycle and standard vivarium conditions. Two cohorts of mice were
used, the first cohort consisted of APP + PS1 mice aged 6 months (n =16) and
the second cohort consisted of nontransgenic mice aged 9 months (n =12).
Animals in each cohort were assigned to two groups. Group one received a
control vector expressing GFP (first cohort n=8; second cohort n=6). Group two
received AAV vector expressing the membrane bound endothelin converting
enzyme sequence (first cohort n =8; second cohort n=6). All groups were
sacrificed after six weeks post intracranial injection.
Surgical Procedure
Immediately before surgery mice were weighed then anesthetized using
isoflurane. Surgery was performed using a stereotaxic apparatus. The cranium
was exposed using an incision through the skin along the median sagittal plane,
and two holes were drilled through the cranium over the right cortex injection site
and the right hippocampal injection site. Previously determined coordinates for
burr holes, taken from bregma were as follows; frontal cortex, anteroposterior, 1.5 mm; lateral, -2.0 mm, vertical, 3.0 mm, hippocampus, anteroposterior, 2.7mm; lateral -2.5 mm, vertical, 3.0 mm. Burr holes were drilled using a dental
drill bit (SSW HP-3, SSWhite Burs Inc., Lakewood, NJ). Injections of 2 μl of total
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volume of each of the viral vectors in sterile PBS at a concentration of 1 X 1012
vg/ml were dispensed into hippocampus and cortex over a period of 4 min using
a 26 gauge needle attached to a 10 μl syringe (Hamilton Co., Reno, NV). The
incision was then cleaned and closed with surgical staples. Animals were
recovered within 10 minutes and housed singly until time of sacrifice.
Immunohistochemistry
Six weeks post surgery, mice were weighed, overdosed with pentobarbital
(200 mg/kg;) and perfused with 25 ml of 0.9% normal saline solution then 50 ml
of freshly prepared 4% paraformaldehyde. Brains were collected from the
animals immediately following perfusion and immersion fixed in 4%
paraformaldehyde for 24 h. Mouse brains were cryoprotected in successive
incubations in 10%, 20%, 30% solutions of sucrose; 24 h in each solution.
Subsequently, brains were frozen on a cold stage and sectioned in the horizontal
plane (25 μm thickness) on a sliding microtome and stored in Dulbecco’s
phosphate buffered saline (DPBS) with 0.2% sodium azide solution at 4 ˚C.
Six sections 100 μm apart spanning the site of injection were chosen and
free-floating immunochemical and histological analysis was performed to
determine ECE expression using anti-HA biotinylated rabbit polyclonal antibody
at a concentration of 1:1000 (Roche, Indianapolis, IN), total Aβ using a rabbit
primary anti-Aß serum at a concentration 1:10,000 and a secondary anti-rabbit
antibody (Serotec, Raleigh, NC). Another series of sections were mounted on
slides and stained with Congo red to assess compact congophilic positive plaque
load. Immunohistochemical procedural methods are analogous to those
39

described by Gordon et al. 2002, for each marker. Six to eight sections from
each animal were placed in multisample staining tray and endogenous
peroxidase was blocked (10% methanol, 3% H202, in PBS). Tissue samples were
permeabilized (with 0.2% lysine, 1% Triton X-100 in PBS solution), and
incubated overnight in appropriate primary antibody. Sections were washed in
PBS then incubated in corresponding biotinylated secondary antibody (Vector
Laboratories, Burlingame, CA). The tissue was again washed after a 2 h
incubation period and then incubated with Vectastin® Elite® ABC kit (Vector
Laboratories, Burlingame, CA) for enzyme conjugation. Finally, sections were
stained using 0.05% diaminobenzidine and 0.3% H202. For anti-HA 0.5%
nickelous ammonium sulfate was added for color enhancement. Tissue sections
were then mounted onto slides, dehydrated, and cover slipped. Each
immunochemical assay omitted some sections from primary antibody incubation
period to evaluate nonspecific reaction of the secondary antibody.
Congo red histology was performed using sections that were premounted
on slides then air dried for a minimum of 24 hours. The sections were rehydrated
for 30 seconds before beginning staining protocol. For Congo red, hydrated
sections were incubated in an freshly prepared alkaline alcoholic saturated
sodium chloride solution (2.5mM NaOH in 80% alcohol) for 20 min, then
incubated in 0.2% congo red in alkaline alcoholic saturated sodium chloride
solution for 30 minutes. Slides with sections were rinsed through three changes
of 100% ethanol, and cleared through three changes of xylene and finally
coverslipped with DPX. Histological sections from control animals treated with
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rAAV expressing GFP were mounted on slides and dehydrated through a series
of increasing concentrations of ethanol. The mounted sections were then
cleared in three changes of histoclear and coverslipped with DPX.
Stained sections were imaged using an Evolution MP digital camera
mounted on an Olympus BX51 microscope at 100X final magnification (10 X
objective). Six horizontal brain sections (100µm apart; every 4th section) were
taken from each animal and four nonoverlapping images near the site of injection
from each of these sections were captured (24 measurements per mouse). All
images were taken from the same location in all animals. Quantification of
positive staining product surrounding and including the injection sites in the right
anterior cortex and the right hippocampus and the corresponding regions in the
left hemisphere were determined using Image-Pro® Plus (Media Cybernetics®,
Silver Springs, MD). Quantifications of the right regions, ispilateral to the
injection site, were calculated and ANOVA statistical analysis was performed
using StatView® version 5.0.1 (SAS Institute, Raleigh, NC).
Enzyme Activity Assay
ECE activity was characterized and adapted from a previous fluorometric
assay method (Johnson and Ahn, 2000) for a 96 well plate format with slight
modifications. Six weeks post injection brain tissue was removed then dissected
immediately following sacrifice and frozen at -80 ºC. The tissue from each
animal was rapidly thawed and homogenized with the Ultra-Turrax T8 motordriven homogenizer (IKA-Labortechnik, Germany) in solubilizing buffer
containing 20 mM Tris-HCl, pH 7.4, 250 mM sucrose immediately prior to
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assaying (Iwata et al., 2002). Samples were then centrifuged at 100,000 x g, 4
ºC for 45 min using an Avanti J-30I Centrifuge (Beckman Instruments, Inc., Palo
Alto, CA) to obtain a soluble fraction and a membrane fraction. The membrane
fraction was resuspended in buffer containing 20 mM Tris-HCl, 250 mM sucrose,
pH 7.4. Protein concentration was determined from the homogenate, membrane
fraction and soluble fractions from each sample using a general BCA assay
(Pierce). Aliquots of the cell lysate (5 μg) were incubated with 10 μM (final) of
the fluorogenic peptide (MOCA- Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)OH), (R&D Systems) in MES buffer (sodium phosphate pH 6.8 containing 0.1M
NaCl). MOCA- Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-OH is efficiently
quenched by resonance energy transfer to the dinitrophenyl group and the
continuous fluorescent intensity is increased upon internal cleavage of the
peptide (ECE-1 cleavage between the Ala-Phe bond). The increased
fluorescence produced from cleavage of the substrate was measured using a
Molecular Devices fMax spectrofluorometer plate reader (MDS Analytical
Technologies, Sunnyvale, CA) with a 60 min time point to normalize independent
experiments. A standard curve of (7-methoxycoumarin-4-yl) acetyl (MOCA) was
analyzed along with each assay and used to convert the relative fluorescence
units (RFU) to the moles of MOCA produced by the respective cell lysates.
Parallel assay reactions of all samples (in triplicate) were carried out in the
presence of an ECE specific inhibitor (SM19712, Sigma Aldrich) at a
concentration of 20 μM (Umekawa et al., 2000), (Matsumura et al., 2000). ECE
specific activity was considered to be the difference in RFU between samples
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including SM19712 from the total activity samples (no SM19712). Values were
calculated and expressed as nanomoles MCA/min/μg protein.
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FIGURE 1: (A) DIAGRAM OF ECE CONSTRUCT AND (B) WESTERN
ANALYSIS OF ECE EXPRESSION IN HEK 293 CELLS. (A) Diagrammatic
representation of the rAAV construct expressing the ECE synthetic gene under
the control of the chicken β-actin (CBA) promoter. (B) Western analysis of ECE
expressed in 293 cells using an anti-HA antibody. Lane 1, 293 cell lysate; lane 2,
ECE transfected cell lysate, lane 3, conditioned media from untransfected cells,
lane 4 media from cells transfected with ECE.
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FIGURE 2: ECE ENZYMATIC ACTIVITY OBTAINED FROM MOUSE
HIPPOCAMPAL REGIONS AFTER INJECTION OF rAAV VIRUS
EXPRESSING ECE PROTEIN. ECE-like specific activity is higher in the
membrane fraction and homogenate of the hippocampal tissue in the ECE
treatment group compared to the control group. The star (*) indicates
significance with a p-value < 0.05. Error bars indicate ± standard error of the
mean value from triplicates for each sample (specific activity/min/μg protein) for
each treatment group (n=6 per group).
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FIGURE 3: EXAMINATION OF ECE EXPRESSION USING ANTI-HA
IMMUNOREACTIVITY IN THE HIPPOCAMPUS AND ANTERIOR CORTEX.
Panel A shows slight ECE expression in granule cells of the dentate gyrus of the
left contra lateral hippocampus following intracranial administration of ECE into
the right hippocampus. Panel B shows strong ECE expression detected at the
site of vector injection. Panel C shows strong ECE expression in the anterior
cortex. Panel D shows slight ECE expression along the midline and some
expression in the lateral septum of left (contra lateral) side following intracranial
administration of ECE into the right anterior cortex. fi = fimbtria; LS = lateral
septum; CC = corpus callosum; dg = dentate gyrus; CA1 = Cajal Area 1; CA3 =
Cajal area 3; Magnification = 40X and Scale bar = 120 μm
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FIGURE 4: ECE AND GFP EXPRESSION PROFILES IN MICE BRAINS
FOLLOWING rAAV ADMINISTRATION. Panels A shows strong ECE
expression in the right anterior cortex following intracranial administration of ECE
vector. Panel B shows GFP expression in the anterior cortex following
intracranial administration of control GFP vector. Panel C shows ECE
expression in pyramidal cells in CA2 region of the right hippocampus. Panel D
shows GFP expression in the CA3 region of the hippocampus. Panel E shows
slight ECE expression in CA4 neurons of the dentate gyrus of the left contra
lateral hippocampus. Panel F shows no positive expression in the left uninjected
hippocampus following intracranial injection of GFP vector into the right
hippocampus. Scale bar = 50μm (panels A, C, E). Scale bar = 25 μm (panels B,
D, F).
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FIGURE 5: TOTAL AMYLOID LOAD IS REDUCED FOLLOWING
INTRACRANIAL ADMINISTRATION OF rAAV-ECE-HA VECTOR. Panels A
and B show Aβ immunostaining in the right cortex and hippocampus respectively
of animals receiving intracranial injection of control vector, GFP. Panels C and D
show Aβ immunostaining in right cortex and hippocampal regions respectively of
mice receiving intracranial injection of ECE. Scale bar = 120μm. Panel G shows
the percent area of positive staining, normalized to the control, for both cortex
(left) and hippocampus (right) after AAV-ECE injection. The asterisk (*) indicates
significant reduction compared with control values with p-values < 0.05.
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FIGURE 6: CONGOPHILIC COMPACT PLAQUE LOAD IS REDUCED
FOLLOWING INTRACRANIAL ADMINISTRATION OF ECE-HA rAAV
VECTOR. Panels A and B show total congophilic staining in the right cortex and
hippocampus respectively of animals receiving intracranial injection of control
vector, GFP. Panels C and D show congophilic positive staining in right cortex
and hippocampal regions respectively of mice receiving intracranial injection of
ECE. Magnification = 40X, scale bar = 120μm. Panel E shows the percent area
of positive staining, normalized to the control, for the cortical (right) and
hippocampal (left) injected regions. The star (*) indicates significance with a pvalue < 0.05.
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ABSTRACT
The accumulation of β-amyloid (Aß) peptides in the brain has been
recognized as an instigating factor in Alzheimer’s disease (AD) pathology.
Recently, it has been argued that clearance of Aβ is partially dependent upon
several endogenous zinc metalloproteases. Gene therapy using adenoassociated viral (AAV) vectors are an effective means of delivering transgenes
encoding for these specific proteases which include neprilysin, endothelin
converting enzyme, and insulin degrading enzyme to regions in the brain affected
by AD pathology. In this study the convection enhanced delivery method using
the step-design cannula (Bankiewicz, 2005) was used to deliver recombinant
AAV (rAAV) vectors expressing either a native, membrane bound form of human
neprilysin gene (NEP-n) or an engineered, secreted form of the neprilysin gene
(NEP-s) into the right hippocampus and right frontal cortical regions of the mouse
brain. The control group was treated with an rAAV vector expressing a mutant
neprilysin gene (NEP-m) with a single amino acid substitution in the active site
rendering it inactive. Six weeks after injection, immunohistochemistry for NEP
revealed strong expression throughout the hippocampus in animals treated with
the NEP-n and NEP-m vectors. Animals treated with the NEP-s showed
expression in a smaller portion of the hippocampus compared to the NEP-n
treated group. Immunohistochemistry for total Aß was significantly decreased in
animals receiving the NEP-n and NEP-s viral vectors when compared to control
animals in both the hippocampus and cortex. Congo red staining followed a
similar trend revealing significant decreases in the hippocampal fissure and CA1
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regions and the cortex for NEP-n and NEP-s treatment groups compared to mice
given control treatments. These data suggest that increasing the expression of
certain endogenous β-amyloid degrading enzymes through gene therapy using
the CED step cannula provides and efficient means of increasing transgene
distribution and ultimately may provide a promising therapeutic avenue through
which to treat AD.

INTRODUCTION
Alzheimer’s disease (AD) is the most common form of senile dementia
that can occur sporadically or as a result of genetic mutations in the genes
encoding presenilin 1, presenilin 2, or amyloid precursor protein (APP). These
mutations result in the overproduction of Aß peptides which ultimately lead to the
formation of extracellular amyloid plaques and intracellular neurofibrillary tangles
consisting of hyperphosphorylated tau. The AD cases with these autosomal
dominant mutations, commonly referred to as early onset AD or familial AD
(FAD) (Fidani and Goate1992), account for only 1-2% of all AD cases.
Interestingly, the more common late onset AD cases do not seem to over
produce Aβ peptide species suggesting that there is a deficit in the clearance
mechanisms which are normally involved in regulation of Aβ levels in the brain.
Therefore, the accumulation of Aβ in late onset AD is attributed to an imbalance
between its production and degradation/clearance.
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Several endogenous proteases have been shown to degrade Aβ in the
brain and other tissues both in vivo and in vitro. This family of zinc
metalloproteases, include neprilysin (NEP), insulin degrading enzyme (IDE;
insulysin), and endothelin converting enzymes (ECE-1 and ECE-2). Other
proteases that appear to play a role in Aß metabolism include matrix
metalloproteinase-9 (Yan et al., 2006) and cathepsin B (Mueller-Steiner et al.,
2006) and plasmin (Turner et al., 2002). Down-regulation of these degrading
enzymes within the brain during aging could potentially contribute to Aβ
accumulation eventually leading to development of AD pathology (Caccamo et
al., 2005); (Yasojima et al., 2001).
NEP is a membrane bound a 92-kDa glycosylated ectoenzyme whose
active site is oriented outside the cell. NEP belongs to the M13 sub family of
neutral endopeptidases, and has a range of regulatory activities as it degrades
numerous bioactive peptides (Turner et al., 2000), (Iwata et al., 2000a). Iwata et.
al. in 2000 first demonstrated the ability of NEP to degrade Aβ peptides in the
brain parenchyma and also illustrated that suppressing NEP would lead to an
increase in Aβ deposition (Iwata et al., 2000a). NEP activity decreases with age
in amyloid depositing regions, such as the cortex and hippocampus, yet
remained unchanged in areas such as the striatum (Iwata et al., 2002),
(Yasojima et al., 2001). NEP deficient mice showed a significant increase in
amyloid deposition as opposed to their wild type counterparts indicating that NEP
activity plays significantly impacts Aβ pathology (Iwata et al., 2000c), (Marr et al.,
2004).
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Recently, viral vector gene therapy has emerged as a viable approach to
the delivery of potentially therapeutic genes. Several vectors and serotypes have
been developed with improved efficiency, specificity, and safety (Thomas et al.,
2003). In the present study we investigate the effects of upregulating the NEP
enzyme by using a recombinant adeno-associated viral (rAAV) vector, serotype
5, on Aβ load in the brain using a novel convection enhanced delivery
administration technique to further increase area of distribution and potentially
increase transduction efficiency of the transgene (a limitation of viral vector gene
therapy). rAAVs are parvoviruses that require a helper virus, typically Adenovirus
or herpes simplex virus, in order to support viral replication (Berns and Parrish,
1996). rAAV vectors are desirable candidates for gene therapy in the central
nervous system because AAV is a nonpathogenic virus; it has low
immunogenicity and it is deficient for replication due to the removal of all the viral
encoded genes. Further, rAAV serotype 5 vectors are very efficient in infecting
neuronal cells and maintaining long term expression (Burger et al., 2005),
(Mandel et al., 2006). Therefore we have chosen to examine the efficacy of a
rAAV serotype 5 vector to deliver the recombinant expressed NEP cDNA. The
rAAV vectors used in this study express either a membrane bound native form of
the NEP cDNA, or a modified form of the NEP cDNA that is secreted into the
extracellular compartment. We observed a significant reduction in the levels of
Aβ in the mice injected with the NEP viruses, both the native NEP and the
secreted NEP appeared to reduce the levels of Aβ load significantly compared to
the mutated NEP in both the hippocampus and the anterior cortex.
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MATERIALS AND METHODS
Generation of NEP Gene Constructs and rAAV Production:
The NEP gene (GI:4503442) was cloned using polymerase chain reaction (PCR)
from a GenePool cDNA library obtained from Invitrogen. The primers used for the
full length NEP were
GAGGAATTCACCGGTCCACCATGCGGGGCGTGTGGCCGCCCCCGGTGTC
(contains an Eco RI and Age I restriction sites, 5' primer) and
GAGATCGATTACCAGACTTCACACTTGTGAGGCGG (contains a Cla I and Ale
I restriction sites, 3' primer). The PCR product was cloned into pBluescript and
sequenced to confirm sequence identity. The NEP was then cloned into the
vector called pTR5-MCS at the Eco RI and Cla I cloning sites. This vector
contains the AAV terminal repeats for AAV virus production and the CBA
promoter for NEP mRNA transcription. A Hemagglutinin (HA) tag was added to
the C-terminus of NEP gene at the Ale I restriction site. The following
oligonucleotides
GTGTGAAGTCTGGATGGCTTCTAGCTATCTTATGACGTGCCTGACTATGCCA
TGTAA and its compliment were annealed and ligated to the vector. Generating
the soluble truncated form of NEP (232-2313 bp): The 5' primer that was used for
this PCR was
GAGGAATTCACCGGTGCAGGACTGGTGGCCTGCTTGGGCAGC, and the 3'
primer was the same as above. The PCR product was cloned as described for
the full length NEP including the addition of a HA-tag. To add the secretion signal
sequence the following oligonucleotide and its compliment were annealed and
61

ligated at the Age I site of the construct
[CCGGTCCACCATGAAGTTATGGGATGTCGTGGCTGTCTGCCTGGTGCTGC
TCCACACCGGCGTCCG]. The sequence was confirmed to be in frame with the
NEP gene coding frame. This signal peptide sequence was derived from the
GDNF gene. The NEP-m was generated via site directed mutagenesis of the
NEP-n construct. The codon for glutamic acid 585, GAA, was changed to encode
for valine, GTA. The recombinant viruses were generated and purified using the
method of Zolotukhin et al. (2002). Infectious rAAV particles are expressed as
vector genomes (v/g)/mL. Vector genomes were quantitated using the dot plot
protocol, with a probe for the CBA promoter, as described by (Zolotukhin et al.,
2002).
Transgenic Mice
APP + PS1 mice (Holcomb et al., 1998) were acquired from the breeding
colonies at the University of South Florida. Multiple mice were housed together
whenever possible until the time of the experiment; mice were then singlyhoused 1 week before surgical procedures until the time of sacrifice. Study
animals were given water and food ad libitum and maintained on a twelve hour
light/dark cycle and standard vivarium conditions. Mice in this colony have been
interbred for the last 8 years and have had the retinal degeneration mutation
(rd1) removed by selective breeding.
In study 1, two cohorts of mice were used, the first cohort consisted of
APP + PS1 mice aged 6 months (n =32) and a second cohort 6 mo old APP +
PS1 mice (n =18) were treated at separate times. Animals in each cohort were
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assigned to one of three groups. Group one received a control vector expressing
mutated NEP (first cohort n=9; second cohort n=6). Group two received rAAV
vector expressing native neprilysin transgene (first cohort n =12; second cohort
n=6). Group three received the rAAV vector expressing the secreted neprilysin
transgene (first cohort n = 11; second cohort n=6). All groups were sacrificed
after six weeks post intracranial injection at 7.5 mo of age.
In study 2, APP + PS1 mice were 15 months of age at the time of
treatment and were assigned to one of two groups. Group 1 received the NEP-s
rAAV vector while group two received the control vector which was rAAV
expressing GFP. Mice were sacrificed at 20 mo of age.
Surgical Procedure
Study 1
Immediately before surgery mice were weighed then anesthetized using
isoflurane. Surgery was performed using a stereotaxic apparatus. The cranium
was exposed using an incision through the skin along the median sagittal plane,
and two holes were drilled through the cranium over the right anterior cortex
injection site and the right hippocampal injection site. Previously determined
coordinates for burr holes, taken from bregma were as follows; anterior cortex,
anteroposterior, 1.5mm; lateral, -2.0mm, vertical, 3.0mm, hippocampus,
anteroposterior, -2.7mm; lateral -2.5mm, vertical, 3.0mm. Burr holes were drilled
using a dental drill bit (SSW HP-3, SSWhite Burs Inc., Lakewood, NJ). Injections
of 2μl of total volume of each of the viral vectors in sterile PBS at a concentration
of 1.5 X 1011 vg/ml were dispensed into hippocampus and cortex over a period of
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2 min. using a 27 gauge step design cannula needle (see below) attached to a
10 μl syringe (Hamilton Co., Reno, NV). The incision was then cleaned and
closed with surgical staples. Animals were recovered within 10 minutes and
housed singly until time of sacrifice.
Step Design Cannula
The step design cannula was used for all intracranial surgeries. Fused
silica tubing (polymicro technologies, Pheonix, AZ) was inserted into a 27 gauge
Hamilton blunt ended needle and fixed in place with super glue (Krauze et al.,
2005). The end of the silica tubing was cut leaving 1mm of tubing protruding
from the end of the Hamilton needle.
Study 2
Immediately before surgery fifteen month old mice were weighed then
anesthetized using isoflurane. Surgery was performed in a similar manner
mentioned previously. Four holes were drilled through the cranium over the right
and left cortex injection site and the right and left hippocampal injection sites with
predetermined coordinates listed previously. NEP rAAV vectors were
administered intracranially using a 26 gauge beveled Hamiliton needle (Hamilton
Co., Reno NV). Injections of 2 μl were given over a four min period at a rate of
0.5µl/min.
Immunohistochemistry
In study 1, 6 weeks post surgery; mice were weighed, overdosed with
pentobarbital (200 mg/kg) and perfused with 25 ml of 0.9% normal saline solution
then 50 ml of freshly prepared 4% paraformaldehyde. Brains were collected from
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the animals immediately following perfusion and immersion fixed in 4%
paraformaldehyde for 24 hrs. Mouse brains were cryoprotected in successive
incubations in 10%, 20%, 30% solutions of sucrose; 24hrs in each solution.
Subsequently, brains were frozen on a cold stage and sectioned in the horizontal
plane (25 μm thickness) on a sliding microtome and stored in Dulbecco’s
phosphate buffered saline (DPBS) with 0.2% sodium azide solution at 4˚C.
Eight sections 100 μm apart spanning the site of injection were chosen
and free-floating immunochemical and histological analysis was performed to
determine transgene expression using anti-HA biotinylated rabbit polyclonal
antibody at a concentration of 1:1000 (Roche, Indianapolis, IN), total Aβ using a
rabbit primary anti-Aß serum at a concentration 1:10,000 and a secondary antirabbit antibody (Serotec, Raleigh, NC). Another series of sections were mounted
on slides and stained with Congo red to assess compact congophilic positive
plaque load. Immunohistochemical procedural methods are analogous to those
described by Gordon et al. 2002, for each marker. Six to eight sections from
each animal were placed in multisample staining tray and endogenous
peroxidase was blocked (10% methanol, 3% H202, in PBS). Tissue samples were
permeabilized (with 0.2% lysine, 1% Triton X-100 in PBS solution), and
incubated overnight in appropriate primary antibody. Sections were washed in
PBS then incubated in corresponding biotinylated secondary antibody (Vector
Laboratories, Burlingame, CA). The tissue was again washed after a 2 h
incubation period and incubated with Vectastin® Elite® ABC kit (Vector
Laboratories, Burlingame, CA) for enzyme conjugation. Finally, sections were
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stained using 0.05% diaminobenzidine and 0.3% H202. For anti-HA 0.5%
nickelous ammonium sulfate was added for color enhancement. Tissue sections
were then mounted onto slides, dehydrated, and coverslipped. Each
immunochemical assay omitted some sections from primary antibody incubation
period to evaluate nonspecific reaction of the secondary antibody.
Congo red histology was performed using sections that were premounted
on slides then air dried for a minimum of 24 hours. The sections were rehydrated
for 30 seconds before beginning the staining protocol. For Congo red, hydrated
sections were incubated in an freshly prepared alkaline alcoholic saturated
sodium chloride solution (2.5mM NaOH in 80% alcohol) for 20 min, then
incubated in 0.2% Congo red in alkaline alcoholic saturated sodium chloride
solution for 30 minutes. Slides with sections were rinsed through three changes
of 100% ethanol, and cleared through three changes of xylene and finally
coverslipped with DPX. Histological sections from control animals treated with
rAAV expressing GFP were mounted on slides and dehydrated through a series
of increasing concentrations of ethanol. The mounted sections were then
cleared in three changes of histoclear and coverslipped with DPX.
Stained sections were imaged using an Evolution MP digital camera
mounted on an Olympus BX51 microscope at 100X final magnification (10 X
objective). Eight horizontal brain sections (100µm apart; every 4th section) were
taken from each animal and four nonoverlapping images near the site of injection
from each of these sections were captured (32 measurements per mouse). All
images were taken from the same location in all animals. Quantification of
66

positive staining product surrounding and including the injection sites in the right
frontal cortex and the right hippocampus and the corresponding regions in the left
hemisphere were determined using Image-Pro® Plus (Media Cybernetics®,
Silver Springs, MD. Quantification of percent area of positive stain for cortex and
hippocampus for both right and left hemispheres was determined. Data were
analyzed using ANOVA statistical analysis followed by Fisher’s LSD test for
individual means differences as recommended by the computer software
program StatView® version 5.0.1 (SAS Institute, Raleigh, NC).
Enzyme Activity Assay
NEP activity of the three different NEP constructs was characterized and
adapted from a previous fluorometric assay method (Johnson and Ahn, 2000)
and the NEP ELISA kit (R&D Systems) for a 96 well plate format with slight
modifications. HEK 293 cells were transfected with NEP-n, NEP-m, and NEP-s
plasmids and control cells were transfected with a GFP plasmid using
lipofectamine 2000 per invitrogen protocol. Cells were harvested after 72 hrs.
and samples were centrifuged at 1,000 x g 4º C for 45 min. using Beckman J6HC Centrifuge (Beckman Instruments, Inc., Palo Alto, CA) to obtain cell media
fraction and a cell pellet containing the membrane fraction. The membrane
fraction was resuspended in M-PER mammalian protein extraction reagent buffer
(Thermo Scientific, Rockford, IL) to obtain a cell lysate. Protein concentration
was determined from the cell media and cell lysate containing the membrane
fractions from each sample using a general BCA assay (Per Pierce Protocol).
Aliquots of the cell media and membrane fractions were (100 μg) were incubated
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in NEP ELISA plate containing NEP capture antibody. The plate was washed
with PBS buffer then incubated with 20 μM (final) of the fluorogenic peptide
(MOCA- Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-OH), (R&D Systems) in
Tris-HCL buffer (sodium phosphate pH 7.4 containing 0.1M NaCl) MOCA- ArgPro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-OH is efficiently quenched by
resonance energy transfer to the dinitrophenyl group and the continuous
fluorescent intensity is increased upon internal cleavage of the peptide (NEP
cleavage between the Ala-Phe bond). The increased fluorescence produced from
cleavage of the substrate was measured using a Molecular Devices fMax
spectrofluorometer plate reader (MDS Analytical Technologies, Sunnyvale, CA)
with a 60 min time point to normalize independent experiments. A standard
curve of (7-methoxycoumarin-4-yl) acetyl (MOCA) was analyzed along with each
assay. Values were calculated and expressed as RFU/ min/ ml protein. Data
were analyzed using ANOVA statistical analysis test.

RESULTS
Three rAAV vectors expressing different versions of human NEP were
developed. cDNAs were packaged in AAV vectors to generate either the native,
membrane bound, form of the enzyme (denoted NEP-n), a secreted form of the
enzyme (denoted NEP-s) or an enzymatically-deficient mutant enzyme (denoted
NEP-m). The secreted form of the enzyme contained a signal peptide in place of
the transmembrane domain of the native enzyme to direct the enzyme's
secretion into the extracellular compartment (Fig 1). The gene sequences are
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under the control of the hybrid chicken β-actin cytomegalovirus (CBA) promoter
sequence and were tagged with haemagglutinin (HA) peptide sequence for
detection within the brain and discrimination from endogenous NEP. The control
group received the rAAV expressing NEP-m cDNA, which contains a single point
mutation in the active site, E585V, rendering the expressed enzyme inactive.
Prior to virus production the NEP constructs were tested in HEK 293 cells to
evaluate the expression cassettes and the effectiveness of the signaling peptide
in directing secretion of the NEP-s gene product. Cell lysate and conditioned
media from transfected and untransfected cells were examined by Western blot
analysis to determine NEP expression. Untransfected cell lysate and media
were negative for NEP protein expression. NEP-n and NEP-m protein expression
was only detected in the cell lysate fraction and not the media. In contrast, NEP-s
protein was detected in both the cell lysate and the media indicating that the
signaling peptide did effectively direct secretion of the NEP protein.
rAAV vectors for NEP-m, NEP-n and NEP-s were injected unilaterally into the
right hippocampus and right anterior cortical regions of six month old APP + PS1
mice. Animals received 2 μl of virus at a flow rate of 2.5 μl/min and at a
concentration of 1.5 x 1011 vg/mL. The transgene expression of NEP was
evaluated six weeks after injection. Gene expression in the mice which received
either the NEP-n or the NEP-s was compared to control animals which received
NEP-m or were untreated.
Immunostaining of the tissue with an anti-haemagglutinin (HA) antibody
revealed NEP expression in all animals for NEP-n, NEP-m and NEP-s. The gene
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expression patterns filled virtually all of the hippocampus. The staining for NEP-n
and NEP-m was greater in intensity than the staining for NEP-s. NEP-n was
detected in CA4 neurons in the hilus and CA2 and CA3 neurons of the
hippocampus pyramidal cell layer (Fig. 2A).

Some expression of NEP-n was

even noticeable in the entorhinal cortex. Interestingly, it appears that the cell
bodies in the dentate granule cell layer were not stained as intensely as the
corresponding neuropil, suggesting some dendritic localization of the transfected
protein. NEP-s was detected in cell bodies of CA4 neurons in the hilus, some
CA3 neurons as well as a few cells in the molecular layers of hippocampus.
NEP-s expression was of noticeably less intense and limited in area of
distribution compared to that of NEP-n and NEP-m expression (Fig 2C). It is
uncertain the degree to which this reflects reduced expression, or diffusion of the
soluble enzyme in vivo or during tissue processing. NEP-m staining pattern was
very similar to the pattern with NEP-n (Fig. 2B) revealing expression throughout
the hippocampus in the dentate gyrus as well as in all CA regions.
When the cortical regions were analyzed for expression, there was again
a greater amount of NEP-n and NEP-m expression than NEP-s (greater intensity
of HA staining; Fig 3). NEP-n as well as NEP-m positive expression was
concentrated in the anterior cortex (Fig 3A and B), but was observed also in the
striatum and corpus callosum and to small extent in the contralateral hemisphere.
Again, NEP-m and NEP-n expression profiles were very similar, with expression
largely confined to the neuropil and little staining of the neuronal somata. NEP-s
cortical HA staining was less intense than that of NEP-n HA staining and was
70

confined to largely to somatic areas of neurons, conceivably in vesicular
compartments in preparation for secretion (Fig. 3C). Overall, intensity of HA
immunohistochemical staining in the cortical region of the brain appeared less
intense than in the hippocampus possibly indicating a lower level of the gene
expression of NEP in this region. Hippocampal and anterior cortical regions of
uninjected animals showed no noticeable HA staining (Fig 2D and 3D).
The rAAV NEP-s, NEP-m and NEP-n vector constructs were tested for
enzyme activity in vitro using HEK 293 cells. Cells were transfected using NEPn, NEP-m and NEP-s plasmids and control cells were transfected with the GFP
plasmid. All cells were harvested 72 hrs after transfection using lipofectamine
2000. The NEP specific activity was determined as RFU/min/ml protein. HEK
293 cells transfected with NEP-n had significantly higher NEP specific activity in
the cell lysate containing the membrane fraction than the cells transfected with
the NEP-m, NEP-s and the control GFP transfected cells (Fig 4). NEP specific
activity of the lysate from NEP-s transfected cells was also significantly greater
than NEP-m and GFP transfected cell lysates. In addition, the NEP-s specific
activity in the cell media was significantly greater than the NEP-n, NEP-m, and
GFP transfected cells (Fig 4).
Our next goal was to evaluate the effects of a single intracranial
administration of a rAAV vector containing either the secreted or native form of
the NEP gene in APP + PS1 transgenic mice to determine the effect of over
expression of the transgene on amyloid deposition. In study 1 rAAV vectors
were injected unilaterally into the right anterior cortex and hippocampus of six
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month old mice. The control group was treated with rAAV containing a NEP-m
gene. Total Aβ load was ascertained six weeks after intracranial injections by
immunohistochemical methods. The regional Aβ distribution and density in APP
+ PS1 transgenic mice that were control animals were similar to aged matched
untreated animals reported by us previously (Gordon et al., 2002).
Immunohistochemistry for Aβ revealed both darkly stained compact plaques and
more lightly stained diffuse plaque deposits in the APP+PS1 animal tissue (Fig
5A and 5D). Plaque deposition was distributed throughout the cortical regions as
well as in the hippocampus (although most concentrated in the molecular layers
of the dentate gyrus and the CA1 region, surrounding the hippocampal fissure).
Animals injected with the control rAAV-NEP-m showed Aβ immunohistochemical
staining patterns throughout the cortex and hippocampus comparable to those of
untreated APP transgenic mice of the same age. A notable decrease in the
amount of hippocampal Aβ staining was observed in animals injected with either
the rAAV expressing NEP-n or NEP-s six weeks after the time of injection when
compared to animals injected with the control rAVV-NEP-m vector (Fig. 5A-5F).
The reductions in Aβ deposition were not only limited to the areas surrounding
the cortical and hippocampal injection sites. Significant reductions were also
notable in corresponding areas contralateral to the site of injection (although only
a few cells showed very faint positive HA staining in the contralateral anterior
cortex and hippocaompus). ANOVA analysis of total Aß in the ipsilateral
hemisphere revealed significant decreases of, 78% and 65% in the anterior
cortex and hippocampus respectively, in mice receiving NEP-n injections.
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Decreases in total Aβ were also observed in mice receiving the NEP-s rAAV with
significant declines of 60% in the anterior cortex and 56% in the hippocampus
(Fig. 6A). Quantification of total Aß in the contralateral hemisphere showed
significant reductions of 56% and 36% in the anterior cortex and hippocampus
respectively, of mice receiving NEP-n. Similarly, significant decreases of 53%
and 44% in total Aβ of the contralateral anterior cortex and contralateral
hippocampus respectively, were seen in mice receiving NEP-s (Fig. 6B).
Congophilic plaque load was analyzed following intracranial injections of
rAAV vectors. The density of congophilic labeling was substantially less than Aβ
immunohistochemistry, staining only fibrillar Aβ deposits as expected (Gordon et
al., 2002). Animals injected with the control rAAV-NEP-m showed positive
congophilic staining patterns throughout the cortex and hippocampus
comparable to those of untreated APP transgenic mice of the same age (Fig. 7A
and 7D). Figures 6B and 6E show that the presence of congophilic staining for
the mice receiving the NEP-n vector was visibly less, especially in the
hippocampus, compared to both the control animals and the animals that
received the NEP-s vector (Fig 7C and 7F). ANOVA analysis revealed that
animals receiving the NEP-n rAAV showed significant reductions in the
hippocampal region (56%) and in the anterior cortex (56%; Fig 8A) ipsilateral to
the site of injection. rAAV expressing NEP-s also had significant decreases in
the compact plaque load in both the hippocampus (51%) and cortical regions
(57%;Fig 8A). When compact plaque load was calculated in the contralateral
hemisphere and compared to the control group, significant decreases were
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observed only in the hippocampus (49%) of animals receiving the NEP-s vector
treatment (Fig 8B). Animals receiving the NEP-n showed a decreased trend but
no statistical difference in congophilic staining from the NEP-m. No significant
decreases of Congo red staining were noted in the contralateral anterior cortex of
animals receiving either treatment (Fig 8B).
Study 2
In study 1 we demonstrated that either NEP-s or NEP-n could reduce
amyloid accumulation when tested in a prevention type of study. Study 2 was
designed to test NEP-s, which appeared slightly superior to NEP-n at sites
distant from the injection, in mice with large amounts of preexisting amyloid
deposits, what some would term a therapeutic type of study design. Aged APP +
PS1 transgenic mice (15 months of age) were injected into hippocampus and
anterior cortex bilaterally. Tissues were collected 5 mo later when mice were 20
mo old.
Total Aβ load was reduced following intracranial administration of rAAVNEP-s in aged mice. Panels A and C of fig. 10 show positive
immunohistochemical staining of total Aβ in the hippocampus and cortex
respectively of aged APP+PS1 mice treated with rAAV-NEP-s. Panels B and D
of Fig. 9 showed positive Aβ staining in the hippocampus and cortical regions of
untreated aged mice. Panel E shows quantification of Aß immunostaining of
NEP-s treated and untreated 20 mo old APP+PS1 mice. Total Aβ was reduced
significantly in the left anterior cortex as well as in the left and right hippocampus
following treatment with the NEP-s vector compared to control untreated animals.
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Total congophilic staining is reduced following intracranial administration of
rAAV-NEP-s in aged 20 month old mice. Panels A and C of Fig. 11 show total
positive congophilic staining in the hippocampus and cortex respectively of
APP+PS1 mice treated with rAAV-NEP-s. Panels B and D of Fig. 11 show
positive congophilic staining of the hippocampus and cortex respectively of
untreated 20 month old mice. Panel E of Fig. 11 shows quantification of
congophilic staining in NEP-s and untreated 20 Mo old APP+PS1 mice. Total
congophilic staining was significantly reduced in the left and right anterior cortex
as well as the left and right hippocampal regions in animals receiving treatment
with the NEP-s vector compared to untreated control animals.

DISCUSSION
Several recent findings have clearly implicated the important role of
endogenous proteases such as neprilysin in the catabolism of Aβ peptides in the
brain. Also known as enkephalinase and CD10, it is capable of cleaving
enkephalins and terminating peptidergic neurotransmission. In addition to NEP,
other endogenous Aβ degrading proteases maintain a conserved catalytic
domain which includes a zinc binding motif, HEXXH (Turner et al., 2000). Other
proteases in addition to the zinc metalloproteases that appear to play a role in Aß
metabolism include matrix metalloproteinase-9 (Yan et al., 2006) and cathepsin
B (Mueller-Steiner et al., 2006) and plasmin (Turner et al., 2001). Downregulation of these degrading enzymes within the brain during aging could
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potentially contribute to Aβ accumulation eventually leading to development of
AD pathology (Caccamo et al., 2005), (Yasojima et al., 2001).
Deficiency in the expression of NEP and other metallopeptidases in the
aged brain and in animal knockout models correlates with plaque accumulation in
a region specific manner (Iwata et al., 2000), (Eckman et al., 2001), (Fukami et
al., 2002), (Yasojima et al., 2001b), (Farris et al., 2004), (Saito et al., 2003),
(Caccamo et al., 2005), (Miners et al., 2006). Enzyme kinetic studies using
specific NEP inhibitors have shown that neprilysin can efficiently degrade
numerous peptides on the N-terminus of hydrophobic amino acid residues, which
is essential for the efficient catabolism of the Aβ peptide (Marie-Claire et al.,
1997), (Shimada et al., 1996), (Hoang et al., 1997), (Turner et al., 2001),
(Leissring et al., 2003), (Hersh, 2003).

Furthermore, in vivo studies show that

an increase in the enzyme activity of amyloid degrading enzymes specifically
neprilysin, endothelin converting enzyme, and insulin degrading enzyme, have a
significant effect on both intracellular and extracellular Aβ levels in the brain
(Hama et al., 2001), (Zou et al., 2006), (Eckman et al., 2006), (Guan et al., 2008).
Most recently, Farris et al., demonstrated that when the expression of
endogenous NEP is partially or completely inhibited both Aβ deposition and
cerebral amyloid angiopathy are significantly exacerbated (Farris et al., 2007b).
Subsequently, peptidases have become popular targets for Alzheimer’s disease
therapies.
Previously, we examined the effects of the overexpression of ECE-1 gene
on amyloid load in the APP + PS1 mouse model (Carty et al., 2006). In the
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current study, we examine the effectiveness of rAAV to deliver NEP into
hippocampus and anterior cortex of the mouse brain to determine its effects on
amyloid burden. In particular, we are interested in developing a delivery method
that increases the dissemination of therapeutic levels of NEP protein. Previous
studies involving gene therapy approaches for the treatment of Alzheimer’s
pathology have used viral vectors to reduce Aβ deposition by overexpressing Aβ
degrading enzymes, including NEP, ECE and IDE and more recently Cathepsin
B, a cysteine protease also implicated in the lysosomal degratory pathway of Aβ
peptides (Marr et al., 2003), (Iwata et al., 2004), (Mueller-Steiner et al., 2006). A
comparison of gene transfer studies indicate that overexpression of neprilysin
appears to have the most pronounced effect on plaque load in the brain (Farris et
al., 2007a), (Eckman et al., 2003), (Hersh et al 2008), (Spencer et al., 2008).
Marr et al (2003) used lentiviral vector and were successful in reducing amyloid
levels in APP Tg mice but only moderately peptides (Marr et al., 2003). In
addition, others have shown that the transgenic overexpression of NEP and IDE
crossed with transgenic APP mice significantly reduces amyloid accumulation in
the brain (Leissring et al., 2003), (Poirier et al., 2006), (Meilandt et al 2009).
Iwata et al.used AAV, as in this study, to express NEP-n and were also
successful in reducing Aβ levels in the hippocampus of Tg2576 mice.
In this paper, we further explore the use of different rAAV expressing
different forms of the NEP gene. Particularly, we examine a secreted form of the
NEP in addition to using the CED delivery method to increase distribution and
ultimately total area of gene expression. We also determine the effect of both the
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native and secreted versions of NEP expression in the anterior cortex and
hippocampus comparing the relative distribution and differences in NEP gene
expression in specific cell types in the brain. Unlike previous gene transfer
studies with these proteases we use the double transgenic APP + PSI mouse
model which have a very aggressive amyloid deposition profile and exhibit
memory deficits at a younger age than single transgenic amyloid depositing
models. Recombinant AAV has become widely used for the transduction of
neuronal cells. rAAV is nonpathogenic, has low immunogenicity, lacks all viral
genes and is capable of long term expression in neurons. This profile makes
rAAV a good candidate for the use as a gene therapy vector for neurological
disorders (Mandel et al 2006), (Mandel and Burger 2004). One limitation with a
gene therapy approach for a disease such as Alzheimer’s is that the therapeutic
protein must be delivered to the whole brain. Unfortunately, the intracranial
injections into the brain parenchyma using simple diffusion does not allow for
efficient uptake of the transgene or significant dispersion of the AAV vectors to
significantly large areas of the affected regions within the brain. Thus if only a
small area of the brain is transduced by the viral vector, multiple injections would
be required to cover the entire brain. Therefore, in an attempt to overcome this
problem we engineered the NEP gene to contain a signal peptide sequence in
the hopes of creating a nucleus from which the expressed protein could diffuse to
greater regions of the brain; thus eliminating the requirement for a large number
of injections. Additionally we implemented a novel infusion technique using the
CED method allowing us to obtain a larger area of distribution of the rAAV
78

vectors upon delivery with a single injection in the brain parachyma both in the
hippocampus and cortical regions of the brain. CED is a method of delivering
clinically relevant volumes of therapeutic agents to significantly larger areas of
the brain in comparison to simple diffusion methods. The CED technique is
designed to utilize the phenomenon of bulk flow and positive pressure to
distribute macromolecules to a large area within solid tissue. Macromolecules
can therefore be administered to significantly larger areas of specific brain
regions by utilizing the advantage of fluid convection within and throughout the
interstitial space in the brain (Leiberman et al. 1995, Sanftner et al 2005). The
greatest area of distribution is therefore achieved by using an increased and
optimal pressure gradient, flow rate, and volume of liquid material (Sanftner et
al., 2005). One of the mechanistic limitations of the CED method as well as the
simple injection method is the reflux of the injected material up the injection tract.
In 2002 Krauze et. al. developed a reflux free step cannula design which
effectively minimizes reflux by placing silicone coated tubing within the stainless
steel blunt end cannula creating a step that prevents the backflow of fluid. The
optimization of more efficient cannula designs coupled with the encouraging
results from studies showing enhanced gene transfer and distribution
emphasizes the therapeutic potential of the CED method in helping overcome
some of the mechanical disadvantages of gene delivery in regards to gene
therapy (Krauze et al., 2005b).
Implementing these techniques, rAAV serotype-5 NEP vectors were
injected unilaterally into the mouse hippocampus and anterior cortex.
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Examination of the expression profile, using anti-HA immunohistochemisty, of the
expressed NEP reveals that the rAAV constructs of both NEP-m and NEP-n can
transduce several different neuronal and glial cell types within the mouse brain.
Interestingly, it appears that the cell bodies in the dentate molecular layer were
not stained as intensely as the corresponding axonal projections of these cells
which were very darkly stained. This may suggest that the expressed NEP is
processed in the endoplasmic reticulum and golgi apparatus of the cell body,
then transported along the axon via vesicles to the synaptic terminal. These
results are consistent with data published in 2006 by Huang et al. describing the
normal neuronal metabolism of NEP (Huang et al, 2006) and by Iwata expressing
NEP-n with rAAV (Iwata et al 2004). The expression profiles are also consistent
with the previously published serological specificity of the AAV vectors (Alisky et
al., 2000),(Burger et al., 2004),(Choi et al., 2005). The AAV 5 serotype has
previously been shown to effectively transduce non-dividing neuronal cells as
well as glial cells in the mouse brain.
The NEP-s expression profile revealed less intensity of HA staining when
compared to the NEP-m and NEP-n staining patterns. Cells within the hilus of
the molecular layer were stained as were as cells in the CA3 region of the
hippocampus. We believe that more diffuse staining of the NEP-s construct does
not necessarily mean that this vector had lower transduction efficiency. It is likely
due to the diffusion of the NEP protease throughout the extracellular milieu,
making it more difficult to detect using anti-HA immunohistochemisty compared
to the membrane bound NEP-n protease. However, another explanation for the
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decreased staining of the NEP-s protease may be that once the NEP-s is
secreted the NEP protein or at least the HA-tag is more prone to degradation by
other extracellular proteases. We plan to conduct further investigation of the
expression and activity profile using in vitro studies to delineate the metabolism
of both the NEP-n and NEP-s proteases. Additionally, the NEP-s staining was
more intense in the cortical regions compared to the hippocampus which may
indicate that the signal peptide is processed more effectively in the cortex
compared to the hippocampus. Despite the differences in staining intensity of
the different NEP proteins our in vitro data confirmed that both NEP-n and NEP-s
proteases shown activity, while the NEP-m version did not. Additionally, only the
NEP-s protein showed enzyme activity once secreted into the cell media. We
also plan to re-examine the levels of soluble protease activity in the cortex
compared to the hippocampus of injected animal to see if this is the case in vivo.
Our results demonstrate that the up-regulation of NEP through rAAV
vectors can provide a viable method to decrease the total amyloid deposition in
the brain of amyloid depositing Tg mice. NEP-n and NEP-s were able to
significantly reduce total Aβ deposition in the anterior cortex and hippocampus at
the site of injection. Similarly, both NEP-n and NEP-s significantly reduced the
level of congophilic deposits. Interestingly, when the area of positive staining for
Aβ was analyzed in the hippocampus and cortical regions of the contralateral
hemisphere, both the NEP-s and NEP-n rAAV were able to decrease total Aβ (in
anterior cortex) load compared to the control group. Only NEP-s treated animals
showed significant reductions in total Aβ load in the contralateral hippocampus
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compared to control animals. However, examination of the congophilic deposits
on the contralateral anterior cortex showed no reduction. Interestingly, on the
contralateral hippocampal side there was a 40-50% reduction of congophilic
staining, but only the reduction with NEP-s was statistically significant compared
to the control group. The reduction on the contralateral hemisphere observed
here is likely due to retrograde transport of the rAAV and anterograde transport
of the NEP protein. Retrograde transport of rAAV has previously been reported
(Burger et al 2004). The lower number of neuronal connections between the
ipsilateral and contralateral sides in the anterior cortex compared to those
present in the hippocampus could explain why there is a reduction in congophilic
staining in the contralateral hippocampus and not the contralateral anterior
cortex. Further, since the contralateral anterior cortex showed reduction of total
Aβ load but not congophilic staining it would seem to suggest that a critical
amount of NEP expression is required in order to reduce the insoluble Aβ plaque
formation.
As previously mentioned our findings showed that by implementing the
use of a secreted form of the NEP protease in addition to using the CED method
for intracranial administration, we were able to successfully improve the area of
gene expression to further reduce amyloid load in the brain. An alternative
method which would potentially overcome the limitations of a direct intracranial
injection is to attempt to express the NEP protease in a peripheral fashion.
Previous studies using anti-amyloid vaccines have clearly demonstrated
that effective therapy does not have to cross the blood brain barrier to have a
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significant effect on amyloid load in the brain. It is well established that both
passive and active Aβ immunotherapy can effectively decrease amyloid load
from the brain as well as improve cognitive impairment in transgenic animals
(Morgan et al., 2000), (Janus et al., 2000), (Dodart et al., 2002), (Masliah et al.,
2005), (Wilcock et al., 2004),(Solomon, 2005),(Maier et al., 2006). The
mechanism underlying this phenomenon referred to as the ‘peripheral sink’
hypothesis asserts that amyloid is in a state of equilibrium throughout the body.
Therefore, sequestering and removing amyloid in the periphery will change the
equilibrium such that amyloid will move from the brain into the periphery
(DeMattos et al., 2002), (Matsuoka et al., 2003), (Lemere et al., 2003), (Deane et
al., 2005). Most recently, ex vivo gene transfer studies using cell mediated over
expression of amyloid degrading peptidases have shown initial success and may
provide a useful alternative to passive immunotherapy. Hemming et al in 2007
showed that over expression of secreted neprilysin in primary fibroblasts
reintroduced peripherally into transgenic APP mice showed a robust reduction in
plaque load (Hemming et al., 2007). Additionally, other methods implementing
cell mediated gene expression using both leukocytes and erthrocytes have been
used enhance Aβ degradation in the periphery and in the CNS (Guan et al.,
2008), Lui et al 2008).
We also wanted to examine the effect of increasing NEP expression in
aged animals where there is already significant deposition of Aβ. Evidence has
shown that rAAV viral vectors can successfully transfect neurons in the CNS and
result in sustained and stable long term gene expression in the brain (McCown et
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al., 1996), (McCown, 2005), (Royo et al., 2008), (Spencer et al., 2008). Our
results demonstrate that the rAAV NEP-s vector was able to significantly reduce
both total Aβ load and fibrillar Aβ in aged animals. These data are consistant
with evidence from Spencer et al (2008). As expected, the NEP-s showed strong
expression in the brain 5 months following treatment in older animals 20 months
of age (treatment was at 15 mo. of age) demonstrating persistence and stability
of the transgene expression. Upon observation of congophilic positive plaque
load in 20 mo. old animals compared to plaque load in 15 mo.old animals it
appears that treatment with NEP in the old animals with a large amount of
preexisting plaques simply halts the progression of plaque build up rather than
actively removing compact plaques established well before treatment onset.
Further investigation must be done to verify the aforementioned observation.
Gordon et al. in 2001 showed that congophilic positive staining, primarily
composed of Aβ40, increases until about 12 months of age in the double
transgenic APP+PS1 mouse and remains relatively stable up until 18 months of
age (Gordon et al, 2001).
Although we have yet to perform a detailed examination, initial
observations showed no noticeable toxic effects in mice receiving the NEP
vectors. No neuron loss or gross morphometric changes were observed in fixed
brain tissue. No significant changes in total body weight were noted, indicating
that up regulation of NEP did not appear to have adverse effects or cause
general toxicity in the mouse model during our study period. NEP has been
shown to have other endogenous peptide substrates, including atrial natriuretic
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peptide, substance P, endothelin and enkephalin. It is uncertain whether
interactions between NEP and these other potential substrates in the brain may
cause potential problems although one recent study suggests that high levels of
enkephalins can contribute to memory and cognitive deficits in amyloid producing
mice, further implicating the importance of NEP activity in AD (Meilandt et al.,
2008). Monitoring changes in these NEP peptide substrates between control and
treatment groups may help identify any potentially harmful side effects resulting
from increases in NEP activity. Previous studies have revealed that in the AD
brain as well as in the animal model of AD, NEP are down regulated specifically
in areas that are prone to plaque formation (Yasojima et al., 2001a), (Fukami et
al 2002). Therefore, up-regulation of NEP to restore normal levels of this
endogenous protease should have minimal adverse effects. In future studies, we
could regulate the levels of NEP expression by using an inducible promoter
system which would enable the levels of NEP to be managed as required per
individual and potentially reduce unwanted side effects of continuous high levels
of NEP expression. Future studies which implement a combination of peripheral
and central gene transfer studies can also have additive effect on total amyloid
load in the brain. Another therapeutic gene therapy technique could implement a
cell mediated gene transfer technique in an in vivo fashion. Rivest et al in 2008
demonstrated that injection of lentivirus expressing the TLR2 gene resulted in
successful expression of the gene in bone marrow cells. Additionally, these cells
successfully migrated to the CNS of amyloid depositing transgenic mice ensuing
in a decrease in amyloid pathology (Richard et al., 2008). These findings further
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demonstrate that viral vectors and cell mediated therapy can be combined to
provide a novel therapeutic technique in the treatment of neurological disease.
We have yet to determine if this reduction in the Aβ levels with our NEP-n
or NEP-s rAAV vectors will lead to significant improvement in behavioral tests
such as the Morris water maze in both the young and old populations of
transgenic mice. However, these data are consistent with reports that NEP can
degrade Aß in vitro, and that partial knockdown of the NEP gene leads to more
rapid accumulation of Aß (Farris et al., 2007), (Eckman et al., 2003). The
present work adds to the evidence that NEP plays an important role in Aß
deposition by demonstrating that local overexpression NEP enzyme activity can
dramatically reduce the deposition of amyloid in the brains of APP transgenic
mice. Thus, regulation of NEP through methods such as gene therapy may be
used as a potential therapeutic target for the treatment of Alzheimer's disease
warranting further study into the use of gene therapy techniques in a combinatory
fashion to increase effectiveness while reducing adverse events.
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FIGURE 1: DIAGRAMMATIC REPRESENTATION OF rAAV CONSTRUCTS
EXPRESSING THE NEP GENE UNDER THE CONTROL OF THE CHICKEN βACTIN (CBA) PROMOTER. Note the C-terminal fusion HA tag in both
sequences and the secretion signaling peptide in the NEPHA-s construct. Panel
A shows a gene map of the recombinant AAV NEP-n and NEP-s constructs
under control of the hybrid CBA chicken β-actin promoter. A hemagluttinin tag
has been appended to the NEP encoding sequence to allow for easy detection.
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FIGURE 2: EXAMINATION OF NEP EXPRESSION IN TRANSDUCED CELLS
OF THE HIPPOCAMPUS CONTRALATERAL AND IPSILATERAL TO VECTOR
INJECTION. Strong NEP-n and NEP-m expression is detected using anti-HA
immunostaining in the right hippocampus following intracranial administration of
NEP-n and NEP-m vector (panels A and B, respectively). Panel C shows less
intense diffuse NEP-s expression in granule cells of the dentate gyrus in the right
hippocampus following intracranial administration of NEP-s. Panels D shows no
positive staining in the uninjected hippocampus of an untreated age matched
animal. Magnification = 40X for all panels. dg = dentate gyrus; CA1 = Cajal Area
1; CA3 = Cajal area 3.
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FIGURE 3: EXAMINATION OF EXPRESSION LEVELS OF NEP AFTER
INTRACRANIAL ADMINISTRATION OF rAAV VECTORS INTO THE RIGHT
ANTERIOR CORTEX OF MICE. Panels E and F show strong NEP-n and NEPm expression as detected by anti-HA immunostaining in the anterior cortex and
striatum ipsilateral to the injection site. Panel G shows slightly less intense
diffuse NEP-s expression in the anterior cortex and striatum ipsilateral to the
injection site. Panels H shows no positive staining in the uninjected cortex of
untreated aged matched animals. Str = striatum; CC = corpus callosum; CX=
cortex. Magnification = 40X.
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FIGURE 4: QUANTIFICATION OF NEP SPECIFIC ACTIVITY IN HEK293
TRANSFECTED CELLS. Neprilysin specific activity is significantly higher in the
HEK293 cells transfected with NEP-n in the cell lysate (membrane fraction)
compared to NEP-m, NEP-s, and GFP transfected cell lysates. NEP-s
transfected cell lysates (cell media fraction) showed significantly higher NEP
activity compared to NEP-n, NEP-m and GFP expressing cells. The asterisk (*)
indicates significance with a p-value < 0.05. The number (#) indicates
significance with a p-value < 0.001. Note differences in Y axis scaling for each
panel.
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FIGURE 5: TOTAL AMYLOID LOAD IS REDUCED FOLLOWING
INTRACRANIAL ADMINISTRATION OF NEP-s OR NEP-n rAAV VECTORS.
Aβ immunostaining is observed in mice throughout both hippocampus (panels A,
B and C) and anterior cortex (panel D, E and F). Aβ staining in the ipsilateral
hippocampus of animals receiving intracranial injection NEP-n (panel B) or NEP
–s (panel C) is reduced compared to control vector NEP-m (panel A). Aβ staining
in the right anterior cortex of mice receiving intracranial injection of NEP-s (panel
D) or NEP-n (panel F) is reduced compared to control vector NEP-m (panel B).
Scale bar = 120μm.
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FIGURE 6: QUANTIFICATION TOTAL AMYLOID LOAD IN THE
HIPPOCAMPUS AND CORTICAL REGIONS FOLLOWING INTRACRANIAL
ADMINISTRATION OF rAAV. Panel A shows percent area of positive staining
for total Abeta load of the right cortex and hippocampus ipsilateral to the injection
site. Panel B shows quantification left cortical and hippocampal percent area of
positive staining for total abeta load of the contralateral hemisphere to the
injection site. The star (*) indicates significance with a p-value < 0.05; (**)
indicates p-value <.001.
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FIGURE 7: CONGOPHILIC COMPACT PLAQUE LOAD IS REDUCED
FOLLOWING INTRACRANIAL ADMINISTRATION OF NEP rAAV VECTORS.
Total congophilic staining is observed in mice throughout both hippocampus
(panels A, B and C) and anterior cortex (panel D, E and F). Positive congophilic
staining in the ipsilateral hippocampus of animals receiving intracranial injection
NEP-n (panel B) or NEP-s (panel C) is reduced compared to control vector NEPm (panel A). Congophilic staining in the right anterior cortex of mice receiving
intracranial injection of NEP-s (panel D) or NEP-n (panel F) is reduced compared
to control vector NEP-m (panel B). Scale bar = 120μm.
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FIGURE 8: QUANTIFICATION OF TOTAL CONGOPHILIC LOAD IN THE
HIPPOCAMPUS AND CORTEX FOLLOWING INTRACRANIAL
ADMINISTRATION OF rAAV. Panel A shows quantification of percent area of
positive staining for total congophilic staining of the cortex and hippocampus
ipsilateral to the injection site in the hippocampus and cortex. Panel B shows
quantification of percent area of positive stain of total congophilic staining in the
contralateral hemisphere to the injection site. The star (*) indicates significance
with a p-value < 0.05
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FIGURE 9: DISTRIBUTION OF NEP EXPRESSION 20 WEEKS AFTER rAAV
NEP-S ADMINISTRATION IN AGED APP + PS1 MICE AT 15 MONTHS. Brains
sections were immunostained for NEP with an antibody recognizing both rodent
and human NEP. Panels A, C, and E show NEP expression from mice treated
with rAAV-NEP-s. Panels B, D, and E show no NEP expression from control
animals treated with rAAV-GFP.
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FIGURE 10: TOTAL ABETA LOAD IS REDUCED FOLLOWING
INTRACRANIAL ADMINISTRATION OF rAAV NEP-S IN AGED MICE. Panels
A and C show positive immunohistochemical staining of total abeta in the
hippocampus and cortex respectively of APP+PS1 mice treated with rAAV-NEPs. Panels B and D show positive abeta staining of the hippocampus and cortex
of untreated mice. Panel E shows quantification of Aß immunostaining in NEP-s
and untreated 20 Mo old APP+PS1 mice. Mice were injected at 15 mo of age in
hippocampus and cortex of both hemispheres. RCX = right anterior cortex, LCX=
left anterior cortex, RHPC = right hippocampus, LHPC=left ippocampus. Y axis is
Aß load (percent area occupied by reaction product). ** P < 0.01
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FIGURE 11: TOTAL CONGOPHILIC STAINING IS REDUCED FOLLOWING
INTRACRANIAL ADMINISTRATION OF rAAV NEP-s IN AGED MICE. Panels A
and C show positive immunohistochemical staining of total congo in the
hippocampus and cortex respectively of APP+PS1 mice treated with rAAV-NEPs. Panels B and D show positive abeta staining of the hippocampus and cortex
of untreated mice. Panel E shows quantification of Aß immunostaining in NEP-s
and untreated 20 Mo old APP+PS1 mice. Mice were injected at 15 mo of age in
hippocampus and cortex of both hemispheres. RCX = right anterior cortex, LCX=
left anterior cortex, RHPC = right hippocampus, LHPC=left hippocampus. Y axis
is Aß load (percent area occupied by reaction product). ** P < 0.01

CA1

NEP-s

dg

untreated

CA3

CX

97

REFERENCE LIST
Alisky JM, Hughes SM, Sauter SL, Jolly D, Dubensky TW, Jr., Staber PD,
Chiorini JA, Davidson BL (2000) Transduction of murine cerebellar neurons with
recombinant FIV and AAV5 vectors. Neuroreport 11:2669-2673.
Berns, K. I., Parrish, C. R., 1996. Parvoviridae: The Viruses and Their
Replication. In: D. M. Knipe, P. M. Howley, (Eds.), Fields Virology. Lippincott
Williams and Wilkins, Philadelphia, PA, pp. 2437-2477.
Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier
PJ, Mandel RJ, Muzyczka N (2004) Recombinant AAV viral vectors pseudotyped
with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell
tropism after delivery to different regions of the central nervous system. MolTher
10:302-317.
Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM (2005) Age- and
region-dependent alterations in Abeta-degrading enzymes: implications for
Abeta-induced disorders. Neurobiol Aging 26:645-654.
Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, Gottschall PE,
Gordon MN, Morgan D (2006) Intracranial administration of deglycosylated Cterminal-specific anti-Abeta antibody efficiently clears amyloid plaques without
activating microglia in amyloid-depositing transgenic mice. JNeuroinflammation
3:11.:11.
Choi VW, McCarty DM, Samulski RJ (2005) AAV hybrid serotypes: improved
vectors for gene delivery. CurrGene Ther 5:299-310.
Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, Wu Z, Holtzman DM,
Zlokovic BV (2005) IgG-assisted age-dependent clearance of Alzheimer's
amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci
25:11495-11503.
DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM (2002) Brain to
plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse
model of Alzheimer's disease. Science 295:2264-2267.
Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong
CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory
deficits without reducing brain Abeta burden in Alzheimer's disease model.
NatNeurosci 5:452-457.

98

Eckman EA, Reed DK, Eckman CB (2001) Degradation of the Alzheimer's
amyloid beta peptide by endothelin-converting enzyme. J Biol Chem 276:2454024548.
Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB (2003)
Alzheimer's disease beta-amyloid peptide is increased in mice deficient in
endothelin-converting enzyme. JBiolChem 278:2081-2084.
Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, Xiao HD,
Bernstein KE, Eckman CB (2006) Regulation of steady-state beta-amyloid levels
in the brain by neprilysin and endothelin-converting enzyme but not angiotensinconverting enzyme. JBiolChem 281:30471-30478.
Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB,
Tanzi RE, Selkoe DJ (2004) Partial loss-of-function mutations in insulindegrading enzyme that induce diabetes also impair degradation of amyloid betaprotein. Am J Pathol 164:1425-1434.
Farris W, Schutz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA,
Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ (2007a) Loss of neprilysin function
promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am
J Pathol 171:241-251.
Fukami S, Watanabe K, Iwata N, Haraoka J, Lu B, Gerard NP, Gerard C, Fraser
P, Westaway D, St George-Hyslop P, Saido TC (2002) Abeta-degrading
endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization
inversely correlating with Abeta pathology. Neurosci Res 43:39-56.
Guan H, Liu Y, Daily A, Police S, Kim MH, Oddo S, Laferla FM, Pauly JR,
Murphy MP, Hersh LB (2008) Peripherally expressed neprilysin reduces brain
amyloid burden: A novel approach for treating Alzheimer's disease. J Neurosci
Res.
Hama E, Shirotani K, Masumoto H, Sekine-Aizawa Y, Aizawa H, Saido TC
(2001) Clearance of extracellular and cell-associated amyloid beta peptide
through viral expression of neprilysin in primary neurons. JBiochem(Tokyo)
130:721-726.
Hemming ML, Selkoe DJ, Farris W (2007) Effects of prolonged angiotensinconverting enzyme inhibitor treatment on amyloid beta-protein metabolism in
mouse models of Alzheimer disease. Neurobiol Dis 26:273-281.
Hersh LB (2003) Peptidases, proteases and amyloid beta-peptide catabolism.
Curr Pharm Des 9:449-454.

99

Hoang MV, Sansom CE, Turner AJ (1997) Mutagenesis of Glu403 to Cys in
rabbit neutral endopeptidase-24.11 (neprilysin) creates a disulphide-linked
homodimer: analogy with endothelin-converting enzyme. BiochemJ 327:925-929.
Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, Gerard NP,
Gerard C, Ozawa K, Saido TC (2004) Presynaptic localization of neprilysin
contributes to efficient clearance of amyloid-beta peptide in mouse brain.
JNeurosci 24:991-998.
Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, KawashimaMorishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC (2000) Identification
of the major Abeta1-42-degrading catabolic pathway in brain parenchyma:
suppression leads to biochemical and pathological deposition. NatMed 6:143150.
Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA,
Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C,
Fraser PE, St George-Hyslop P, Westaway D (2000) A beta peptide
immunization reduces behavioural impairment and plaques in a model of
Alzheimer's disease. Nature 408:979-982.
Krauze MT, Saito R, Noble C, Tamas M, Bringas J, Park JW, Berger MS,
Bankiewicz K (2005) Reflux-free cannula for convection-enhanced high-speed
delivery of therapeutic agents. JNeurosurg 103:923-929.
Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe
DJ (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice
prevents plaque formation, secondary pathology, and premature death. Neuron
40:1087-1093.
Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF,
Matsuoka Y, Taylor JW, DeMattos RB, Holtzman DM, Clements JD, Selkoe DJ,
Duff KE (2003) Evidence for peripheral clearance of cerebral Abeta protein
following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis
14:10-18.
Maier M, Seabrook TJ, Lazo ND, Jiang L, Das P, Janus C, Lemere CA (2006)
Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and
learning deficits in an Alzheimer's disease mouse model in the absence of an
Abeta-specific cellular immune response. JNeurosci 26:4717-4728.
Marie-Claire C, Ruffet E, Antonczak S, Beaumont A, O'Donohue M, Roques BP,
Fournie-Zaluski MC (1997) Evidence by site-directed mutagenesis that arginine
203 of thermolysin and arginine 717 of neprilysin (neutral endopeptidase) play
100

equivalent critical roles in substrate hydrolysis and inhibitor binding. Biochemistry
36:13938-13945.
Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, Verma
IM, Masliah E (2003) Neprilysin gene transfer reduces human amyloid pathology
in transgenic mice. JNeurosci 23:1992-1996.
Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D,
Kirby L, Schenk D (2005) Abeta vaccination effects on plaque pathology in the
absence of encephalitis in Alzheimer disease. Neurology 64:129-131.
Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey
E, Lu Y, Shiratori C, Lemere C, Duff K (2003) Novel therapeutic approach for the
treatment of Alzheimer's disease by peripheral administration of agents with an
affinity to beta-amyloid. J Neurosci 23:29-33.
McCown TJ (2005) Adeno-associated virus (AAV) vectors in the CNS. Curr Gene
Ther 5:333-338.
McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ (1996) Differential and
persistent expression patterns of CNS gene transfer by an adeno-associated
virus (AAV) vector. Brain Res 713:99-107.
Meilandt WJ, Yu GQ, Chin J, Roberson ED, Palop JJ, Wu T, Scearce-Levie K,
Mucke L (2008) Enkephalin elevations contribute to neuronal and behavioral
impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci
28:5007-5017.
Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG (2006)
Decreased expression and activity of neprilysin in Alzheimer disease are
associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 65:10121021.
Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K,
Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M,
Arendash GW (2000) A beta peptide vaccination prevents memory loss in an
animal model of Alzheimer's disease. Nature 408:982-985.
Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G,
Esposito L, Mucke L, Gan L (2006) Antiamyloidogenic and neuroprotective
functions of cathepsin B: implications for Alzheimer's disease. Neuron 51:703714.

101

Poirier R, Wolfer DP, Welzl H, Tracy J, Galsworthy MJ, Nitsch RM, Mohajeri MH
(2006) Neuronal neprilysin overexpression is associated with attenuation of
Abeta-related spatial memory deficit. NeurobiolDis 24:475-483.
Richard KL, Filali M, Prefontaine P, Rivest S (2008) Toll-like receptor 2 acts as a
natural innate immune receptor to clear amyloid beta 1-42 and delay the
cognitive decline in a mouse model of Alzheimer's disease. J Neurosci 28:57845793.
Royo NC, Vandenberghe LH, Ma JY, Hauspurg A, Yu L, Maronski M, Johnston J,
Dichter MA, Wilson JM, Watson DJ (2008) Specific AAV serotypes stably
transduce primary hippocampal and cortical cultures with high efficiency and low
toxicity. Brain Res 1190:15-22.
Saito T, Takaki Y, Iwata N, Trojanowski J, Saido TC (2003) Alzheimer's disease,
neuropeptides, neuropeptidase, and amyloid-beta peptide metabolism. SciAging
KnowledgeEnviron 2003:E1.
Sanftner LM, Sommer JM, Suzuki BM, Smith PH, Vijay S, Vargas JA, Forsayeth
JR, Cunningham J, Bankiewicz KS, Kao H, Bernal J, Pierce GF, Johnson KW
(2005) AAV2-mediated gene delivery to monkey putamen: evaluation of an
infusion device and delivery parameters. Exp Neurol 194:476-483.
Schenk D, Hagen M, Seubert P (2004) Current progress in beta-amyloid
immunotherapy. Curr Opin Immunol 16:599-606.
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J,
Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R,
Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M,
Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta
attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature
400:173-177.
Shimada K, Takahashi M, Turner AJ, Tanzawa K (1996) Rat endothelinconverting enzyme-1 forms a dimer through Cys412 with a similar catalytic
mechanism and a distinct substrate binding mechanism compared with neutral
endopeptidase-24.11. Biochem J 315 ( Pt 3):863-867.
Solomon B (2005) Generation of anti-beta-amyloid antibodies via phage display
technology towards Alzheimer's disease vaccination. Vaccine 23:2327-2330.
Spencer B, Marr RA, Rockenstein E, Crews L, Adame A, Potkar R, Patrick C,
Gage FH, Verma IM, Masliah E (2008) Long-term neprilysin gene transfer is
associated with reduced levels of intracellular Abeta and behavioral improvement
in APP transgenic mice. BMC Neurosci 9:109.
102

Turner AJ, Isaac RE, Coates D (2001) The neprilysin (NEP) family of zinc
metalloendopeptidases: genomics and function. Bioessays 23:261-269.
Turner AJ, Brown CD, Carson JA, Barnes K (2000) The neprilysin family in
health and disease. Adv Exp Med Biol 477:229-240.
Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN,
Morgan D (2004) Passive immunotherapy against Abeta in aged APP-transgenic
mice reverses cognitive deficits and depletes parenchymal amyloid deposits in
spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation
1:24.
Yasojima K, McGeer EG, McGeer PL (2001a) Relationship between beta
amyloid peptide generating molecules and neprilysin in Alzheimer disease and
normal brain. Brain Res 919:115-121.
Yasojima K, Akiyama H, McGeer EG, McGeer PL (2001b) Reduced neprilysin in
high plaque areas of Alzheimer brain: a possible relationship to deficient
degradation of beta-amyloid peptide. NeurosciLett 297:97-100.
Zou LB, Mouri A, Iwata N, Saido TC, Wang D, Wang MW, Mizoguchi H, Noda Y,
Nabeshima T (2006) Inhibition of neprilysin by infusion of thiorphan into the
hippocampus causes an accumulation of amyloid Beta and impairment of
learning and memory. JPharmacolExpTher 317:334-340.

103

PAPER 3:
CONVECTION-ENHANCED DELIVERY AND MANNITOL AS A METHOD TO
INCREASE DISTRIBUTION OF AAV VECTORS 5, 8, AND 9 AND INCREASE
GENE PRODUCT IN THE ADULT MOUSE BRAIN.

Carty N.1, Nash K.2, Dickey C.1, Muzyczka N.2, Gordon M.N.1, Morgan D1,
1

Alzheimer’s Research Laboratory, Department of Molecular Pharmacology and

Physiology, School of Biomedical Sciences, University of South Florida College
of Medicine, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA.
2

Department of Molecular Genetics and Microbiology, University of Florida

College of Medicine, Box 100266, Gainesville FL 32610
Niki C Carty: ncarty@hsc.usf.edu
Kevin Nash: Knash@health.usf.edu
Chad Dickey: dickey.chad@gmail.com
Nicholas Muzyczka: NMuzyczka@ufl.edu
Marcia N Gordon: mgordon@hsc.usf.edu
Dave Morgan: dmorgan@hsc.usf.edu
Please address correspondence to:
Dave Morgan
Director, Basic Neuroscience Research
University of South Florida
104

12901 Bruce B Downs Blvd, MDC Box 8
Tampa, FL 33612
USA

ABSTRACT
The use of recombinant adeno-associated viral (rAAV) vectors as a
means of gene delivery to the central nervous system has emerged as a viable
method of gene therapy for the treatment of several types of degenerative brain
diseases. A major disadvantage of typical intracranial injections into the brain
parenchyma is a limited distribution of the rAAV macromolecules to all brain
regions where therapies may be needed. Optimizing specific parameters of the
administration techniques with the purpose of obtaining maximal gene
distribution and gene uptake is an important obstacle to overcome for gene
therapy studies. Convection enhanced delivery (CED) is a method of delivering
clinically relevant volumes of therapeutic agents to significantly larger areas of
the brain. The CED technique is designed to utilize the phenomenon of bulk flow
and positive pressure to distribute macromolecules to a large area within solid
tissue in a direct intracranial injection procedure. In the present study the CED
method using the step-design cannula (Krauze et al., 2005a) was used to deliver
AAV vector serotype 5 expressing GFP into the hippocampus and cortical
regions of the mouse brain. Regions of the hippocampus and cortex receiving
the CED injection showed significantly more robust expression of GFP and an
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increased area of distribution than the simple diffusion method. We also
compare transduction efficiency of AAV serotypes 5, 8, and 9 using CED
administration. Following a single CED injection AAV 9 resulted in the largest
area of distribution in the mouse CNS. Moreover, the CED method, in addition to
systemic administration of mannitol, was used to deliver rAAV vectors (serotypes
5 and 9) expressing GFP into the hippocampus of 11 month old mice. Mannitol
is a blood brain barrier interruptive reagent which also induces hyperosmolarity
thereby reducing intracranial pressure and facilitating the movement of particles
through the interstitial space. Mice were injected intracranially into the right
hippocampus using the CED method with (n=8) or without (n=8) pre treatment
with mannitol delivered intraperitoneally. Animals receiving systemic injections of
mannitol followed by the intracranial CED injection of rAAV into the hippocampus
showed an increased area of distribution compared to animals that did not
receive pre treatment with mannitol. In addition, GFP expression was also
detected in regions distant from the initial site of injection, in animals receiving
the CED method with mannitol, including significant expression in the
contralateral hemisphere to the injection site. These data suggest that by
optimizing injection techniques such as CED in addition to mannitol induced
hyperosmolarity, provides an efficient means of increasing viral vector distribution
and transgene uptake.
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INTRODUCTION
AAV (adeno associated viral) vectors have recently emerged as a
promising and novel mean by which transgenes can be delivered to different
tissue types successfully in a large range of animal species including humans.
AAV have a unique profile with a number of advantageous characteristics which
identify them as one of the most feasible gene transfer vectors in the treatment of
a variety of diseases, including neurological diseases, compared to other viral
vectors. AAVs are one of the smallest viruses, approximately 25 nm in diameter,
and their DNA genome is less than 5 kb which contains two large open reading
frames with inverted terminals repeats located at either end Thomas (Berns,
1990), (Thomas et al., 2003); (Wu et al., 2006). The most attractive
characteristics of AAV is their lack if pathogenicity, persistence of the transgene
as an episome, and long term gene expression. AAV vectors arrive in a variety
of flavors otherwise known as serotypes. The AAV serotype refers to the
efficiency by which the specific AAV can infect a particular cell type through
attachment to specific cell surface receptors. A new AAV serotype is defined by
the inability of an antibody that is reactive to the viral capsid protein of one
serotype in neutralizing those of another serotype (Choi et al., 2005) . The
availability of different AAV serotypes is another major advantage that lends to its
feasibility as a therapeutic in the treatment of neurodegenerative disease.
Through the modification of serotype diversity, a variety different capsid proteins
can be incorporated to create pseudotypes of recombinant AAV (mainly derived
from AAV 2) which can ultimately mediate tropism and transduction efficiencies
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targeted towards specified cell and tissue types throughout the body to optimize
gene therapy (Choi et al., 2005), (Akache et al., 2006), (Cearley and Wolfe,
2006), (Kwon and Schaffer, 2008).
Unfortunately, one of the major disadvantages of a single intracranial
injection of AAV vectors into the brain parenchyma using simple diffusion does
not allow for efficient uptake of the transgene or significant distribution of the AAV
macromolecules to significantly large areas of the affected regions within the
brain. Convection enhanced delivery (CED) is a method of delivering clinically
relevant volumes of therapeutic agents to significantly larger areas of the brain in
a direct intracranial injection procedure in comparison to simple diffusion
methods. The CED technique is designed to utilize the phenomenon of bulk flow
and positive pressure to distribute macromolecules to a large area within solid
tissue. The CED technique was originally proposed by scientists in the early
1990s as a method of delivering drugs, or macromolecules, directly to the
parenchyma that would not normally cross the blood brain barrier (Raghavan et
al., 2006). Due to the lack of approved drugs that can be directly intracranially
administered to the brain and the difficulty in predicting methods that ensure
delivery of the therapeutic agent to its target site, CED remains an experimental
procedure. Furthermore, research of CED delivery devices is under current
investigation by several researchers (Bankiewicz et al., 2000), (Raghavan et al.,
2006).
This CED method has been investigated in gene therapy studies as a way
to increase the distribution of AAV vectors in the brain. Studies conducted by
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Bankiewicz et. al. in 2000 revealed that CED can significantly increase gene
transfer and distribution of AAV expressing AADC in the striatum of MPTPtreated monkeys. The AAV vector was found to be safely distributed throughout
the entire region of the striatum compared to the simple injection method where
the distribution was severely limited (Bankiewicz et al., 2000). Similar results
were replicated in the rat brain by Cunningham et. al. in 2000 with AAV2
expressing thymidine kinase (TK) where the CED method showed robust gene
transfer and increased distribution area within the putamen. CED injections in
the striatum were found distribute the AAV-TK throughout the striatum after a
single injection into this region and TK immunoreactive cells were also found
outside the striatum, in the globus pallidus, subthalamic nucleus, thalamus, and
substantia nigra (Cunningham et al., 2000), (Hadaczek et al., 2006).
One of the mechanistic limitations of the CED method as well as the
simple injection method is the reflux of the injected material from the injection
hole upon the removal of the cannula. In 2002 Krauze et. al. developed a reflux
free step cannula design which effectively eliminates reflux by placing silicone
coated tubing within the cannula creating a step that prevents the backflow of
fluid (Krauze et al., 2005a) . The optimization of more efficient cannula designs
coupled with the encouraging results from studies showing enhanced gene
transfer and distribution emphasizes the therapeutic potential of the CED method
in helping overcome some of the mechanical disadvantages of gene delivery in
regards to gene therapy (Krauze et al., 2005b).
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The use of osmotic agents such as mannitol is another method that can
be used to increase the area of distribution of macromolecules throughout the
CNS. Mannitol is a blood brain barrier interruptive reagent and is also known to
temporarily increase vascular pressure subsequently reducing intracranial
pressure. High concentrations of mannitol intravenously infused are currently
used in patients with traumatic brain disease to reduce intracranial pressure.
This osmotic agent pulls fluid from the CNS by increasing vascular osmotic
pressure. Several studies have also shown that with intra-arterial infusion of
mannitol the blood brain barrier can be opened to enhance the distribution of
chemotherapeutics throughout the CNS in both rats and humans (Nilaver et al.,
1995), (Rapoport, 2001), (Fu et al., 2003). In this particular study we anticipate
that by optimization of these mechanistic strategies in addition to AAV serotype
tissue specificity we can optimize transduction efficiency and increase distribution
area of AAV in the brain.

MATERIALS AND METHODS
Animals
Non transgenic C57BL6 mice were acquired from the breeding colonies at
the University of South Florida. Multiple mice are housed together whenever
possible until the time of use for the study; mice were then singly housed just
before surgical procedures until the time of sacrifice. Study animals were given
water and food (ad libitum) and maintained on the twelve hour light/dark cycle
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and standard vivarium conditions. Mice aged 9 to 11 months were used for all
experimental procedures with an n = 4 - 6 for each experimental group.
Step Design Cannula
The step design cannula was used for all intracranial surgeries. Fused silica
tubing (polymicro technologies, Pheonix, AZ) was inserted into a 27 gauge
Hamilton blunt ended needle and fixed in place with super glue (Krauze et al.,
2005a). The end of the silica tubing was cut leaving 1mm of tubing protruding
from the end of the Hamilton needle.
GFP Expression Using CED
Part A; animals were assigned to one of two cohorts, group one received
AAV vector expressing GFP (n =6). These animals received a single intracranial
injection of the AAV-GFP vector using the CED injection method (5ul/min) or the
traditional injection method (0.5ul/min) into either the right or left hippocampus
and into the right or left frontal cortex. Immediately before surgery mice were
weighed then anesthetized using isoflurane. Surgery was performed on animals
using a stereotaxic apparatus, injections using the CED method were used to
inject into hippocampus and frontal cortex at a flow rate of 5ul/min over a total
period of 2 min. (infusion time of 0.4min) using the CED method described
earlier. The traditional injection method was used to inject into the hippocampus
and frontal cortex at a flow rate of .5ul/min over a total period of 4 min. (infusion
time of 2 min.) also described earlier. The surgical procedure was performed by
exposing the cranium using an incision through the skin along the median sagittal
plane, and two holes were drilled through the cranium over the right frontal cortex
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injection site and the right hippocampal injection site. Previously determined
coordinates for burr holes, taken from bregma were as follows; frontal cortex,
anteroposterior, 1.5mm; lateral, -2.0mm, vertical, 3.0mm, hippocampus,
anteroposterior, -2.7mm; lateral -2.5mm, vertical, 3.0mm. Burr holes were drilled
using a dental drill bit (SSW HP-3, SSWhite Burs Inc., Lakewood, NJ). Each
animal received both injection types in opposite hemispheres to control for
mouse to mouse variability in gene uptake and expression. Six weeks post
surgery mice were weighed, overdosed with pentobarbital (200 mg/kg) and
perfused with 25 ml of 0.9% normal saline solution then 50 ml of freshly prepared
4% paraformaldehyde. Brains were collected from the animals immediately
following perfusion and immersion fixed in 4% paraformaldehyde for 24hrs.
Mouse brains were cryoprotected in successive incubations in 10%, 20%, 30%
solutions of sucrose; 24hrs in each solution. Subsequently, brains were frozen
on a cold stage and sectioned in the horizontal plane (25 μm thickness) on a
sliding microtome and stored in Dulbecco’s phosphate buffered saline (DPBS)
with 0.2% sodium azide solution at 4˚C.
Six to eight sections 100 μm apart spanning the site of injection were
chosen and free-floating immunochemical and histological analysis was
performed to determine gene expression using an anti-GFP antibody at a
concentration 1:3,000 (Chemicon; Temecula, CA). Immunohistochemical
procedural methods were analogous to those described by Gordon et al. 2002 for
each marker. Animal tissue was placed in multisample staining tray and
endogenous peroxidase blocked (10% methanol, 30% H202, in PBS). Tissue
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samples were then permeabilized (with lysine 0.2%, 1% Triton X-100 in PBS
solution), and incubated overnight in appropriate primary antibody. Sections
were washed in PBS then incubated in corresponding biotinylated secondary
antibody (Vector Laboratories, Burlingame, CA). The tissue was again washed
after a 2hr. incubation period and incubated with Vectastin® Elite® ABC kit
(Vector Laboratories, Burlingame, CA) for enzyme conjugation. Finally, sections
were stained using 0.05% diaminobenzidine and 0.3% H202 (for CD45 and FcγR
0.5% nickelous ammonium sulfate was added for color enhancement). Tissue
sections were mounted onto slides, dehydrated, and coverslipped.
Part B of the experiment was to access the safety profile of the CED
injection method immediately following the injection procedure. Animals received
a single injection of saline (n =6) using either the CED method or the traditional
injection method into the right or left hippocampus and frontal cortex. Each
animal received both injection methods into opposite hemispheres to control for
variations between animals with regard to microglial activation and neurotoxicity
to determine the safety profile of the CED technique. Animals were sacrificed 4
days post surgery as described earlier to determine whether the CED technique
causes an acute significant increase in microglial activation or mechanical tissue
damage using an immunohistochemical procedure described earlier. Six
sections 100 μm apart spanning the site of injection were chosen from each
animal for part B of the experiment and free-floating immunochemical and
histological analysis was performed for analysis of the safety profile of the CED
method in comparison to the traditional injection method. A series of sections
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from experiment part B were immunostained for CD45 to determine relative
microglial activation. Each immunochemical assay omitted some sections from
primary antibody incubation period to evaluate nonspecific reaction of the
secondary antibody. Another series of sections from part B were mounted on
slides and stained with fluoro-jade stain (0.001%, Sigma Aldrich, St. Louis, MO)
to assess the degree of neurotoxicity. Fluoro-jade is an anionic fluorochrome
that selectively stains degenerating neurons effectively detecting neuropathic
lesions by fluorescent microscopy (Schmued et al., 1997). A subsequent series
of sections from part B (6 per animal) were mounted on slides and stained with
the Cresyl Violet (Nissle) stain (0.05%, Sigma Aldrich, St. Louis, MO). The cresyl
violet stains all Nissl bodies of the rough endoplasmic reticulum and other acidic
components in all neuronal cytoplasm therefore an absence of staining will
indicate neuron loss. For experiments which were analyzed to determine acute
effects of the CED technique all immunohistochemical staining for CD45 and
fluoro-jade and cresyl violet (Nissl) staining all procedures followed the same
protocol aforementioned 4 days post surgery rather than six weeks post surgery.
GFP Expression with Serotypes AAV 5, 8, and 9
Study animals were assigned to one of three treatment groups receiving
AAV serotype 5, 8, or 9. All AAV vectors contain a coding sequence for green
fluorescent protein (GFP). All animals received an intracranial injection into the
right hippocampus and all injections were performed using the CED technique
described earlier. Each group received a single intracranial injection of 2ul of an
each respective AAV vector expressing GFP (1.5 x 1011vg/ul) into the right
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hippocampus. All intracranial surgeries were performed on a stereotaxic
apparatus using predetermined hippocampal coordinates for the mouse
hippocampus described earlier. Six weeks post injection animals were sacrificed
and brain tissue was collected as described earlier.
GFP Expression with Serotypes AAV 5 or 9 and Mannitol
Animals were assigned to one of four groups. Group 1 and 2 received a
single intracranial injection of 2ul of AAV serotypes 5 and 9 respectively
expressing GFP (1.5 x 1011vg/ul concentration) into the right frontal cortex and
right hippocampus using the CED injection method. Group 3 and 4 also received
a single intracranial 2ul injection of the AAV-GFP serotypes 5 and 9 (1.5 x
1011vg/ul concentration) into the right frontal cortex and hippocampus in addition
to a 200 ul single systemic intraperitoneal injection of 25% mannitol administered
15 minutes before the intracranial injection. The left untreated hemisphere in all
animals remained untreated and used as an internal control. Surgery was again
performed on animals using a stereotaxic apparatus using burr hole coordinates
previously described. Six weeks post injection animals were sacrificed and brain
tissue was collected as described earlier. Sections were immunohistochemically
stained using anti-GFP antibody (1:3000; Chemicon; Temecula, CA) to test for
gene distribution and expression in addition to the markers listed in part A using
tissue animals in each group.
Quantification and Statistical Analysis
All immunostained sections were imaged using an Evolution MP digital
camera mounted on an Olympus BX51 microscope at 100X final magnification
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(10 X objective). Immunoflourescent double labeled images were taken using a
confocal microscope. Six to eight horizontal brain sections (100µm apart; every
4th section) were taken from each animal and four nonoverlapping images near
the site of injection from each of these sections were captured (24
measurements per mouse). All images were taken from the same location in all
animals. Quantification of positive staining surrounding and including the
injection sites in the right frontal cortex and the right hippocampus and the
corresponding regions in the left hemisphere were determined using Image-Pro®
Plus (Media Cybernetics®, Silver Springs, MD). ANOVA statistical analysis was
performed using StatView® version 5.0.1 (SAS Institute, Raleigh, NC).

RESULTS
Non transgenic mice, 9 months old, were injected bilaterally into the
hippocampus using either the CED injection method or the traditional injection
method. The CED injection method was performed as previously stated using
the step design cannula with a flow rate of 5µl/min with a total injection time of
approximately 2 min. including the time the cannula remained in the injection site
to further prevent backflow of the AAV vector material. The simple injection was
done at a flow rate of 0.5µl/min with a total injection time of approximately 4 min.
Each animal received both the CED method in one hemisphere and the
traditional injection method in the opposite hemisphere to control for variations in
gene uptake between individual animals. The animals were survived 4 weeks
post surgery and histology was performed to assess gene distribution and
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expression. Regions of the hippocampus and cortex receiving the CED injection
showed more robust expression of GFP and an increased area of distribution
than the traditional injection method (figure 1).

In addition, GFP expression was

also detected in regions distant from the initial site of injection in the hemisphere
which received the CED injection method. Areas with positive GFP staining
included the entorhinal cortex, as well as some neurons in the striatum and
thalamus. The striatum and entorrhinal cortex showed a significantly increased
area of distribution in the animals receiving the CED injection as opposed to the
traditional injection method. The hippocampal and cortical regions in which the
CED method was implemented also showed an increased intensity of staining
immediately surrounding the cannula tip and in some distal areas in regions
surrounding the injection site. The difference in staining intensity appears to
indicate an increase in gene product (GFP) and potentially indicate that the CED
technique increases the transduction efficiency of the AAV vector by increasing
the susceptibility of the cell to infection.
Part B of the experiment was to determine if safety profile of the CED
method on mechanical damage of parenchymal brain tissue. Brain samples
were analyzed for acute effects of the CED method in a second cohort of
animals. Non transgenic mice (n=6) were bilaterally injected in the same manner
described above (injections were of PBS) using both the CED and traditional
injection methods. The mice were sacrificed and tissue was analyzed 4 days
post injection and histology performed. Neurotoxity was determined using the
fluoro-jade stain which was only positive in a very small area in 2 animals which
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was not significant. Microglial expression was also analyzed to assess the
increase in microglial activation due to the mechanical technique. CD45 is a
protein tyrosine phosphatase that is only expressed when microglial cells
become activated, in this case, as a result of tissue damage (figure 2).
Immunohistochemistry revealed that CD45 staining was increased but not
significantly following the CED injections but this increase was limited to the area
immediately surround the cannula tract (figure 2). In addition the tissue was also
stained for cresyl violet or Nissl. The cresyl violet stains all Nissl bodies of the
rough endoplasmic reticulum and other acidic components in all neuronal
cytoplasm, therefore an absence of staining indicates neuron loss. The results
from the tissue did not reveal any significant areas devoid of Nissl staining
signifying that there was no appreciable neuron loss (Figure 2).
To examine whether AAV serotype was able to affect transduction
efficiency as well as area of distribution three different vector serotypes were
administered into right hippocampus of 11 month old non transgenic mice using
the CED method. A comparison of area of distribution as well as a comparison
of transduced neurons in the hippocampus following administration of AAV
serotypes 5, 8 and 9 each expressing GFP revealed that serotype 9 was
distributed to a significantly greater area than either 8 or 5. Six weeks post
injection, serotypes 8 and 9 not only transduced neurons throughout a large
region of the entire hippocampus but they were also successful in transducing
neurons in the left hippocampus contralateral to the site of injection. Conversely,
AAV serotype 5 was primarily expressed in the neurons of the hippocampus
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ipsilateral to the injection site. GFP positive neurons were limited to the
pyramidal and molecular cell layers dentate gyrus as well as cells in the hilus and
CA1 regions. A few GFP positive cells were observed in the entorhinal cortex in
addition to a few GFP positive cells in the lateral thalamic region directly adjacent
to the medial hippocampal regions but these were insignificant in comparison to
serotypes 8 and 9. AAV 8 and 9 serotypes revealed intense staining of GFP
positive neurons in all three CA regions of the hippocampus as well as very
intense staining of pyramidal cells in the molecular layer of the dentate gyurs and
a large number of positive cells in the hilus in the ipsilateral hippocampus. A
large number of intensely stained cells can also be observed in the entorhinal
cortex of the right hemisphere. It appears that the majority of cells that have
been transduced and are positive for GFP have intense staining not only of the
cell body but the axonal and dendritic projections (although slightly less intense).
These axonal projections are positive throughout the hippocampus and corpus
callosum (which contains axonal connections between the right and left
hemisphere). The GFP positive axons are clearly stained at midbrain level
ventral from the top of the cortex. These axons are positive at the cells bodies
from which they originate in the right contralateral hemisphere to the injections
site, through the midline to the axonal termination site in the left hippocampus.
Very few cells bodies were positively stained in the left uninjected hemispheres
of mice receiving the AAV 8 and 9 serotypes. Observations of the left
hemisphere contralateral to the injections revealed positive staining of the axon
terminals of neurons in the right dentate gyrus and CA regions. Intensely stained
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neurons can also be observed in the right entorhinal cortex for AAV 8 and 9
treatment groups, while the left entorhinal cortex was less intense and as in the
left hippocampus, only axons were positively stained for GFP. Interestingly,
GFP expression in animals receiving either AAV 8 or AAV 9 was observed not
only in regions proximal to the right hippocampal injection site (as with AAV 5), or
the left hippocampus resulting from retrograde axonal transport, but was also
evident in neurons distal to the site of injection. Following a single injection of
AAV 8 or AAV9 GFP positive neurons in these groups were observed in the
anterior cortex, thalamic nuclei, striatum, septal nuclei, superior colliculus,
subiculum and cerebellum of the ipsilateral hemisphere.
Quantification of the percent area of positive stain revealed that AAV9
showed a 5 fold significant increase in the area of distribution in the right
(ipsilateral) hippocampus with the left (contralateral) hippocampus showed an
approximate 6 fold increase in the area of distribution (figure 3). While, AAV
serotype 8 was able to transduce a significantly greater area and number of
neurons than AAV5, it was significantly less effective, therefore distributed to a
significantly smaller region than AAV 9.
Finally, we analyzed whether the osmotic agent, mannitol, could improve
total area of distribution thus enhancing transduction efficiencies of the different
AAV serotypes in addition to the utilization of the CED method for the intracranial
administration. AAV serotypes 5 and 9 (the highest and lowest transducing
vectors in our study respectively) were given via direct intracranial injection using
the CED method to 11 month old non transgenic animals with or without systemic
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pre treatment with mannitol. Animals receiving a systemic injection of 25%
mannitol followed by CED administration into the right hippocampus of AAV 5
showed significantly greater area of GFP expression 6 weeks post injection
compared to animals only receiving AAV 5 administration alone. GFP
expression in animals receiving systemic mannitol was throughout the entire right
hippocampal region and was also observed in the left (contralateral)
hippocampus (figure 4). All brain slices (25µm) in thickness through the
hippocampus showed positive GFP staining in the mannitol treated group while
the animals that did not receive mannitol did not have staining in the most ventral
and dorsal portions of the hippocampus (Figure 4). A 3 fold significant increase
in the percent area of positive GFP stain in the right hippocampus was observed
compared to animals that did not receive mannitol. In the contralateral
hemisphere we observed a 2 fold significant increase in GFP expression in
mannitol treated animals compared to animals without mannitol pretreatment
(figure 4).
All animals receiving AAV 9 administered using CED with or without
systemic mannitol showed much higher GFP expression than animals receiving
AAV 5 similar to our previous findings. In our comparison between animals
receiving AAV 9 with systemic mannitol pretreatment and those that did not
receive mannitol we did not observe significant differences of GFP expression in
the right hippocampus (at the site of injection) or in the left hippocampus
(contralateral to the injection site). GFP expression in the right hemisphere was
within the cell bodies of pyramidal neurons in the CA regions as well as granule
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cells in the dentate gyrus, mossy fibers and cells within the hilus. Axonal
projections making up the perforant pathway of the hippocampus were also
positive for GFP expression. All cell bodies and axonal projections in these
regions were intensely stained revealing a significant amount of GFP expression.
GFP positive neurons were observed in the subiculum and entorhinal cortex
which complete the hippocampal circuit. GFP expression in the left hemisphere
was limited to axonal projections which originate in the right hippocampal regions
(the site of injection). In the left hippocampus a few cells in the hilus were
positive for GFP expression, but most staining was observed in mossy fibers as
well as axonal projections of CA regions presumably of those originating in the
right hippocampus. The left entorhinal cortex was also positive for GFP
expression but significantly less than the right entorhinal cortex (figure 5). This
was also true for cells within the thalamus (figure 5). GFP positive neurons were
also observed in the right thalamic nuclei which receives input from the
subiculum of the hippocampus, and intense staining was observed in white
matter tracts corpus collusum which connect the right and left hemispheres as
well as the hippocampal commissure or commissure of fornix adjoining the right
and left hippocampus. Neurons positive for GFP expression were also observed
in the anterior cortex, caudate putamen, striatum, lateral and dorsal septal nuclei,
superior colliculus, and cerebellum of the ipsilateral hemisphere in both groups
receiving AAV9 independent of whether they received mannitol pretreatment.
To further characterize vector serotype tropism and whether tropism and
transduction efficiency of AAV 5 and AAV9 was modified by mannitol the tissue
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was double labeled using fluorescent immunostaining. Our results, following
injection with either AAV5 or AAV9, showed no co-localization of astrocytes
(GFAP which stains astrocytes) and GFP positive labelling in the dentate gyrus
of the hippocampus (or in any other regions in the brain) (figure 8). This was
noted in all animals receiving either serotype with or without mannitol
pretreatment. GFP labeled cells only co-localized with Neu-N (which stains
neurons) positive staining (figure 8). Positive labelling in the left uninjected
hemisphere was in a few cells in the hilus of the DG but the majority of positive
labelling was in the axons surrounding the cell bodies (figure 8, panel E-H).

DISCUSSION
The recent identification of different AAV serotypes has advanced the
study of rAAV vectors which has quickly become a major dominant focus in the
field of gene therapy. There are a number of studies aimed at characterizing the
different AAV serotypes with respect to transduction efficiency, tissue tropism,
cell surface receptors, intracellular processing, and capsid structure. AAV2
serotype was the first to be cloned into bacterial plasmids by Samulski et. al. in
1982 and to date it is the most characterized of all the serotypes of which a total
of 11 have been discovered (Samulski et al., 1982). AAV5 was originally
discovered in a human clinical sample in 1984 as a contaminant in adenovirus
stock and it contains ITRs that are not unlike the structures of AAV2 ITRs and is
the most divergent of all of the serotypes (Choi et al., 2005), (Wu et al., 2007).
AAV8 was originally isolated from rhesus monkey tissue in 2002 by Gao and
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collegues (Gao et al., 2002). AAV9, like AAV5, was originally discovered in
human tissue, while AAV10 and AAV11 are the most recently identified
serotypes, initially isolated from cynomolgus monkey tissue in 2004 by Mori et.
al., to date have not been fully characterized (Mori et al., 2006), (Wu et al., 2006),
(Wu et al., 2007). Several recent studies have shown that different serotypes
have distinct variations in their transduction efficiencies depending on the specific
cell or tissue type, yet the molecular mechanisms which determine the preferred
target cell for many serotypes remains unknown. Despite what is currently
known concerning different AAV transduction profiles, the data regarding AAV
serotype specific tissue tropism is subject to different interpretation due to
variations in vector titer, promoters, and transgenes between studies. In the
CNS, serotype characterization studies have revealed that AAV1, and 5 have
higher transduction efficiencies than AAV2 throughout all the regions and cell
types of the CNS (Alisky et al., 2000); (Burger et al., 2004), (Burger et al., 2005)
while AAV4 will efficiently transduce specific cell types such as astrocytes within
the subventricular zone (Davidson et al., 2000), (Weber et al., 2003), (Wu et al.,
2006). Studies by Wolfe and collegues also reveal that AAV7, 8, 9 and Rh10
expressing cDNA for lysosomal enzyme are also capable of transducing neurons
within specific regions in the mouse brain. AAV9 and AAVRh10 appeared to
have the highest transduction efficiencies and were found to undergo vector
genome transport through axonal transport pathways (Cearley and Wolfe, 2006,
2007)(Cearley and Wolfe, 2006).
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AAV2 vectors are the most extensively characterized and due to their well
established safety profile and range of infectivity, approximately 20 clinical trails
have been conducted using the AAV2 vector serotypes in numerous patients
(Herzog and Hagstrom, 2001), (Grieger and Samulski, 2005b), (Wu et al., 2006),
(Cai et al., 2009). Phase I/II clinical trails have been initiated utilizing
recombinant AAV 2 vectors for the treatment of human diseases such as cystic
fibrosis, α-1 anti-trypsin deficiency, Parkinson’s disease, Batten’s disease,
muscular dystrophy, hemophilia B, (Robbins and Ghivizzani, 1998) (Zhong et al.,
2008). Unfortunately, one major disadvantage of using AAV in the treatment of
brain disorders is the limitation in the dispersion of specific therapeutic gene or
protein to relevant regions or the entire brain (Cearley and Wolfe, 2007). In this
particular study we aim to characterize and compare transduction efficiencies in
the mouse CNS for AAV serotypes 5, 8, and 9 after a single intracranial
administration and improve distribution of the AAV as well as increase gene
expression in brain regions distal to the injection site using optimal injection
techniques in an innovative manner. Previous data from comparison studies of
different AAV serotypes have shown AAV 2, 5, 7 ,8 and 9 efficiently transduce
neurons in the murine CNS (Fu et al., 2003) (Burger et al., 2004) (Burger et al.,
2005) (Taymans et al., 2007). We hypothesized that we would be able to
sucessfully transduce neurons in the mouse brain after a single intracranial
injection of AAV 5, 8, or 9 (that express GFP) and we will be able to increase the
area of vector distribution using a CED administration technique in addition to
systemic mannitol treatment in a novel combinatory fashion.
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Following a single intracranial injection we successfully demonstrated that
AAV9 was the most efficient serotype in transducing a larger number of neurons
in a larger area of the brain than both AAV 5 and AAV 8. AAV 8 was only slightly
less efficient than AAV 9 and much more efficient that AAV5 at transducing
neurons in the mouse CNS. Our data in consistent with others who have also
shown that both AAV 8 and 9 can more efficiently transduce a larger region of
brain than AAV 5 in a murine animal model and yet others have shown this is
pattern is consistent in other species as well (Cearley and Wolfe, 2006). AAV 9
not only provides superior transduction compared to serotypes 5 and 8 in the
CNS but in other organs such as heart, liver and lung as well as global
transduction of several cell and tissue types in the periphery when systemically
injected (Bish et al., 2008), (Zincarelli et al., 2008). Furthermore, studies have
clearly shown AAV serotype 8 to have significantly superior transduction
efficiency than AAV2 or 5 in murine and nonhuman primate animal models which
is also consistent with our data showing serotype 8 to be more efficient at
transducing neurons in the mouse CNS than serotype 5 (Davidoff et al., 2005).
There are several explanations which may account for the differences in
transduction efficiencies between the different serotypes. AAV must first bind to
the cell surface receptor in order to successfully transduce the neurons once
injected into the brain (Cearley and Wolfe, 2006), (Kwon and Schaffer, 2008),
(Daya and Berns, 2008). This is followed by a series of essential steps; viral
uptake through endocytosis, intracellular trafficking and translocation of the
particle to the nucleus, virion uncoating, synthesis of double stranded DNA and
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finally viral gene expression (Rabinowitz et al., 2004), (Nash et al., 2007), (Kwon
and Schaffer, 2008), (Nash et al., 2009); (Choi et al., 2005); (Cearley and Wolfe,
2006), (Cearley et al., 2008); (Daya and Berns, 2008). Each of these steps is
essential to successful transgene expression and also determines the unique
tropism of the AAV serotype. Although the cell surface binding receptor for AAV
1, 2, 3, 4, and 5 have been previously described, receptors for more recently
discovered serotypes remains unclear. In 1998 Samulski et al determined that
AAV 2 utilizes the heparin sulfate proteoglycan receptor as its binding target and
also uses secondary binding co- receptor targets (including the αVβ5 integrin and
fibroblast growth factor receptor) which help stabilize viral binding thereby
enhancing transduction efficiency (Summerford and Samulski, 1998),
(Summerford et al., 1999), (Qiao et al., 2002), (Qing et al., 2003). AAV 1 has
been shown to bind to the same cell surface receptor and co-receptors as AAV 2,
while AAV 5 has been shown to interact with the sailic acid receptor and platelet
growth factor receptor and AAV 4, similar to AAV5, will bind to the sailic acid
receptor but needs specific carbohydrate linkage to successfully bind to the cell
surface (Walters et al., 2000), (Walters et al., 2001), (Kaludov et al., 2003),
(Akache et al., 2006). Most recently, Akache et al. have demonstrated that AAV
8 uses the 37/67 kD laminin receptor (LamR) to bind to mammalian cells and
overexpression of the LamR receptor results in increased binding of AAV 2,3 8
and 9 (expressing GFP) in vitro and a 2.5 fold increase in GFP expression
(Akache et al., 2006). These data indicate that the differences in expression
patterns between the different AAV serotypes used in the present study is
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primarily mediated by the cells surface receptor that the AAV serotype binds to
as well the co-receptors and the expression patterns of these receptors in the
mouse CNS. Other factors such as those previously mentioned (intracellular
trafficking and translocation of the particle to the nucleus, virion uncoating, and
synthesis of double stranded DNA and gene expression) may play a secondary
role in transduction efficiencies. Finally, the capacity to neutralize viral infection
particles with neutralizing antibodies, generated from a previous exposure, also
can affect the transduction profile of each serotype. Our findings as well as
others confirm that AAV 9 has significantly higher transduction efficiency in
neurons in the CNS compared to AAV 8 and AAV 5. The differences in cell
specific transduction efficiencies are likely a consequence of the effective cellular
entry through cell surface receptor modulation as well as un-packaging and postentry properties of each serotype (Hauck et al., 2004), (Wang et al., 2007). We
speculate that in this study AAV 9 was the most efficient likely due to its effective
and stable binding to specific cell surface receptors possibly the LamR receptor
or other potential receptors in addition to their expression profile within the
murine CNS. AAV 9 may be taken up by the cell more efficiently followed by
more efficient translocation and viral uncoating and un-packaging within the
nucleus of the neuronal cell and efficient DNA replication and expression
properties. The relative importance of each step in the process of transduction in
the mouse CNS remains unclear and warrants more study which would lend to
efforts in creating tailored recombinant AAV vectors with unique and disease
modifying specificity.
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Our next goal was to determine an optimal injection protocol aimed at
improving distribution properties of the AAV vectors within the brain parenchyma.
All of the intracranial injections into the hippocampus were performed using the
CED technique with a modified version of the step design cannula (Bankiewicz et
al., 2000) (Krauze et al., 2005a) which has previously been shown by us and
others to further increase the area of distribution of material in the brain
parenchyma in murine, canine, nonhuman primate as well as in humans
(Bankiewicz et al., 2000), (Krauze et al., 2005b), (Szerlip et al., 2007),
(Cunningham et al., 2008), (Dickinson et al., 2008), (Fiandaca et al., 2008). In
the present study we successfully further increase the area of distribution and
gene expression by combining the CED method with administration of mannitol
systemically approximately 15 min prior to the intracranial injection of AAV. Our
data are consistent with previous studies using AAV 2, in which mannitol further
increased the area of distribution within the striatum of the rat brain (Burger et al.,
2004). We clearly demonstrated that mannitol, by osmotically lowering
intracranial pressure, could significantly increase the area of distribution of AAV 5
after a single CED administration into the DG of the right hippocampus. This
distribution was evident throughout the entire right hippocampus allowing viral
particles to travel to areas throughout the right hippocampus as well as other
areas adjacent to the injection site such as the entorhinal cortex and thalamus
(although the expression was limited to a few cells in these regions). In addition
a significant amount of GFP gene expression was noted in the left uninjected
hemisphere most likely due to axonal retrograde transport which was not as
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apparent without mannitol pretreatment. The increase in GFP expression in the
left hippocampus we attribute to greatly increasing the number of cells in the
injected hemisphere that were exposed and therefore infected and expressing
significantly more GFP that was then transported axonally to the left hemisphere.
Mannitol also increased GFP gene expression in the AAV 9 treatment group in
the entorhinal cortex and thalamus. We did not see significant changes in the
hippocampus due to the preexisting high transduction efficiency of AAV 9
throughout the right and left hippocampi.
Despite the rapidly growing popularity of AAV as a method of gene
delivery, much remains unknown with regard to cellular mechanisms that are
responsible for different AAV characteristics. Although AAV demonstrate longterm gene expression in vivo and a good safety profile, potential risks due to the
host response to these vectors need further study. Unlike adenovirus vectors
which induce expression of chemokines and acute toxicity, AAV have not been
previously associated with an inflammatory response or significant toxcity (Beuler
et al., 1999), (Carter et al., 2000), (Muruve et al., 2004). Some studies have
shown repeated administration of AAV in the periphery results in a hummoral
immune response, generated in the first administration, which dramatically
lowers transduction efficiency upon second administration (Halbert et al.,
1997),(Halbert et al., 1998). This problem can be overcome by host immunosuppression (Halbert et al., 1998), (Manning et al., 1998). The majority of the
human population (an estimated 80%) has been naturally previously exposed to
wt AAV 2 and demonstrates presence of neutralizing anticapsid antibodies
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(Chirmule et al., 1999), (Erles et al., 1999) which could be a potential problem for
clinical success of AAV 2. Recently studies have demonstrated that generating
recombinant AAV can effectively overcome wt AAV neutralizing antibodies
(Mandell et al., 2004). Through modification of wt AAV and the creation of a
variety of rAAV with uniquely tailored specificity, there is immeasurable potential
for the use of AAV as a successful gene therapy technique.
In the present study we investigate not only differences in transduction
profiles of specific AAV serotypes but also optimization of administration
techniques with regard to AAV in the CNS. In recent years, scientists have
conducted several studies aimed at improving transduction efficiencies of AAV
vectors in different tissue types through modification of the AAV genome. The
utilization of a “cross-packaging” strategy which essentially enables an unbiased
direct comparison of the transduction rates without influence of ITRs on
transgene expression has recently become a novel way to create recombinant
AAV vectors (Rabinowitz and Samulski, 2000), (Rabinowitz et al., 2004), (Grieger
and Samulski, 2005a), (Wu et al., 2006). To accomplish this the Cap genes of
different serotypes are placed downstream of the AAV2 Rep genes which
ultimately allows the generation of serotypes specific capsids while the packaged
genomes within the capsids are identical, these are also referred to as hybrid
viruses (Rabinowitz et al., 2002), (Wu et al., 2006). In addition to
transcapsidation first described by Rabinowitz et. al. in 2002 there are several
other techniques to accomplish the formation of a hybrid virus armed with
specific modifications to enhance efficiency of gene uptake, transfer, and
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expression in a specified therapeutic avenue. These include absorption
modifications where the capsid surface is modified to carry a foreign antibody
that will bind to the cell surface receptor of interest to increase absorption
efficiency. Mosaic capsids are another method to increase transduction
efficiency. This technique involves creating a mixture of viral capsid proteins
from different serotypes at various ratios in order to combine tissue tropisms of
interest (Xiao et al., 1999), (Rabinowitz and Samulski, 2000), (Kruger et al.,
2008). Finally, chimeric capsids can also provide a means of increasing
transduction of a particular specificity and this technique involves the packaging
of capsid proteins with foreign peptide sequences, such as a hemagglutinin (HA)
tag fused at either the N or C terminus of the capsid coding sequence to alter
tissue tropism (Yang et al., 1999), (Bowles et al., 2003), (Wu et al., 2006).
Despite the rapidly growing body of knowledge in the field of AAV vector
serology there is still much to be done. In addition to the 11 AAV serotypes that
have been found, over 100 AAV variants have also been discovered. Delineating
differences in transduction properties, and defining distinct characteristics of
each virus is a burgeoning area of investigation. The technological advances in
recombinant molecular biology have permitted investigators to construct a myriad
of recombinant AAV vectors that can be customized to take advantage of
differences in transduction profiles which can be targeted for several different cell
types. In addition, optimization of administration techniques that increase
distributive properties of AAV such as CED and mannitol have improved gene
delivery capacity of these vectors suggesting near limiteless potential they may
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provide as a superior gene transfer vehicle through which to treat a variety of
neurological diseases.
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FIGURE 1: GFP EXPRESSION IS INCREASED FOLLOWING INTRACRANIAL
ADMINISTRATION OF AAV5 USING CONVECTION ENHANCED DELIVERY.
Percent positive area stained for anti-GFP is increased in the hippocampus,
cortex and thalamus in 9 month old mice using CED method (5μl/min flow rate).
The percent positive staining of GFP is significantly increased in the striatum and
entorhinal cortex using the CED method compared to traditional injection
method. The star (*) indicates significance with a p-value < 0.05. Magnification
100X on Olympus BX51.
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FIGURE 2: CED METHOD DOES NOT RESULT IN NEURON LOSS OR
SIGNIFICANT INCREASE IN CD45 EXPRESSION. Nissl staining showed no
obvious loss of neurons in the hippocampus following either the CED injection
method (panel B) or the traditional injection method (panel A). CD45
immunostaining is increased (panel E) but not significantly in animals receiving
the CED injection (panel D) compared to animals receiving the traditional
injection (panel C). Quantification of CD45 immunostaining is represented as %
Area stain (panel E). Magnification 40X on Olympus BX51.
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FIGURE 3: COMPARISON OF AAV SEROTYPES 5, 8, AND 9 EXPRESSING
GFP. Expression of GFP in the right and left hippocampus following a single
CED intracranial injection into the right hippocampus of AAV5, 8, and 9
serotypes. AAV 9 was distributed to a significantly larger area of the
hippocampus in both the left and right hippocampus (panels A and B) following
treatment than both AAV serotype 8 and 5 (panel C-F). The star (*) indicates
significance with a p-value < 0.05. Magnification 40X on Olympus BX51.
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FIGURE 4: GFP EXPRESSION IS INCREASED FOLLOWING
ADMINISTRATION OF AAV5 USING CED AND SYSTEMIC MANNITOL.
Percent positive area stained for anti-GFP is significantly increased in the right
and left hippocampus in 11 month old mice following CED delivery of AAV5 and
systemic mannitol pretreatment (panel C and D) compared to animals injected
with AAV 5 and did not receive systemic mannitol (panel A and B). Panel E
shows quantification of percent area positive stain for anti-GFP
immunohistochemistry. The star (*) indicates significance with a p-value < 0.05.
Magnification 40X on Olympus BX51 (panels A-D).
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FIGURE 5: GFP EXPRESSION IS INCREASED IN THE THALAMUS AND
ENTORINAL CORTEX FOLLOWING ADMINISTRATION OF AAV9 USING
CED AND SYSTEMIC MANNITOL. Positive area stained for anti-GFP was
intense throughout the entire hippocampus for all 11 month old mice following
CED delivery of AAV9 with (panels A and B) or without systemic mannitol
pretreatment (panels C and D). A larger area of positive area staining was
evident in the both the left and right entorhinal cortex and the right thalamus
following CED delivery of AAV9 in animals pretreated with systemic mannitol
(panels G and H) compared to animals that did not receive systemic mannitol
(panels E and F). Magnification 40X on Olympus BX51 (panels A-H).
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FIGURE 6: QUANTIFICATION OF ANTI-GFP STAINING FOLLOWING AAV 9
ADMINISTRATION. Quantification of Percent positive area stained for anti-GFP
is significantly increased in the thalamus and entorhinal cortex in 11 month old
mice following CED delivery of AAV9 and systemic mannitol pretreatment (panel
B) No significant difference in anti-GFP staining was noted in the right or left
hippocampus following AAV 9 administration and systemic mannitol
pretreatment. The star (*) indicates significance with a p-value < 0.05.
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FIGURE 7: TRANSDUCTION EFFICIENCY IN HIPPOCAMPUS FOLLOWING
AAV5 AND AAV9 ADMINISTRATION. Transduction of GFP following AAV 5
and AAV9 administration into the hippocampus. GFP is expressed in the dentate
gyrus granule and pyramidal cell bodies and axons in CA regions in the
hippocampus primarily in the right hemisphere following a single intracranial
injection of AAV 5 using CED method and systemic mannitol administration into
the right hippocampus and in axonal projections in the left hippocampus (panels
C and D; and E-H). GFP is expressed in neuronal cell bodies and axonal
projections in all regions of right hippocampus following AAV 9 injections using
CED and systemic mannitol administration (panels A and B). GFP expression is
primarily in axonal projections eminating from the right hippocampus as well as in
some neuronal cell bodies in the hilus of the dentate gyrus (panels I-K).
Magnification 40X panels A-D; magnification 100X panels E-K.
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FIGURE 8: TRANSDUCTION EFFICIENCY AND GFP EXRESSION IN CELL
TYPES FOLLOWING AAV 5 AND AAV9 ADMINISTRATION INTO
HIPPOCAMPUS. GFP is expressed in the granule and pyramidal cell layers in
the hippocampus as well as in neurons in entorhinal cortex primarily in the right
hemisphere following a single intracranial injection into the right hippocampus.
Panels A-D shows no co-localization (panel D) of astrocytic staining (GFAP)
(panel B) and GFP positive labeling (panel A) in the dentate gyrus of the
hippocampus (or in any other regions in the brain). This was noted in all animals
receiving either serotype. Positive labelling in the left uninjected hemisphere was
in a few cells in the hilus (panel E) of the DG. Co-localization of NeuN and GFP
positive staining indicate that mainly neurons were transfected in this region
(panel E-H). The majority of positive labelling was in the axons surrounding the
cell bodies (panel E). Panels I-L show staining of the entorhinal cortex ipsilateral
to the injection site. Co-localization of GFP positive cells and Neu-N (panel L)
indicates that AAV transfect mainly neurons in this region. Magnification 100X.
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CONCLUSIONS

Alzheimer’s disease (AD) is the sixth leading cause of death in the United
States and has been known as one of the most pervasive and devastating forms
of dementia afflicting the aged population worldwide accounting for 70% of all
dementia cases. Although the pathological etiology which causes a slow
progressive decline in normal brain function is well characterized, we have yet to
identify novel therapeutics that result in the cessation of the disease process and
a marked overall significant and longterm improvement in cognitive function.
Unfortunately, with the steady increase in life expectancy of our aged population,
the number of individuals over the age of 65 affected with this disease is rapidly
increasing and will continue to increase by approximatly 50% over the next two
decades. Current estimations predict that 10 million baby boomers will develop
AD in the coming years. AD causes emotional trauma to family members and
caregivers in addition to generating a growing economic burden as healthcare
costs continue to rise in accordance with the increasing number of individuals
who suffer from the disease. Finding a novel therapeutic to delay onset of
symptoms, improve cognitive function and potentially prevent further mental
decline is essential to relieve both ecomonic and emotional burdens which may
plague many individuals in the near future.
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The pathological disease process of AD that instigates the destruction of
neurons in the CNS is thought to ultimately result in the progressive decline in
mental function and cognitive abilities that manifest as a general loss of memory
that is severe enough to interfere with daily life. This decline in memory can be
an early clinical symptom of AD. Because there are several other types of
dementia that have overlapping symptom patterns, a true diagnostic confirmation
of AD is the presence of neuritic plaques composed of beta-amyloid (Aβ) and
intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein
identified in post-mortem brain tissue.
The Aβ peptide which was first discovered in 1984 has for decades been
identified as the central pathological feature from which all other
neuropathological insults that occur in AD disease progression stem (Glenner et
al., 1984). The Amyloid Cascade Hypothesis, first described by John Hardy and
David Allsop circa 1991 suggests that it is the the overproduction and ensuing
accumulation of Aβ peptides, resulting from the abberant processing of APP that
is the fundamental event which then drives the formation of phosphorylated tau
into neurofibrillary tangles which then result in disruption and disregulation of
synaptic transmission, eventually causing the death of neurons and manifestation
of dementia (Hardy and Allsop, 1991), (Selkoe, 1991a, 2001), (Tanzi, 2005).
This theory has provided a roadmap of AD pathology for decades and is
supported by a number of epidemiological genetic studies, molecular in vitro
studies as well as in vivo studies using animal models of amyloid accumulation.
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The role of APP protein metabolism in AD pathogenesis has been
extensively studied, although its native biological role is still only speculative.
Some studies suggest that APP is involved in synaptic formation and repair as
well as neuronal plasticity (Wang et al., 2006), (Priller et al., 2006). Recent
studies provide substantial evidence that APP expression is upregulated during
neuronal differentiation following neural injury. Additionally, APP has been
implicated to participate in cell signaling, long-term potentiation, and cell
adhesion but only a limited number of studies have been done in this area to
date (Zheng et al., 2006), (Priller et al., 2006). APP undergoes numerous post
translation modifications (De Strooper et al., 2000) as well as many types of
proteolyic processing. A number of genetic studies clearly illustrate that
mutations in APP can cause the over production of Aβ peptides resulting in an
increased ratio of the more fibrillogenic Aβ1-42/1-40 (Wang et al., 1999), (Ling et
al., 2003). The APP gene has been localized to chromosome 21 and thus as a
result AD-like neuropathology is consistently observed in Down’s syndrome or
trisomy 21, due to the increased APP expression and thus higher Aβ levels
(Glenner and Wong, 1984).
Unfortunately, the autosomal dominant genetic mutations that result in AD
(originally identified during the 1990’s) which include the APP mutations and the
presenilin mutations (PS1 and PS2), occur infrequently and account for a
miniscule percentage of the current population (approximately 1-2 %) which
suffers from the disease (Selkoe, 1991b), (Nunan and Small, 2002), (Saito et al.,
2003). These FAD (familial AD) mutations also result in very aggressive disease
152

progression and clinical symptoms can become apparent as early as 30 to 40
years of age but most commonly before the age of 65 (Selkoe, 1991c). Thus the
overwhelming majority of AD cases occur in an age dependent manner at a rate
that increases exponentially with age. Recently, a more thorough investigation
into the cellular processes that mediate the sporadic late onset AD cases has
become a dominant approach in the identification of specific targets in the
treatment of AD.
The identification of the FAD mutations and the role they play in the
production of the toxic Aβ peptides (due to abberant changes in APP processing)
gave rise to the first generation of Aβ overexpressing mouse models of AD. The
PDAPP mouse model of AD was the first transgenic mouse containing the
overexpressed mutant human APP and provided a new animal model through
which to investigate mechanisms of amyloid deposition and removal (but did not
contain tau pathology nor neuron loss) (Games et al., 1995). Other transgenic
mouse models followed including the Tg2576 which was the first mouse model to
show learning memory deficits that were closely correlated with age dependent
amyloid deposition in a reliable fashion (Hsiao et al., 1996), (Morgan et al.,
2000), (Ashe, 2006). Additional transgenic mouse models of AD include the
double transgenic APP + PS1 mutations that harbor an increased aggressive
pathology that begins at a younger age than that of the afor-mentioned single
transgenic animals. These mice also show learning and memory deficits at an
early age (which again correlated with paranchymal amyloid load) compared to
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the mouse models with only the APP mutations (Borchelt et al., 1997), (Citron et
al., 1998), (Holcomb et al., 1998), (Gordon et al., 2002).
The development of mouse models of Aβ accumulation and deposition
paved the way for the development of several therapeutic target strategies that
have evolved over recent years and yet unfortunately an effective therapeutic
that can permanently reverse cognitive deficits suffered by AD patients remains
elusive. Currently, there are two types of medications approved for the
treatment of AD which include cholinesterase inhibitors and N –methyl –D
aspartate (NMDA) antagonist. Although some patients respond initially to these
drugs they do not modify the disease process, only having a transient moderate
effect on clinical symptoms with a host of unappealing side effects. The lack of
disease modifying drugs for AD has fueled research efforts focused on
development of novel therapeutics that have the potential to halt its progression
and improve clinical symptoms.
The supposition that Aβ is the primary toxic pathogenic agent that
accumulates subsequently inducing a number of other pathogical abnormalities
has provided the catalyst driving several therapeutic approaches aimed at
lowering Aβ levels in the brain to treat AD (Hardy and Allsop, 1991), (Turner et
al., 2004). Although Aβ toxicity has been extensively studied and is generally
accepted, the specific form of Aβ aggregate that is the primary caustic moiety
contributing to neuron dysfunction is still debated. Initial reports identified fibrillar
Aβ as the major toxic species which subsequently resulted in decreased synaptic
function and neuronal death. Current reports have refuted these initial findings
154

revealing that large Aβ deposits or plaques may in fact play a neuroprotective
role. Their formation may provide a mechanism in which smaller soluble Aβ
moieties are sequestered into larger insoluble aggregates preventing them from
causing destruction. Specifically, the soluble oligomeric Aβ assemblies have
been implicated as the driving factor in AD pathogenesis as they exhibit potent
toxicity in their capacity to significantly decrease long term potentiation (LTP),
contribute to learning and memory deficits in vivo and induce neuronal cell death
in vitro (Lambert et al., 1998), (Naslund et al., 2000), (Klein, 2002), (Glabe,
2005), (Townsend et al., 2006), (Selkoe, 2008), (Varvel et al., 2008). Under
normal physiological conditions Aβ is constitutively produced and catabolized in
the brain which suggests that it may have a role as a physiological metabolite of
APP processing. Furthermore, recent studies have shown that picomolar
concentrations of Aβ containing both monomers and oligomers cause an
increase in hippocampal long term potentiation and improved memory whereas
higher concentrations in the nanomolar range, Aβ conversely causes a reduction
in potentiation by modifiying the activity of voltage-dependent Ca + channels and
GTPase activity in neurons (Cirrito et al., 2003), (Puzzo et al., 2008); (Koudinov
and Berezov, 2004). These results suggest the production of low levels of Aβ is
a normal physiological process involved in modulating neurotransmission that
occurs during learning and memory. Conversely, high levels of Aβ leads to
deficits in neurotransmission eventually leading cognitive deficits manifested as
dementia (Cirrito et al., 2003), (Haass and Selkoe, 2007), (Puzzo et al., 2008).
The link between Aβ levels and its influence on learning and memory has been
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supported by several in vivo studies involving APP knockout mice that show
impairments in memory and LTP (Seabrook et al., 1999). These studies have
provided one focus of disease modification strategies pertaining to drugs that can
potentially inhibit Aβ formation, a process requiring β and γ secretase activity
(Selkoe, 1991b), (Hardy and Selkoe, 2002). The identification of the essential
enzyme BACE 1, a transmembrane aspartyl protease that is believed to
contribute to the majority of β-secretase activity, required for the production of Aβ
in the brain initially provided a novel therapeutic target for the treatment of AD.
Thus finding effective inhibitors of BACE 1 was an early disease modification
approach in the development of AD drug targets. The first BACE 1 knockout
animal models were initially characterized in 2001, and fortuitously did not show
any phenotypic deleterious consequence while showing a decrease in Aβ in the
brain (Roberds et al., 2001), (Dominquez et al., 2001), (Turner et al., 2004).
Unfortunately, BACE 1 inhibitors have shown little success which may be due to
the fact that BACE 1 has recently been found to have several endogenous
substrates. Upon further investigation it has been revealed that BACE 1
knockout mice have several deleterious phenotypes including premature death,
cognitive deficits, and hypermyelination (Dominguez et al., 2001), (Turner et al.,
2004).
Targeting γ-secretase activity provided yet another disease modifying
therapeutic approach initially receiving a great deal of attention and support in
the initial stages of developing drug targets for the treatment of AD. In vivo
studies involving γ-secretase and PS1 knockout models reveal the essential role
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it plays Notch signaling (an important transmembrane protein that is essential
during development) rendering these animals non viable (Shen, 1998). Although
γ-secretase inhibitors can successfully reduce Aβ synthesis, accumulation and
deposition, they have also been shown to improve cognition. Blocking BACE 1
activity also prevents Notch signaling and chronic dosing of this class of inhibitors
has been shown to have several deleterious effects including changes in the
spleen, thymus, and gastrointestinal changes (Searfoss et al., 2003), (Milano et
al., 2004), (Wong et al., 2004). The expression of both β and γ-secretase is
ubiquitous and evidence that they maintain important activity in several essential
physiological processes has limited their potential as viable therapeutic targets
for AD drug development.
Another therapeutic strategy that has recently gained more momentum in
the AD research community as a possible drug target aimed at modifying the AD
disease process, involves modifying mechanisms of Aβ degradation (as opposed
to targeting its synthesis through secretase inhibition). The normal synthesis and
catabolism of the Aβ peptide has been demonstrated to be a dynamic process
involving several endogenous β-amyloid degrading enzymes and include a family
of zinc metalloprotease expressed in the periphery and in the brain. In contrast
to inherited FAD, the accumulation of Aβ in late onset sporadic AD, has been
implicated to be the result of an imbalance between Aβ production and removal.
This deficiency in the removal process has been attributed to abnormal
accumulation and formation of Aβ deposits in the brain (Selkoe, 2001), (Saito et
al., 2003), (Turner et al., 2004). Deficits in the normal Aβ removal is mediated
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through several contributing cellular processes, including drainage by diffusion of
Aβ into the extracellular matrix, low-density lipoprotein related receptor protein 1
(LRP-1) mediated transport across blood vessels into the circulation acting as a
peripheral sink (Sagare et al., 2007), (Deane et al., 2009), and enzymatic
degradation through endogenously expressed proteases (Iwata et al., 2001),
(Saito et al., 2001), (Saito et al., 2003). Although a growing number of
endogenous proteases have been implicated in several studies as having
amyloid degrading capabilities in vitro, only a small minority of these have been
identified as major contributing factors in the pathological accumulation of Aβ
peptides in the brain. Under normal physiologic conditions the catabolism of Aβ
is mediated through the activation of neprilysin, endothelin converting enzyme,
insulin degrading enzyme, angiotensin converting enzyme and matrix
metalloproteases 2, 6 and 9, all of which belong to a family of zinc
metalloproteinases (Mentlein et al., 1998), (Carson and Turner, 2002),
(Mukherjee and Hersh, 2002), (Saito et al., 2003), (Turner et al., 2004), (Mouri et
al., 2006), (Turner and Nalivaeva, 2007), (Miners et al., 2008). More recently,
additional proteases that have been shown to have several cleavage locations
along the Aβ peptide thus may contribute to maintaining homeostatic Aβ levels,
include plasmin, mitochondrial peptidasome (PreP) and cathepsins B and D
(Turner and Nalivaeva, 2007).
A growing body of evidence from both in vivo and in vitro data, including
data presented in papers 1 and 2, support the importance of these proteases in
preventing the aberrant accumulation of Aβ in the brain. A series of in vitro
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studies first identified insulin degrading enzyme and neutral endopeptidase (later
recognized as neprilysin) as proteolytic enzymes capable of cleaving the Aβ
peptide at multiple sites. Subsequently, a series of studies published in 2001
and 2002 by Saido and Iwata et al clearly established NEP as a major modulator
of Aβ metabolism in the brain (Iwata et al., 2000), (Iwata et al., 2001), (Saito et
al., 2001), (Iwata et al., 2002). Furthermore, post mortem analysis of human AD
brain tissue showed a distinct correlation between increases in Aβ deposition and
decreases in NEP mRNA levels as well as NEP and IDE protein levels in a
region specific manner compared to control individuals (Yasojima et al., 2001b),
(Yasojima et al., 2001a), (Caccamo et al., 2005). Further investigation into the
link between NEP and Aβ under normal physiological conditions has attempted
to identify cellular mechanisms that may modify NEP gene expression in the AD
brain environment. Pardossi-Piquard et al, in 2005, proposed that NEP gene
transcription under normal physiological conditions can be upregulated by the
βAPP intracellular domain (ACID), the cytosolic fragment generated following
cleavage of APP by γ-secretase (Pardossi-Piquard et al., 2005). These data
support the speculation that Aβ production/degradation may be closely linked but
does not explain decreased NEP expression in the post mortem AD tissue or the
net accumulation and deposition of amyloid in late onset AD cases. Interestingly,
Jiang and collegues in 2008 provide additional molecular mechanisms that
contribute to Aβ metabolism, reporting that ApoE, a known risk factor in late
onset AD, can bind Aβ and promote its degradation (Jiang et al., 2008). Once
bound to Aβ it is postulated that the ApoE can acts as a chaperone allowing
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efflux out of the brain across the blood brain barrier though specific receptors
LRP1 or VLDL (Poirier, 2000), (Deane et al., 2004), (Zlokovic et al., 2005),
(Deane and Zlokovic, 2007) or facilitate its degradation by NEP and IDE in the
late endosome of microglia (Jiang et al., 2008). The efficiency with which ApoE
binds soluble Aβ, either facilitating or slowing its degradation, is dependent on
the lipidation state and specific isoform. Unfortunately the underlying molecular
mechanisms modulating this process have yet to be clarified. The overall
accumulation and deposition of Aβ, particularly in late onset sporadic AD, is likely
the result of the additive effects of multiple deleterious events occurring over time
which influence production, accumulation and fibrillogenesis, and degradation.
These data are supported by a large number of in vivo studies with
transgenic animal models to further understand the roles of specific enzymes in
the catabolism of Aβ. Initial reports of mice deficient of these enzymes,
specifically NEP, ECE, and IDE demonstrated significant increases in steady
state levels of Aβ in the brain. Eckman and collegues reported that the dual
knockdown of NEP and ECE resulted in an additive cumulative effect on amyloid
load in the brain (Eckman et al., 2006). Additional studies using the direct
transduction of neurons resulting in the increased expression in a variety of βamyloid degrading enzymes including NEP, ECE, IDE, MMP-2 and 9, plasmin
and cathepsin B were accompanied by the significant reductions in the overall Aβ
in vitro (Marr et al., 2004), (Mueller-Steiner et al., 2006), (Yan et al., 2006). In
vivo studies involving gene transfer methods for the treatment of Alzheimer’s
pathology using viral vectors have had some success in reducing Aβ deposition
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by overexpressing Aβ degrading enzymes, including NEP, ECE and IDE and
more recently Cathepsin B, a cysteine protease also implicated in the lysosomal
degratory pathway of Aβ peptides (Marr et al., 2004), (Mueller-Steiner et al.,
2006). The degree to which each enzyme contributes to the overall catabolism
of Aβ is not entirely delineated. Some reports identify neprilysin as having the
most pronounced effect on plaque load in the brain, while others identify MMP-9
as the most efficient proteolytic enzyme in the degradation of Aβ, compared to
others, due to its ability to degrade both fibrillar and monomeric forms of Aβ in
vitro (Eckman et al., 2003), (Yan et al., 2006), (Farris et al., 2007), (Hersh and
Rodgers, 2008), (Spencer et al., 2008).
In paper 1 we investigate the effectiveness of overexpessing ECE on
amyloid load in the more aggressive model of Aβ deposition double transgenic
APP+PS1 mice using rAAV vectors as a method of gene therapy. Recombinant
AAV has become widely used for the transduction of neuronal cells. AAV is
nonpathogenic, has low immunogenicity, lacks all viral genes and is capable of
long term expression in neurons. Thus making rAAV an attractive method for the
use as a gene therapy vector for neurological disorders (Burger et al., 2005),
(Mandel et al., 2006). Moreover, rAAV is currently being examined in a number
of neurological clinical trials (Mandel and Burger, 2004). Six weeks post
intracranial injection of rAAV-ECEHA serotype 5, into the right hippocampus and
anterior cortical regions, we demonstrated successful transduction of several
different neuronal cell types in the mouse CNS including CA4 neurons in the
hilus and CA3 neurons of the hippocampus pyramidal cell layer (paper 1, figure
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3) . We also were able to show transduction of neurons in the dentate molecular
layer, as well as a number of round cells possibly oligodendrocytes. The positive
transduction of cells in the CNS although concentrated at the injection sites was
also evident in regions distal from these regions and was detected in the
striatum, entorhinal cortex, subiculum, and corpus callosum along the midline of
the ipsilateral hemisphere. Additionally, some positive neurons in the
contralateral left hippocampus were also detected. These findings are consistent
with Burger and collegues, and are believed to result from retrograde transport of
the virus along axonal projections originating in the right hippocampus and
synapsing in the left hippocampus (Burger et al., 2004). Positive transduction of
neurons expressing ECE were evidenced by anti HA immunohistochemistry. Not
only were we able to show an increase ECE expression following rAAV
treatment, but were successfully demonstrate that the transduced neurons show
a 70% increase in ECE activity compared to control rAAV-GFP animals.
Furthermore, this increase in ECE activity resulted in significant decreases in
total amyloid load and congophilic plaque load in these regions (paper 1, figure 5
and 6). Our data are consistent with reports that ECE can degrade Aβ in vitro,
and that partial knockdown of the ECE gene leads to more rapid accumulation of
Aß in transgenic mouse models (Eckman and Eckman, 2005).
Our results from paper 1 showed that modification of ECE expression
through the use of rAAV vectors contributes to degradation of Aβ, ultimately
decreasing both total Aβ and congophilic load in the brain. In paper 2 we
investigate whether overexpression of neprilysin will have an equal or greater
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effect on Aβ levels. In vivo data demonstrating NEP contributes to Aβ
degradation, has been proven by results that show an increase in endogenous
Aβ levels in a gene dose dependent manner. Decreased NEP protein
expression thus contributes to plaque formation and increase CAA levels in NEP
knockout animal studies (Farris et al., 2007). Similar results were obtained with
NEP specific inhibitors that dramatically decrease NEP activity also resulting in
significant increases in endogenous Aβ levels in mice (Iwata et al., 2001),
(Eckman and Eckman, 2005), (Iwata et al. 2001), ( Eckman et al. 2005).
Previously reported gene transfer studies demonstrated that treatment of amyloid
depositing APP transgenic mice using lenti virus and AAV to overexpress NEP
could significantly decelerate/decrease amyloid accumulation (Marr et al., 2003),
(Iwata et al., 2004); (Iwata et al 2004), (Marr et al 2003).
In Paper 2 we investigate both the effectiveness of rAAV to deliver NEP to
neurons in the mouse brain as well as novel means of increasing dispersion of
the virus and gene product to therapeutically relevent regions within the mouse
CNS. Specifically, we examine transduction efficiency and area of distribution of
two different NEP constructs (a membrane bound or an engineered secreted
form; NEP-n and NEP-s respectively) in the hippocampus and anterior cortex.
Conclusively, we compared the effects of overexpression of both NEP enzymes
on amyloid burden. Unlike previous gene transfer studies aimed at modification
of AD pathology, we administered rAAV by convection enhanced delivery
method, initially described by Krauze and collegues, in an effort to increase the
dispersion of the rAAV to larger regions in the brain parenchyma to improve gene
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transduction efficiency and increase levels of NEP protein expression to obtain a
larger global effect on total amyloid burden.
Six weeks post injections of rAAV vectors administration into the right
hippocampal and anterior cortical regions, we were able to obtain successful
gene transfer NEP constructs which include those previously mentioned, NEP-n
and NEP-s as well as an inactive mutant NEP (NEP-m) construct. We were able
to transduce a variety of neuronal cell types similar to those reported in paper 1
due to the fact that we used the same AAV serotype 5. Positive NEP expression
revealed by anti-HA immunohistochemistry showed staining concentrated in
areas at the site of injection in the hippocampus and anterior cortex as well as in
sites distal from the injection site. NEP protein expression was evident
thoughout the entire hippocampus and some staining was observed in the
entorhinal cortex in the right hemisphere (ipsilateral to the injection site). Miminal
staining was also observed in the contralateral hippocampus of animals receiving
the NEP-n and NEP-m rAAV. Staining was also seen in the striatum and corpus
callosum and to small extent in the ipsilateral hemisphere along the midline.
The staining for NEP-n and NEP-m was greater in intensity covering a larger
region both in the hippocampus and anterior cortex compared to the staining for
NEP-s (Paper 2, Fig. 2A and 2C). The NEP-s construct was engineered, through
modification of the membrane binding sequence to instead encoding a signal
peptide sequence in the hopes of creating a nucleus from which the expressed
protein could diffuse to greater regions of the brain; thus eliminating the
requirement for a large number of injections. The NEP-s expression profile
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revealed less intensity of HA staining when compared to the NEP-m and NEP-n
staining patterns. Cells within the hilus of the molecular layer were stained as
were as cells in the CA3 region of the hippocampus. Although the NEP-s
showed less intense staining this may have been due to the diffusion of the NEP
protease throughout the extracellular matrix. Diffuse secreted NEP protein may
not be concentrated in a specified region, making it more difficult to detect using
anti-HA immunohistochemisty compared to the membrane bound NEP-n
protease. An alternative explanation for the NEP-s staining pattern may be that
once the NEP-s is secreted the NEP protein or possibly the HA-tag is more prone
to degradation by other extracellular proteases that is would not otherwise be
exposed to upon secretion not necessarily that this vector had lower transduction
efficiency.
Although NEP-s staining was significantly less intense (compared to the
other constructs), the anterior cortex showed significantly more intense staining
compared to the hippocampus. This result may indicate that the signal peptide
is processed more effectively in the cortex compared to the hippocampus.
Despite the differences in staining intensity of the different NEP proteins, in vitro
data confirmed that both NEP-n and NEP-s proteases showed significant levels
of enzyme activity in the cell pellet, while the NEP-m version did not.
Additionally, only the media from NEP-s transfected cells showed significant
enzyme activity. The in vitro activity data was further corroborated with results
from our examination of amyloid burden in APP+PS1 mice following treatment
with the rAAV NEP constructs. NEP-n and NEP-s were able to significantly
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reduce total Aβ deposition and congophilic deposits in the anterior cortex and
hippocampus at the site of injection.

Examination of Aβ staining in the

contralateral hemisphere revealed that NEP-s rAAV significantly decreased total
Aβ load in hippocampus and cortex compared to the control group. NEP-n
treated animals showed significant decreases in total Aβ in the contralateral
anterior cortex but not the hippocampus. More, interestingly, examination of
congophilic staining on the contralateral hippocampal side revealed there was
approximately 40% and 50% reductions with the NEP-n and NEP-s treatments
respectively, but only the reduction with NEP-s was statistically significant
compared to the control group. No reductions in congophilic staining were
observed in the contralateral anterior cortex with either NEP constructs. The
reduction on the contralateral hemisphere observed here is likely due to
retrograde transport of the rAAV which has been previously reported (Burger et
al., 2004; Iwata et al., 2004) and anterograde transport of the NEP protein. No
expression was detected in the contralateral cortex which may be due a
decreased number of neuronal connections between the right and left cortices
compared to those in the hippocampus. This may explain our results which show
a reduction in congophilic staining in the contralateral hippocampus and not the
contralateral anterior cortex. We were also able to demonstrate decreases in
amyloid load in aged 20 month old APP+PS1 mice following overexpression of
NEP-s for five months (injections were administered bilaterally at 15 months).
Total Aβ was reduced significantly in the left anterior cortex as well as in the left
and right hippocampus following treatment with the NEP-s vector compared to
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control untreated animals. Total congophilic staining was also significantly
reduced in both contralateral and ipsilateral hemisphere in the hippocampi and
cortices following intracranial administration of rAAV-NEP-s. Our results reported
here in paper 2 are consistent with data previously reported by Iwata et al in
2004 using rAAV to overexpress NEP in young and old APP transgenic mice
(Iwata et al., 2004). Our results also revealed that we were able to show more
substaintial decreases in Aβ load in both the ispilateral and contralateral
hemisphere’s following NEP overexpression in the more aggressive amyloid
depositing double transgenic mouse model in both young and old animals.
Additionally, we demonstrate reductions were not limited to soluble forms of Aβ
but signifcant reductions in congophilic load as well. An explanation for
decreases in congophilic staining may be that NEP degrades oligomeric and
monomeric soluble Aβ aggregates (Kanemitsu et al., 2003), (Yan et al., 2006),
generally believed to be the toxic precursors to fibrillar insoluble aggregates
preventing accumulation rather than actively degrading existing deposits.
Ultimately, the engineered NEP-s construct was more efficient in decreasing
fibrillar Aβ load in the contralateral hemisphere compared to the NEP-n and
control vectors, while the NEP-n more efficiently decreased total Aβ load, in the
ipsilateral hemisphere. As previously mentioned our findings showed that by
implementing the use of a secreted form of the NEP protease in addition to using
the CED method for intracranial administration, we were able to successfully
improve the area of gene expression and further reduce amyloid load in the
brain. We speculate that these findings result from the ability of NEP-s to diffuse
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readily throughout the extracellular matrix upon secretion therefore obtaining
access (more readily than membrane bound NEP-n) to both intracellular and
extracellular pools of Aβ aggregates.
The AAV 5 serotype has previously been shown to effectively transduce
non-dividing neuronal cells as well as glial cells in the mouse brain. Our data
support this finding, demonstrating that by using rAAV serotype 5 expressing
different human gene constructs of NEP or ECE; we can transduce several
different neuronal and glial cell types. The expression profiles for the gene
transfer experiments in papers 1 and 2 are also consistent with the previously
published serological specificity of the AAV vectors (Alisky et al., 2000), (Burger
et al., 2004), (Choi et al., 2005). Although the transduction of specific cell types
were similar between study animals receiving ECE constructs and NEP
constructs the staining patterns within the neurons were different. Unlike ECE,
staining patterns for NEP revealed less intense staining in the cell bodies in the
dentate molecular layer compared to the corresponding axonal projections of
these cells which were very darkly stained. These results are consistent with
data published by Huang et al. and Iwata et al., describing the normal neuronal
metabolism of NEP processing first in the endoplasmic reticulum then in golgi
apparatus of the cell body and finally transported along the axon via vesicles to
the synaptic terminal (Iwata et al., 2004); (Iwata et al 2004), (Huang et al., 2006).
Although we demonstrate that both ECE and NEP significantly decrease amyloid,
due to the differences in injection methods we cannot directly compare the
efficiency by which ECE and NEP decrease Aβ load in the APP+PS1 aminal
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model. Despite this caveat, we can conclude that by implementing novel the
CED delivery method in addition to modification of the NEP construct directing its
secretion allowed significantly increased area of vector distribution thus exposing
more cells to viral infection and ultimately enhancing gene expression levels
following a single intracranial injection. Due to the differences in localization of
endogenous amyloid degrading enzymes, a list which is continually growing, it is
likely that they each contribute to the normal catabolism of Aβ maintaining its
basal levels in the brain. In vitro studies have identified that each of the
proteases have distinctive Aβ cleavage sites that yield unique fragments (Iwata
et al., 2001)(Yan et al., 2006), (Nalivaeva et al., 2008). Additionally, some
proteases, including NEP, IDE, ECE and ACE have been shown to only degrade
monomeric soluble Aβ. NEP can also degrade toxic oligomer forms and still
others including plasmin and MMP-9 have been shown to degrade fibrillar Aβ. It
is therefore likely that the different proteases play an additive role in maintaining
homeostatic endogenous levels of Aβ in the brain degrading different pools of Aβ
aggregates ultimately preventing deposition.
Although we have identified rAAV as a potential gene transfer method
through which we can upregulate amyloid degrading enzymes to modify AD
pathology in vivo, there are limitations and obstacle that must be overcome to
make gene therapy a more attractive therapeutic approach in the clinic. One of
the current limitations of gene therapy is obtaining reliable gene transfer
techniques that will provide therapeutically relevant levels of gene product.
Specifically, with the treatment of neurological disorders, methods involving a
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direct intracranial injection are limited due to gene transduction and expression
being confined to a very small region primarily at the site of injection. This
limitation would require numerous injections to overcome the site specific
expression of the gene of interest adding to potential complications. We address
this issue in paper 3 through the investigation of several novel mechanisms
aimed at enhancing gene transduction efficiency and improving distribution of
viral vectors within the parachyma to increase gene product. Specifically, we
investigated the different transduction characteristics of three different serotypes,
AAV5, AAV8, and AAV 9 each of which express GFP (green fluorescent protein)
in the mouse CNS. Additionally, we implemented a novel “convection enhanced
delivery technique” using a slightly modified reflux free cannula design (Krauze et
al., 2005a) to dispense AAV directly into the brain parenchyma. Finally, we
attempt to optimize the CED injection method and distribution parameters by
using a reflux free cannula design in addition to pre-treatment with hyperosmotic
mannitol, an agent that decreases intracranial pressure, administered by
intraperitoneal injection. Previous reports have demonstrated CED, which
employs positive pressure and a high flow rate, to dramatically facilitate
widespread distribution of AAV within the parachyma following a single
intracranial injection (Bankiewicz et al., 2000), (Cunningham et al., 2000). In
addition we have modified the CED cannula using a step design (Krauze et al.,
2005a) which we have customized to provide a more efficient method to prevent
reflux of AAV suspension following administration (paper 3, materials and
methods). A comparison of AAV vectors revealed that each AAV serotype
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showed distinctly different transduction patterns with AAV 9 being the most
efficient transducer of neurons in several brain regions in the ipsilateral
hemisphere as well as the contralateral hemisphere (paper 3; figure 2). AAV 5
was the least efficient and showed the smallest region of vector distribution and
GFP expression, while AAV 8 showed similar patterns of transduction to AAV 9
but showed a decreased amount of GFP expression. Our findings as well as
others confirm that AAV 9 has significantly higher transduction efficiency in
neurons in the CNS compared to AAV 8 and AAV 5 (Cearley and Wolfe, 2006).
The differences in transduction patterns may be a result of different binding
affinity to specific cell surface receptors as well as un-packaging and post-entry
properties of each serotype (Hauck et al., 2004), (Wang et al., 2007). We
speculate that in this study the efficiency of AAV 9 transduction of neurons may
be due to its effective and stable binding to cell surface receptors possibly the
LamR receptor or other potential receptors. It may also be that specific capsid
proteins allow AAV 9 to be taken up by the cell more efficiently followed by more
efficient translocation and viral uncoating and un-packaging within the nucleus of
the neuronal cell and efficient DNA replication and expression properties.
Additionally, anti-GFP immunohistochemistry revealed that AAV 9 treated
animals had the most intense darkly stained pattern of both cell bodies and
axonal projections, compared to animals treated with AAV 5 or 8. These results
may indictate that cells tranduced with AAV9 may be producing more GFP which
is later transported via vesicles within the cell body and along axons to regions
that have connectivity with the injection site in both the ipsilateral and
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contralateral hemispheres. Another possible explanation for the high
transduction efficiency of AAV 9 recently proposed by several research groups,
may be that more than one AAV 9 virion can transduce a single cell and that
once a viral particle gains entry into the cell it may be easily transported axonally
to other regions of the brain (Passini et al., 2002), (Burger et al., 2004), (Cearley
and Wolfe, 2006). Despite differences in vector distribution and GFP expression,
all three serotypes appear to primarily transduce neurons, which was proven by
co-localization of double labeled NeuN, a neuronal marker, and GFP in the
mouse CNS. Double labeling of GFP and GFAP, a marker for astrocytes,
showed no co-localization of the two proteins indicating that AAV did not
tranduce astrocytes. These data are consistent with previous reports of AAV 5, 8
and 9, transduction patterns in the murine CNS (Burger et al., 2004), (Davidoff et
al., 2005), (Broekman et al., 2006), (Cearley and Wolfe, 2006). A clear
understanding of AAV characteristics that mediate cellular mechanisms
underlying viral infectivity of specific cell and tissue type would advance efforts to
create tailored recombinant AAV vectors with disease modifying specificity.
Once AAV 9 was identified in our study as having the highest transduction
efficiency in the mouse CNS following a single CED intracranial injection, we
investigated the effects that mannitol had on vector distribution. We determined
that systemic pre-treatment with hyperosmotic mannitol significantly improved
vector distribution of AAV. Previous reports have demonstrated improved
distribution of AAV 2 following direct intracranial injection into the striatum
(Burger et al., 2004) and thalamus (Fu et al., 2003) with intravascular
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administration of mannitol or co- administration with rAAV into the parachyma
(Mastakov et al., 2002). The effects of hyperosmotic mannitol in previous studies
has been reported to cause an efflux of water out of surrounding tissue or brain
cells and increasing the porosity of the extracellular matrix (Rapoport, 2001),
(Neeves et al., 2007). Additionally, in 2002, Sandberg and collegues
investigated the affects of mannitol administration on CED delivery in the rat
brain stem and did not find significant differences or improved distribution
parameters for CED with either systemic administration or co-administration of
mannitol. We assert that this may have been due to the slow infusion rate,
0.1µl/min, or the large molecula size of the molecule delivered (FITC-dextran)
(Sandberg et al., 2002). In contrast, we use a high flow rate (2.5 µl/min) to
administer very small AAV vector particles to the hippocampus resulting in
widespread distribution of AAV throughout the entire hippocampal region and to
regions distal to the site of injection in both the ipsilateral and contralateral
hemispheres (paper 3; figures 3 & 4).
The efficacy and safety profile of the CED technique has been well
established in both animal studies and in human trials (Laske et al., 1997), (Chen
et al., 1999), (Bankiewicz et al., 2000). In recent years the CED method has
gained acceptance and popularity as an extremely effective method to enhance
delivery of an expanding list of different molecules with wide range molecular
sizes including therapeutics agents, proteins, macromolecules, viral vectors, and
nanoparticles in the brain (Cunningham et al., 2008), (Kikuchi et al., 2008),
(Perlstein et al., 2008), (Song and Lonser, 2008), (Patel et al., 2009). Most
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recently, this novel technique has been implemented in several clinical trials to
delivery therapeutics agents for the treatment of Parkinson’s disease and
glioblastoma multiform (Lopez et al., 2006), (Vogelbaum, 2007), (Vogelbaum et
al., 2007). Despite its clinical efficacy, the parameters under which CED can be
optimized providing further distribution are still under investigation. Our data are
consistent with previous reports describing significantly improved distribution of
rAAV in the parenchyma. We also demonstrate that by combining the CED with
mannitol further enhanced distribution parameters for CED administration of AAV
particles. In addition to CED and mannitol, investigators have used co-infusions
of heparin with rAAV 2 (Mastakov et al., 2002) (Nguyen et al., 2001) (Hadaczek
et al., 2006) or bFGF (basic fibroblast growth factor) (Hadaczek et al., 2004) to
significantly increase viral distribution in the CNS. Presumably, these molecules
increase viral spread by preventing or limiting the interaction between the virion
particle and its cellular receptor or co-receptor thus masking the a significant
portion of the potential viral receptors, thereby increasing the number of cells that
can potentially be infected by decreasing the cells that undergo infection by
multiple virion particles (Mastakov et al., 2002). Unfortunately, due to the
potential risks of these agents they may have little clinical appeal but identifying
an alternative method of improving viral spread in the CNS by mediating cell
surface receptor interactions is a viable approach to improving rAAV efficiency.
Overall we provide convincing evidence that Aβ levels can be modified
through regulation of endogenous β-amyloid degrading enzymes in the brain,
which suggests that these enzymes contribute to the normal catabolism of Aβ
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peptides preventing its accumulation and deposition. Moreover, we show that
significant up-regulation of these enzymes specifically NEP and ECE can be
achieved through gene therapy using rAAV vectors that provide reliable, stable
gene expression and viable gene product with significant enzyme activity.
Furthermore, we demonstrate the potential for the use of rAAV as a clinical
therapeutic in the treatment of AD by providing novel methods that improve viral
distribution to larger regions of the brain parenchyma, a major obstacle that must
be overcome in the field of gene therapy. We demonstrate that optimal injection
techniques in addition to serotype specific AAV characteristics can significantly
enhance transduction efficacy and overall disease modifying capacity. Further
investigation must be done to fully understand and characterize cellular
mechanisms underlying viral infectivity of AAV thus unlocking the true potential of
their use in the treatment of neurological diseases.
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